An evaluation of trimetazidine as a therapeutic intervention in a newly established ex vivo mouse model of acute heart failure by Breedt, Emilene S.
An evaluation of trimetazidine as 
a therapeutic intervention in a 
newly established ex vivo mouse 
model of acute heart failure 
Emilene S. Breedt 
Thesis presented in fulfilment of the requirements for the 
degree of Masters in Science in the Faculty of Science at 
Stellenbosch University 
Department of Physiological Sciences 
Supervisor: Prof. M. Faadiel Essop 
Co-Supervisor: Dr. Lydia Lacerda 
March 2016
I 
“The Road goes ever on and on 
Down from the door where it began. 
Now far ahead the Road has gone, 
And I must follow, if I can, 
Pursuing it with eager feet, 
Until it joins some larger way 
Where many paths and errands meet. 
And whither then? I cannot say” 
― J.R.R. Tolkien, The Fellowship of the Ring 
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Acute heart failure (AHF) is the most common primary diagnosis for hospitalized heart diseases in 
Africa.  Although Sub-Saharan women are more prone to suffer from de novo AHF at a much 
younger age, females have historically been underrepresented in biomedical research studies.  As 
increased fatty acid oxidation (FAO) with heart failure triggers detrimental effects within the 
myocardium, we hypothesized trimetazidine (TMZ) (a partial FAO inhibitor) treatment will provide 
cardio protection to control and diabetic mouse hearts subjected to AHF.  We further hypothesized 
that TMZ efficacy will be influenced by different phases of the estrous cycle. 
Aims  
1) Establish an unique ex vivo AHF model using hearts isolated from db/db mice and their lean 
control littermates (db/+); 2) Evaluate whether FA-albumin filtering can replace the gold standard 
method of dialysis for perfusate preparation; 3) Assess whether we can identify the different phases 
namely proestrus, estrus (follicular phase), metestrus and diestrus (luteal phase) of the estrous cycle 
in the female mice; and 4) Evaluate TMZ as a therapeutic option in our ex vivo AHF model for normal 
and obese/diabetic mice, respectively, ascertain if there are sex-based differences, and determine 
whether the phases of the estrous cycle can influence cardio protection.  
Methods  
The Langendorff retrograde isolated heart perfusion system was employed to establish an ex vivo 
AHF model that consisted of three phases: Stabilization – Krebs-Henseleit buffer (10 mM glucose) at 
100 cmH2O (25 minutes); Critical Acute Heart Failure (CAHF) – (2.5 mM glucose, 1.2 mM palmitic 
acid bound to 3% bovine serum albumin [BSA]) at 20 cmH2O (25 minutes); and Recovery Acute Heart 
Failure (RAHF) – (10 mM glucose, 1.2 mM palmitic acid bound to 3% BSA) at 100 cmH2O (25 
minutes). 5 µM TMZ was administered in the perfusate at either the CAHF or RAHF phase for the full 
duration of the respective phase. The filter versus dialysis experiments were run for 30 minutes in 
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Krebs-Henseleit buffer (10 mM glucose, 1.2 mM palmitic acid bound to 3% BSA). Phases of the 
estrous cycle were determined by vaginal smear cytology or “wet smears” and viewed under a light 
microscope. Enzyme-linked immunosorbent assays (ELISA) were utilized to measure serum hormonal 
levels while Western blotting was employed to assess protein expression levels.  
Results  
Our model mimicked de novo AHF in the switch from stabilization to CAHF and partial recovery in 
the switch from CAHF to RAHF.  This study established that the dialysis method for FA-BSA 
preparations can be substituted by a simple filtering protocol.  While vaginal smear cytology 
confirmed acyclicity of obese females (therefore lost follicular phase), lean females exhibited normal 
estrous cycle phases.  Commercial ELISA kits were not adequately sensitive to detect hormonal 
fluctuations. All groups displayed a severe decrease in function during CAHF and recovery with RAHF 
(vs. CAHF). Lean and obese males benefited equally from TMZ treatment administered during the 
RAHF phase.  The lean females in the two main phases of the estrous cycle (follicular and luteal) 
responded in distinct ways.  Here lean follicular females were the only group to respond to TMZ 
treatment during the CAHF phase, while lean luteal females did not respond to therapy but rather 
displayed an inherent cardio protection that was lost with obesity. Obese luteal females also 
benefited from TMZ treatment during RAHF.  No changes were observed in protein expression levels 
of 3-keotacyl-CoA thiolase (3-KAT) nor pyruvate dehydrogenase (PDH). 
Conclusion 
A novel ex vivo mouse AHF model has successfully been established and utilized the filtering method 
as opposed to the gold standard dialysis method.  TMZ as a therapy for AHF showed great promise in 
improving functional recovery of mice subjected to the AHF protocol.  Sex differences were present 
only in lean groups where the phases of the estrous cycle influenced therapy, while obesity only 
affected TMZ efficacy in females. The optimization of cardiac metabolism by TMZ emerges as a novel 
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and worthy therapeutic option to investigate for the treatment of AHF in normal and diabetic 
patients (for both genders).  
Opsomming 
Inleiding 
Akute hartversaking (AHF) is die mees algemene primêre diagnose vir gehospitaliseerde hartsiektes 
in Afrika.  Alhoewel vrouens van Sub-Sahara Afrika meer geneig is om te ly aan de novo AHF op 'n 
veel jonger ouderdom, is vrouens histories onderverteenwoordig in biomediese navorsingstudies.  
Verhoogde vetsuuroksidasie (FAO) tydens hartversaking lei tot nadelige gevolge binne die 
miokardium.  Ons vermoed behandeling met trimetazidine (TMZ) ('n gedeeltelike FAO inhibitor) sal 
beskerming bied aan kontrole en diabeet muis harte onderworpe aan AHF.  Ons vermoed verder dat 
TMZ se doeltreffendheid beïnvloed sal word deur verskillende fases van die estrussiklus. 
Doelwitte 
1) Stel 'n unieke ex vivo AHF model op met behulp van harte geïsoleer vanaf db/db muise en hul 
skraal kontrole werpselmaats (db/+); 2) Evalueer of die filtrering van vetsuur-albumien die standaard 
metode van dialise vir perfusaat voorbereiding kan vervang; 3) Assesseer of ons die verskillende 
fases naamlik proestrus, estrus (follikulêre fase), metestrus en diestrus (luteale fase) van die 
estrussiklus in die vroulike muise kan identifiseer; en 4) Evalueer TMZ as 'n terapeutiese opsie in ons 
ex vivo AHF model vir normale en oorgewig/diabeet muise, onderskeidelik, stel vas of daar geslag-
gebaseerde verskille teenwoordig is, en bepaal of die fases van die estrussiklus kardiale beskerming 
kan beïnvloed. 
Metodes 
Die Langendorff retrograde geïsoleerde hartperfusie stelsel is gebruik om 'n ex vivo AHF model te 
vestig wat bestaan uit drie fases: Stabilisasie – Krebs-Henseleit buffer (10 mM glukose) by 100 
cmH2O (25 minute); Kritieke Akute Hartversaking (CAHF) – (2,5 mM glukose, 1,2 mM palmitiensuur 
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gebind aan 3% van bees serum albumien [BSA]) by 20 cmH2O (25 minute); en Herstellende Akute 
Hartversaking (RAHF) - (10 mM glukose, 1,2 mM palmitiensuur gebind tot 3% BSA) by 100 cmH2O (25 
minute).  TMZ (5 μM) is toegedien in die perfusate óf by die CAHF of RAHF fase vir die volle duur van 
die onderskeie fase. Die filtrering teenoor dialise eksperimente is uitgevoer vir 30 minute met Krebs-
Henseleit buffer (10 mM glukose, 1,2 mM palmitiensuur gebind tot 3% BSA).  Fases van die 
estrussiklus was bepaal deur vaginale smeer sitologie of "nat smere" en besigtiging onder 'n 
ligmikroskoop.  Ensiem-gekoppelde immunosorberende toetse (ELISAs) is gebruik om hormonale 
vlakke in serum te meet, terwyl Westerse klad analises gebruik is om vlakke van proteïen uitdrukking 
te evalueer. 
Resultate 
Ons model boots de novo AHF na in die oorskakeling van die stabilisering fase na CAHF en 
gedeeltelike herstelling in die oorskakeling van CAHF na RAHF. Hierdie studie het vasgestel dat die 
dialise metode vir die vetsuur-BSA voorbereidings vervang kan word deur 'n eenvoudige filtrasie 
protokol.  Vaginale smeer sitologie het bevestig dat oorgewig wyfies nie normaal deur die 
estrussiklus sirkuleer nie, terwyl skraal wyfies wel normaal deur die fases van die siklus beweeg.  
Kommersiële ELISA toetse se sensitiwiteit was nie voldoende om hormonale afwykings vas te stel 
nie.  Alle groepe het 'n ernstige afname in funksionaliteit getoon tydens CAHF en herstel met RAHF 
(teenoor CAHF).  Skraal en oorgewig mannetjies het ewe veel voordeel getrek uit TMZ behandeling, 
toegedien tydens die RAHF fase. Die skraal wyfies in die twee hoof-fases van die estrussiklus 
(follikulêre en luteale fases) het  op verskillende maniere gereageer.  Hier was die skraal follikulêre 
wyfies die enigste groep om te reageer op die TMZ behandeling tydens die CAHF fase, terwyl skraal 
luteale wyfies nie reageer het op behandeling nie, maar eerder 'n inherente kardiale beskerming 
getoon het wat afwesig was met vetsug. Oorgewig luteale wyfies het ook voordeel getrek uit TMZ 
behandeling tydens RAHF. Geen veranderinge is waargeneem in proteïen uitdrukking vlakke van 3-
keotacyl-KoA thiolase (3-KAT) en piruvaatdehidrogenasekompleks (PDH) nie. 




'n Nuwe ex vivo muis AHF model is suksesvol gevestig en die filtrasie metode was ingestel in 
teenstelling met die goue standaard dialise metode.  As terapie teen AHF, is TMZ heel belowend in 
die verbetering van funksionele herstel van muise onderworpe aan die AHF protokol.  
Geslagsverskille is slegs waargeneem in skraal groepe waar die fases van die estrussiklus terapie 
beïnvloed het, terwyl  TMZ doeltreffendheid slegs in wyfies deur vetsug affekteer is. Die optimisering 
van hart metabolisme deur TMZ terapie kom na vore as 'n nuwe en waardige terapeutiese opsie om 
te ondersoek vir behandeling van AHF in normale en diabetiese pasiënte (van beide geslagte). 
  





Nothing is ever achieved by an individual, therefore I would like to thank the team who motivated 
and, when necessary, pushed me forward. 
To my supervisor and mentor, Prof. M. Faadiel Essop, thank you for guiding me through the 
challenges of science, for teaching me a unique view of scientific thinking and for your patience and 
guidance. Mostly, thank you for believing in me and giving me this opportunity. 
For always being available and supportive, I would like to thank my co-supervisor Dr. Lydia Lacerda 
for being the brightest light in the dark and difficult times. I want to thank you not only for the 
technical support but much, much more. Your unique approach to problem solving has taught and 
cultured my scientific skills to a level I never thought possible. You always reeled me back in when I 
gave up. None of this would have been possible without your witty humor and “go get them” 
attitude. You truly are irreplaceable. 
I would like to point out individual members of CMRG, who were always willing to share their 
knowledge and expertise. Dr. Joseph Danzil, thank you for all your support and assistance these past 
two years. I would also like to thank Dr. Rudo Mapanga, for volunteering her time and expertise to 
better my project and this thesis. 
To Mr. Noël Markgraaf (manager of the Stellenbosch University Animal Facility) and Mrs. Judith 
Farao (animal technician), thank you for your time, patience and willingness to help. It cannot be 
neglected to mention and thank you for taking such good care and endowing so much love onto the 
stars of this thesis.  
For expanding my knowledge and keeping me intellectually stimulated, I would like to thank the 
Department of Physiological Sciences and especially the Cardio-Metabolic Research Group. 
  
Stellenbosch University  https://scholar.sun.ac.za
IX 
 
To the guardian of my sanity, Anel Sparks. Thank you for being my companion and not jumping ship 
for dragging you out of bed at dawn in your December holidays. You were a solid place of solace to 
whom I could always turn to. You were always there through thick and thin, through the successes 
and through the deep, deep miseries. I could never really express the full extent of my gratitude. 
For support, friendship and planned/spontaneous coffee breaks, I would like to thank Jana Wurz. We 
have proven that no science is a success without a solid flow of caffeine, laughter and tears.  
To Dr. Anneke Brand, I would like to extend my deepest gratitude for her help with the translating 
invlolved in this thesis.  
For my parents, I would like to express my sincere gratitude for all that you have sacrificed for me 
without which I would not be where I am. 
We would like to thank Tygerberg animal hospital and Stellenbosch animal hospital for supplying us 
with the catheters.  
Lastly, a special thank you to the National Research Foundation for providing the financial support to 
make all this possible. 
  
Stellenbosch University  https://scholar.sun.ac.za
X 
 
List of conferences 
 
 The International Cell Death Society meeting (May 2014). Protea hotel, Stellenbosch. 
Attended. 
 
 Physiological Society of South Africa (September 2015). Khaya iBhubesi, Parys. Runner up in 
the Johnny van der Walt poster prize competition. 
  
Stellenbosch University  https://scholar.sun.ac.za
XI 
 
Table of contents 
 
Declaration .............................................................................................................................................................. II 
Abstract .................................................................................................................................................................. III 
Opsomming ............................................................................................................................................................. V 
Acknowledgements .............................................................................................................................................. VIII 
List of conferences .................................................................................................................................................. X 
Table of contents ................................................................................................................................................... XI 
List of figures ........................................................................................................................................................ XIV 
List of tables ......................................................................................................................................................... XVI 
List of abbreviations ............................................................................................................................................. XIX 
List of measurements ......................................................................................................................................... XXVI 
 
Chapter 1: Introduction .......................................................................................................................................... 1 
1.1 The Grim Reaper’s calling card ..................................................................................................................... 2 
1.2 Defining matters of the (failing) heart .......................................................................................................... 2 
1.3 Acute heart failure: the burden of disease ................................................................................................... 4 
1.4 Unheard voices from the hearts of women .................................................................................................. 7 
1.5 The sources, co-conspirators and presentation of the failing heart ........................................................... 10 
1.5.1 Diabetes .............................................................................................................................................. 11 
1.5.2 Obesity ................................................................................................................................................ 12 
1.6 Mechanics of the flourishing heart ............................................................................................................. 14 
1.6.1 Fatty acid β-oxidation .......................................................................................................................... 15 
1.6.2 Glucose oxidation and the Randle cycle .............................................................................................. 18 
1.6.3 Electron transport chain ..................................................................................................................... 20 
1.7 Pathology of acute heart failure ................................................................................................................. 22 
1.7.1 Hemodynamics .................................................................................................................................... 23 
1.7.2 Molecular effects of co-morbidities .................................................................................................... 29 
1.7.3 Metabolism of the failing heart ........................................................................................................... 37 
1.8 Effects of sex hormones.............................................................................................................................. 39 
1.9 Treatment of acute heart failure ................................................................................................................ 43 
1.9.1 Biomarkers .......................................................................................................................................... 43 
1.9.2 Current treatments ............................................................................................................................. 44 
1.10 Movement towards metabolic-mediated therapies ................................................................................. 47 
1. 11 Trimetazidine ........................................................................................................................................... 48 
1.12 Summary................................................................................................................................................... 50 
1.13 Hypothesis and aims ................................................................................................................................. 50 
Stellenbosch University  https://scholar.sun.ac.za
XII 
 
Chapter 2: Materials and methods ....................................................................................................................... 51 
2.1 Animals and ethics statement..................................................................................................................... 52 
2.2 Vaginal cytology .......................................................................................................................................... 53 
2.3 Testing filter versus dialysis ........................................................................................................................ 54 
2.4 Acute heart failure retrograde Langendorff heart perfusion ...................................................................... 55 
2.4.1 Perfusing mouse hearts ....................................................................................................................... 55 
2.4.2 Rationale of the model ........................................................................................................................ 56 
2.5 Treatment with trimetazidine ..................................................................................................................... 58 
2.6 Producing murine ventricular balloons for the Langendorff heart perfusion ............................................. 59 
2.6.1 Optimization of ventricular balloons ................................................................................................... 59 
2.6.2 Constructing ventricular balloons for mouse heart perfusions ........................................................... 60 
2.7 Blood and tissue collection ......................................................................................................................... 62 
2.8 Analysis ....................................................................................................................................................... 62 
2.8.1 Evaluation of serum levels of estradiol and progesterone .................................................................. 62 
2.8.2 Evaluation for protein expression levels .............................................................................................. 63 
2.9 Statistical analysis ....................................................................................................................................... 64 
 
Chapter 3: Results ................................................................................................................................................. 65 
3.1 Characterizing the estrous cycle ................................................................................................................. 66 
3.2 Comparing the filter and dialysis method ................................................................................................... 68 
3.3 Establishing the ex vivo mouse model of acute heart failure ...................................................................... 70 
3.4 Effects of trimetazidine treatment with acute heart failure ....................................................................... 72 
3.4.1 Acute heart failure: males ................................................................................................................... 72 
3.4.2 Acute heart failure: females ................................................................................................................ 79 
3.4.3 Acute heart failure: males and females ............................................................................................... 91 
3.4.4 Summary of perfusion results ........................................................................................................... 103 
3.5 3-KAT and PDH expression ........................................................................................................................ 105 
 
Chapter 4: Discussion .......................................................................................................................................... 107 
4.1 Discussion ................................................................................................................................................. 108 
4.1.1 Aim 1: Establish the de novo acute heart failure mouse model ....................................................... 109 
4.1.2 Aim 2: Fatty acid-albumin filtering versus the gold standard dialysis method ................................. 110 
4.1.3 Aim 3: Identify and establish the four phases of the estrous cycle in female mice .......................... 111 
4.1.4 Aim 4: Evaluate the therapeutic value of TMZ under various conditions ......................................... 112 
4.2 Conclusion ................................................................................................................................................ 118 
4.3 Limitations and future research ............................................................................................................... 119 
 
Stellenbosch University  https://scholar.sun.ac.za
XIII 
 
References .......................................................................................................................................................... 120 
Addendum A ....................................................................................................................................................... 167 
Addendum B ....................................................................................................................................................... 168 
Addendum C ....................................................................................................................................................... 170 
Addendum D ....................................................................................................................................................... 171 
A.D.1 Preparation of RIPA buffer (modified Radio Immuno PrecipitAtion buffer) and protein extraction ... 171 
A.D.2 Bradford protein determination ............................................................................................................ 173 
A.D.3 Sample preparation ............................................................................................................................... 175 
A.D.4 Casting and running SDS-PAGE gels ...................................................................................................... 176 
A.D.5 Densitometry and normalization to whole protein: ............................................................................. 181 
A.D.6   Western blot images ........................................................................................................................... 182 
Addendum E ....................................................................................................................................................... 183 
 
   
Stellenbosch University  https://scholar.sun.ac.za
XIV 
 
List of figures 
 
Figure 1.1: Acute heart failure (AHF) prevalence in Sub-Saharan Africa by age 
distribution 
6 
Figure 1.2:  Fatty acid β-oxidation in a nut shell  16 
Figure 1.3:  Mitochondrial fatty acid β-oxidation spiral 17 
Figure 1.4:  The Randle cycle 19 
Figure 1.5:  Mitochondrial respiratory/electron transfer chain 21 
Figure 1.6:  Hemodynamic pathophysiology of systemic and pulmonary edema 25 
Figure 1.7:  Cellular events as obesity (over nutrition) contributes to impaired 
insulin signaling 
33 
Figure 1.8:  Dysfunctional roads to heart failure due to insulin resistance and 
associated oxidative stress 
34 
Figure 1.9:  Characteristic pathological pathways activated by hyperglycemia in 
diabetic cardiomyopathy (DCM) 
36 
Figure 2.1:  Schematic representation of the modified retrograde Langendorff 
model to induce acute heart failure (AHF) 
57 
Figure 2.2:  Schematic representation of treatment regime 58 
Figure 3.1: Stages of the estrus cycle characterized by vaginal cytology 66 
Figure 3.2: Average estradiol and progesterone levels in serum of lean female 
mice throughout the estrus cycle 
67 
Figure 3.3: Characterization and comparison of the filter and dialysis method in 
lean male mice 
68 
Figure 3.4: RPP and (dp/dt)max in establishing the ex vivo mouse model of acute 
heart failure (AHF) in lean male mice 
70 
Figure 3.5: Effect of trimetazidine (TMZ) treatment during the CAHF phase on RPP 
and (dp/dt)max of lean and obese males 
72 
Figure 3.6: Effect of trimetazidine (TMZ) treatment during the RAHF phase on RPP 
and (dp/dt)max of lean and obese males 
75 
Figure 3.7: Effect of trimetazidine (TMZ) treatment during the CAHF phase on RPP 
and (dp/dt)max of lean females (follicular and luteal phase) 
79 
Figure 3.8: Effect of trimetazidine (TMZ) treatment during the RAHF phase on RPP 
and (dp/dt)max of lean females (follicular and luteal phase) 
82 
Figure 3.9: Effect of trimetazidine (TMZ) treatment during the CAHF phase on RPP 86 
Stellenbosch University  https://scholar.sun.ac.za
XV 
 
and (dp/dt)max (lean and obese females) 
Figure 3.10: Effect of trimetazidine (TMZ) treatment during the RAHF phase on RPP 
and (dp/dt)max (lean and obese females) 
88 
Figure 3.11: Effect of trimetazidine (TMZ) treatment during the CAHF phase on RPP 
and (dp/dt)max of lean males and lean follicular females 
91 
Figure 3.12: Effect of trimetazidine (TMZ) treatment during the CAHF phase on RPP 
and (dp/dt)max of lean males and lean luteal females 
92 
Figure 3.13: Effect of trimetazidine (TMZ) treatment during the RAHF phase on RPP 
and (dp/dt)max of lean males and lean follicular females 
94 
Figure 3.14: Effect of trimetazidine (TMZ) treatment during the RAHF phase on RPP 
and (dp/dt)max of lean males and lean luteal females 
96 
Figure 3.15: Effect of trimetazidine (TMZ) treatment during the CAHF phase on RPP 
and (dp/dt)max of  obese males and females 
99 
Figure 3.16: Effect of trimetazidine (TMZ) treatment during the RAHF phase on RPP 
and (dp/dt)max of obese males and females 
101 
Figure 3.17:  Effect of trimetazidine (TMZ) treatment on 3-KAT expression during 
the RAHF phase 
105 
Figure 3.18:  Effect of trimetazidine (TMZ) treatment on PDH expression during the 
RAHF phase 
106 
Figure 4.1: Acute heart failure (AHF) ex vivo model – the principle 114 
Figure A1:  Cling wrap cone for the construction of mouse ventricular balloons 170 
Figure A2:  Constructing mouse ventricular balloons 170 
Figure A3:  Mouse ventricular balloon 170 
  
Stellenbosch University  https://scholar.sun.ac.za
XVI 
 
List of tables 
 
Table 1.1:  Acute Heart Failure Syndrome (AHFS) 3 
Table 1.2:  Features of patients with AHF in the ADHERE (USA), EHFS (Europe) and 
THESUS-HF (Sub-Saharan Africa) 
6 
Table 1.3:  Classifications of acute heart failure (AHF) 22 
Table 1.4:  Derangement in myocardial substrate metabolism 38 
Table 1.5:  Parallel assessment and treatment of acute heart failure 45 
Table 1.6:  Untailored treatment for acute heart failure (AHF) 46 
Table 2.1:  Group allocations 52 
Table 3.1: Characterization and comparison of the filter and dialysis method in 
lean male mice 
69 
Table 3.2:  Establishing the ex vivo mouse model of acute heart failure (AHF) in 
lean male mice 
71 
Table 3.3:  Effect of trimetazidine (TMZ) treatment during the CAHF phase (lean 
males) 
73 
Table 3.4:  Effect of trimetazidine (TMZ) treatment during the CAHF phase (obese 
males) 
73 
Table 3.5: Comparing the effect of trimetazidine (TMZ) treatment during the 
CAHF phase (lean and obese males) 
74 
Table 3.6:  Effect of trimetazidine (TMZ) treatment during the RAHF phase (lean 
males) 
76 
Table 3.7:  Effect of trimetazidine (TMZ) treatment during the RAHF phase (obese 
males) 
76 
Table 3.8:  Comparing the effect of trimetazidine (TMZ) treatment during the 
RAHF phase (lean and obese males) 
77 
Table 3.9:  Effect of trimetazidine (TMZ) treatment during the CAHF phase (lean 
follicular females) 
80 
Table 3.10:  Effect of trimetazidine (TMZ) treatment during the CAHF phase (lean 
luteal females) 
80 
Table 3.11:  Comparing the effect of trimetazidine (TMZ) treatment during the 
CAHF phase (lean follicular and luteal females) 
81 
Table 3.12:  Effect of trimetazidine (TMZ) treatment during the RAHF phase (lean 83 




Table 3.13:  Effect of trimetazidine (TMZ) treatment during the RAHF phase (lean 
luteal females) 
83 
Figure 3.14:  Comparing the effect of trimetazidine (TMZ) treatment during the 
RAHF phase (lean follicular and luteal females) 
84 
Table 3.15:  Effect of trimetazidine (TMZ) treatment during the CAHF phase (obese 
luteal females) 
86 
Table 3.16:  Comparing the effect of trimetazidine (TMZ) treatment during the 
CAHF phase (lean and obese luteal females) 
87 
Table 3.17:  Effect of trimetazidine (TMZ) treatment in the RAHF phase (obese 
luteal females) 
88 
Table 3.18:  Comparing the effect of trimetazidine (TMZ) treatment during the 
RAHF phase (lean and obese luteal females) 
89 
Table 3.19:  Comparing the effect of trimetazidine (TMZ) treatment during the 
CAHF phase (lean males and lean follicular females) 
92 
Table 3.20:  Comparing the effect of trimetazidine (TMZ) treatment during the 
CAHF phase (lean males and lean luteal females) 
93 
Table 3.21:  Comparing the effect of trimetazidine (TMZ) treatment during the 
RAHF phase (lean males and lean follicular females) 
95 
Table 3.22:  Comparing the effect of trimetazidine (TMZ) treatment during the 
RAHF phase (lean males and lean luteal females) 
97 
Table 3.23:  Comparing the effect of trimetazidine (TMZ) treatment during the 
CAHF phase (obese males and females) 
100 
Table 3.24:  Comparing the effect of trimetazidine (TMZ) treatment during the 
RAHF phase (obese males and females) 
102 
Table 3.25:  Comparing the effects of the ex vivo acute heart failure (AHF) model 
on control groups 
103 
Table A1:  Krebs-Henseleit buffer for mouse heart - stabilization phase 168 
Table A2:   Krebs-Henseleit buffer for mouse heart - CAHF and RAHF phase 169 
Table A3:  Standard curve for Bradford protein determination 173 
Table A4:  Laemmli’s loading buffer 175 
Table A5:  Working solutions of running buffer and TBS-T 176 
Table A6:  Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 177 




Table A7:  Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
stacking gel 
177 
Table A8:  Representative western blot images 182 
Table A9:  Raw perfusion results for filter and dialysis groups 183 
Table A10:  Raw perfusion results for establishing the ex vivo mouse model of 
acute heart failure 
184 
Table A11: Raw perfusion results lean males 185 
Table A12:  Raw perfusion results obese males  186 
Table A13:  Raw perfusion results lean follicular females  187 
Table A14:  Raw perfusion results lean luteal females  188 
Table A15:  Raw perfusion results obese females  189 
Table A16:  Calculating raw perfusion results into a percentage ratio 190 
Table A17:  Comparing the effects of the ex vivo acute heart failure (AHF) model 






Stellenbosch University  https://scholar.sun.ac.za
XIX 
 
List of abbreviations 
 
(dp/dt)max Index of myocardial contraction velocity 
3-KAT 3-keotacyl-CoA thiolase  
ACC Acetyl-CoA carboxylase  
ACE Angiotensin converting enzyme 
ADCHF Acute decompensating of chronic heart failure  
ADHERE Acute Decompensated Heart Failure National Registry 
ADHF Acute decompensated heart failure 
ADP Adenosine 5′-diphosphate 
AGEs Advanced glycation end products 
AHA American Heart Association 
AHF Acute heart failure  
AII Angiotensin II  
AKT-1 Protein kinase B 
AMP Adenosine 3', 5'-monophosphate 
AMPK AMP-activated protein kinase 
ANOVA Analysis of variance  
ANT Adenine nucleotide translocase  
ATP Adenosine 5′-triphosphate 
AVP Arginine vasopressin  
BAD B-cell lymphoma-2-associated death promoter 
Bcl-2 B-cell lymphoma-2 
BMI Body mass index 
BNP B-type natriuretic peptide  
bpm Beats per minute 
BSA Bovine serum albumin 
BUN Blood urea nitrogen  
Ca2+ Calcium 
CaCl2.2H2O  Calcium chloride 
CAD Coronary artery disease 
CAHF Critical acute heart failure 
CaMK Calcium-calmodulin dependent kinase  
Stellenbosch University  https://scholar.sun.ac.za
XX 
 
CAT Carnitine acetyl transferase  
CHF Chronic heart failure 
Co. Corporation 
CO2 Carbon dioxide 
CoQ Coenzyme Q  or ubichinone 
COX-2 Cyclo-oxygenase- (COX) 2  
CPAP Continuous positive airway pressure  
CPT-1 Palmitoyltransferase- (CPT) 1  
CPT-2 Palmitoyltransferase- (CPT) 2  
Cr/PCr Creatine/phosphocreatine 
CRP C-reactive protein  
CT Acylcarnitine translocase 
CTP Citrate transport protein 
CVD Cardiovascular disease  
CyC Cytochrome c 
CYP3A Cytochrome P4503A 
DAG Diacylglycerol 
DCM Diabetic cardiomyopathy  
dH2O Distilled water  
DNA Deoxyribonucleic acid 
DNV Distended neck veins 
ECG Electrocardiography 
ECL Enhanced Chemi-Luminescence  
EDTA  Ethylenediaminetetraacetic acid 
EHFS II  EuroHeart Failure Survey II 
ELISA Enzyme-linked immunosorbent assays  
eNOS Endothelial nitric oxide synthase 
ER Endoplasmic reticulum 
ERK-1/2 Extracellular signal-regulated kinase- (ERK) 1/2 
ESC European Society of Cardiology  
ET-1 Endothelin- (ET) 1  
ETC Electron transport chain 
F-6-P Fructose-6-phosphate 
Stellenbosch University  https://scholar.sun.ac.za
XXI 
 
FA- Fatty acid anions 
FABP Fatty acid-binding proteins  
FACS Fatty acyl-CoA synthase  
FADH2 1, 5-dihydroflavin adenine dinucleotide 
FAO Fatty acid β-oxidation  
FAs Fatty acids  
FATP Fatty acid transporter  protein 
FAU Fatty acid uptake 
G-3-P Glyceraldehyde-3-phosphate 
G-6-P Glucose-6-phosphate 
GC–MS/MS Gas chromatography–tandem mass spectrometry 
GAPDH Glyceraldehyde phosphate dehydrogenase  
GIK Glucose-insulin-potassium 
GLUT-1 Glucose transporter- (GLUT) 1 
GLUT-4 Glucose transporter-  (GLUT) 4 
GO Glucose oxidation  
GSH Glutathione 
GSK-3β Glycogen synthases kinase- (GSK) 3β  
GU Glucose uptake 
H+ Proton/hydrogen ion 
H20 Water 
HBP Hexosamine biosynthetic pathway 
HDL High-density lipoproteins 
HF Heart failure 
ICAM-1 Intercellular adhesion molecule- (ICAM) 1  
IL-1 Interleukin- (IL) 1 
IL-10 Interleukin- (IL) 10 
IL-18 Interleukin- (IL) 18 
IL-1β Interleukin- (IL) 1β  
IL-6 Interleukin- (IL) 6 
Inc. Incorporated 
iNOS Inducible nitric oxide synthase 
IRS-1 Insulin receptor substrate- (IRS) 1  
Stellenbosch University  https://scholar.sun.ac.za
XXII 
 
JNK C-Jun N-terminal kinase 
K+ Potassium 
KATP ATP-sensitive potassium channel 
KCl  Potassium chloride 
KIM-1 Kidney injury molecule- (KIM) 1  
LAP  Left atrial pressure 
LC–MS/MS Liquid chromatography–tandem mass spectrometry 
LDH Lactate dehydrogenase 
LDL Low-density lipoprotein  
L-FABP L-type fatty acid-binding protein 
LLC. Limited Liability Company 
LPL Lipoprotein lipase  
Ltd. Limited 
LVDevP Left ventricular developed pressure 
LVEDP Left ventricular end diastolic pressure 
LVEDP Left ventricular end diastolic pressure  
LVESP Left ventricular end systolic pressure  
MAPK Mitogen-activated protein kinase  
MCD Malonyl-CoA decarboxylase 
MCT Monocarboxylate transporter 
MgCl2.6H2O  Magnesium chloride 
MIM Mitochondrial inner membrane  
MOM Mitochondrial outer membrane 
MPTP Mitochondrial permeability transition pore 
MR-proADM Adrenomedullin 
MTE Mitochondrial thioseterase 
mTOR Mammalian target of rapamycin  
Na+ Sodium 
Na₂CO₃ Sodium carbonate  
Na3VO4  Sodium orthovanadate 
NaCl Sodium chloride 
NADH Nicotinamide adenine nucleotide 
NADPH Nicotinamide adenine dinucleotide phosphate 
Stellenbosch University  https://scholar.sun.ac.za
XXIII 
 
NaF Sodium fluoride 
NaH2PO4 Monosodium phosphate 
NaHCO3 Sodium bicarbonate 
NCX Na+/Ca 2+exchanger 
NF-kB Nuclear factor -kB  
NGAL Neutrophil gelatinase-associated lipocalin  
NIPPV Non-invasive positive pressure ventilation 
NO Nitric oxide 
NOGPs Non-oxidative glucose pathways 
NOS Nitric oxide synthase 
NP-40 Tergitol-type NP-40 
NT-proBNP N-terminal of the prohormone brain natriuretic peptide 
NYHA New York Heart Association 
O2 Oxygen 
OS Oxidative stress 
PAI-1  Plasminogen activator inhibitor- (PAI) 1 
PAP Pulmonary arterial pressure  
PARP Poly (ADP ribose) polymerase  
PCr/ATP  Phosphocreatine/ATP  
PDBP Pulmonary diastolic blood pressure  
PDH Pyruvate dehydrogenase  
PDHK Pyruvate dehydrogenase kinase 
PDHP Pyruvate dehydrogenase phosphatase  
PFK-1 Phosphofructokinase- (PFK) 1 
PI3-K Phosphatidylinositol 3- (PI3) kinase 
PKA Protein kinase A  
PKC Protein kinase C  
plc. Public Limited Company 
PMSF Phenylmethylsulfonyl fluoride  
PPAR-α Peroxisome proliferator activated receptor- (PPAR) alpha 
PTEN Phosphatase and tensin homolog deleted on chromosome 10 
PVDF Polyvinylidene fluoride 
RAAS Renin-angiotensin-aldosterone-system  
Stellenbosch University  https://scholar.sun.ac.za
XXIV 
 
RAGE Receptor for advanced glycation end products 
RAHF Recovery acute heart failure 
RIPA RadioImmunoPrecipitAtion 
RNS Reactive nitrogen species  
ROS Radical/reactive oxygen species  
RPP Rate pressure product 
RyR Ryanodine receptors  
S6K S6 kinase 
SBP Systolic blood pressure 
SDS Sodium dodecyl sulfate 
SDS-PAGE Sodium dodecyl sulfate- (SDS) polyacrylamide gel electrophoresis- 
(PAGE) 
SEM Standard error of the mean  
SERCA-2 Sarco(endo)plasmic reticulum calcium-ATPase- (SERCA) 2  
SO2   
_ Superoxide 
SOCS-3 Suppressor of cytokine signaling- (SOCS) 3 
SpO2 Arterial oxygen saturation 
SR Sarcoplasmic reticulum 
ST2 Suppression of tumorigenicity  
TAG Triacylglycerol 
TBS-T Tris-Buffered Saline -Tween 20  




THESUS-HF The Sub-Saharan Africa Survey of Heart Failure 
TMZ Trimetazidine 
TNF-α Tumor necrosis factor- (TNF) alpha  
Tris-HCl Tris-hydrogen chloride 
TSH Thyroid stimulating hormone 
UA/CR Urinary albumin/creatinine ratio 
UCPs Uncoupling proteins 
VCAM-1 Vascular cell adhesion molecule- (VCAM) 1  
Stellenbosch University  https://scholar.sun.ac.za
XXV 
 
VEGF Vascular endothelial growth factor 
VLDL Very-low-density lipoprotein  
β-TP β-trace protein  
ΔμH
+ Change in electrochemical gradient 
 
  
Stellenbosch University  https://scholar.sun.ac.za
XXVI 
 
List of measurements 
 
˚C Degree Celsius 
< Less-than 
> Bigger-than 
≤ Less than or equal to 
≥   Bigger than or equal to 
µg Microgram 
µg/ml  Microgram per milliliter 
µl Microliter 
µm Micrometer 
½ One half 
¾ Three quarters  
au Arbitrary unit 
cm Centimeters 
cmH2O  Centimeter of water 
g Gram 
kg Kilogram per square meter 
kg/m2  Kilogram per square meter 
L Liter 
m2 Square meter 
mA Milliampere 
mg Milligram 
mg/kg Milligram per kilogram 
ml milliliter 
ml/kg/h milliliter per kilogram per hour 
mm millimeter 
mM/L  Millimol per liter 
mmHg Millimeter of mercury  
ng/ml Nanogram per milliliter 
pg/ml Picogram per milliliter 
rpm Revolutions per minute 
V Volt 
Stellenbosch University  https://scholar.sun.ac.za
XXVII 
 
v/v Volume/volume percent 
w/v Mass/volume percent 
x g Times earth's gravitational force 
 
Stellenbosch University  https://scholar.sun.ac.za
1 
 
Chapter 1: Introduction  
1.1 The Grim Reaper’s calling card ......................................................................................................... 2 
1.2 Defining matters of the (failing) heart .......................................................................................... 2 
1.3 Acute heart failure: the burden of disease ................................................................................... 4 
1.4 Unheard voices from the hearts of women .................................................................................. 7 
1.5 The sources, co-conspirators and presentation of the failing heart ........................................... 10 
1.5.1 Diabetes ............................................................................................................................... 11 
1.5.2 Obesity ................................................................................................................................. 12 
1.6 Mechanics of the flourishing heart ............................................................................................. 14 
1.6.1 Fatty acid β-oxidation .......................................................................................................... 15 
1.6.2 Glucose oxidation and the Randle cycle .............................................................................. 18 
1.6.3 Electron transport chain ...................................................................................................... 20 
1.7 Pathology of acute heart failure ................................................................................................. 22 
1.7.1 Hemodynamics..................................................................................................................... 23 
1.7.2 Molecular effects of co-morbidities ..................................................................................... 29 
1.7.2.1 Obesity .......................................................................................................................... 29 
1.7.2.2 Diabetes ........................................................................................................................ 31 
1.7.3 Metabolism of the failing heart ........................................................................................... 37 
1.8 Effects of sex hormones .............................................................................................................. 39 
1.9 Treatment of acute heart failure ................................................................................................ 43 
1.9.1 Biomarkers ........................................................................................................................... 43 
1.9.2 Current treatments .............................................................................................................. 44 
1.10 Movement towards metabolic-mediated therapies................................................................. 47 
1. 11 Trimetazidine ........................................................................................................................... 48 
1.12 Summary ................................................................................................................................... 50 
1.13 Hypothesis and aims ................................................................................................................. 50 
  
Stellenbosch University  https://scholar.sun.ac.za
2 
 
1.1 The Grim Reaper’s calling card 
Cardiovascular diseases (CVD) remain the leading cause of global mortality accounting for 29.6% of 
all deaths. In Europe, this statistic rises to an average 45%, where in women 49% (40% of men) 
succumb to CVD (Townsend et al., 2015). According to the American Heart Association (AHA), heart 
failure (HF) affects 5.1 million individuals in the United States (>20 years old) and this is expected to 
increase by 25% by 2030 (Go et al., 2013). Moreover, the socio-economic burden of CVD 
progressively expands with the increasing incidence of diabetes and obesity as a result of lifestyle 
choices and poor control of CVD risk factors (Atella et al., 2009).  
1.2 Defining matters of the (failing) heart  
HF is a clinical syndrome that is characterized by several symptoms that lead to intolerance to effort 
as well as fluid retention as a result of an increased neurohumoral response due to cardiac 
dysfunction. Thus the pathophysiological condition known as ‘heart failure’ can be defined as a state 
where the heart does not pump sufficient blood to meet the metabolic demands of the body  
(Chawla & Rajput, 2012).  
The lesser known and “sister” of HF, acute heart failure (AHF), poses challenges in terms of a 
straightforward definition and classification as it is a complex clinical syndrome that varies 
extensively in terms of underlying pathophysiologic mechanisms and clinical presentations (Metra et 
al., 2010). AHF is defined by the European Society of Cardiology (ESC) guidelines as “a rapid onset or 
change in the signs and symptoms of HF, with accompanying raised natriuretic peptide levels and 
the resulting need for urgent therapy” (Mebazaa et al., 2015). AHF can also be defined in terms of a 
patient’s signs, presentation and duration of symptoms.  Here a patient is placed into one of the two 
main groups that constitute the bigger AHF umbrella, with the first being acute de novo HF where 
patients have no pre-existing HF and this is therefore the initial manifestation of HF symptoms. By 
contrast, the second group or acute decompensated HF (ADHF) represents a condition where pre-
existing HF is rapidly deteriorating. Only once the complexity of the underlying pathology is 
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understood can the two conditions be distinguished. ADHF can also be further divided into de novo 
HF and acute decompensation of chronic HF (ADCHF) (Metra et al., 2010). To further add to such 
complexity, acute de novo HF, advanced refractory HF and ADHF also fall under the umbrella term 
‘Acute Heart Failure Syndrome’ (AHFS) (De Luca et al., 2007). Multiple AHFS schemes, each 
containing their own classifications and cut-off points have been proposed and utilized, while others 
opt to employ combined schemes (Dickstein et al., 2008; Gheorghiade et al., 2005; Gheorghiade & 
Pang, 2009; Jessup et al., 2009; Pang et al., 2010). The term AHFS has recently been accepted by 
Europe, France and the United States to include five separate yet overlapping classifications and 
presentations (Laribi et al., 2012) (Table 1.1).  
AHFS – five clinical classifications and scenarios of AHF  
Hypertensive AHF  SBP high (often > 150 mmHg) 
 Rales on auscultation 
 SpO2 in room air < 90% 
 Preserved systolic ventricular function 
 Chest radiograph consistent with PE 
Chronic decompensated HF  History of hospitalization for a similar episode 
 No signs of hypertensive crisis or cardiogenic shock 
Cardiogenic shock  Low cardiac output 
 Low blood pressure: SBP < 90 mmHg 
 Oliguria < 0.5 ml/kg/h 
 Heart rate > 60/min 
Right HF  Predominant right signs: jugular distension 
 Organ congestion: liver, kidney 
HF and ACS  Rales and/or signs of low flow following a myocardial 
   infarction 
 
Thus it is abundantly clear that no distinct definition is currently available for AHF, therefore there is 
limited uniformity within the clinical setting and also in terms of research endeavors in this field. 
Table 1.1: Acute Heart Failure Syndrome (AHFS).  Recently, three large epidemiological studies 
in Europe (EuroHeart survey), France (EFICA) and the United States (ADHERE) accepted this 
syndrome to consist of five classifications of which the underlying pathophysiology is separate, 
yet overlapping. AHF: acute heart failure, AHFS: acute heart failure syndrome, HF: heart failure, 
SBP: systolic blood pressure, PE: acute pulmonary edema, ACS: acute coronary syndrome, SpO2: 
arterial oxygen saturation. Adapted from Laribi et al.,2012. 
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1.3 Acute heart failure: the burden of disease  
AHFS that results in hospitalization is the most commonly diagnosis-related group in Medicare 
patients in the United States and is also the most expensive (Fang et al., 2008; Hunt et al., 2005; 
Rosamond et al., 2008). Patients usually seek medical help for congestion and fluid overload and not 
low cardiac output (Adams Jr. et al., 2005; Gheorghiade et al., 2006).  Metra et al. (2010) 
demonstrated that AHF has a 3-8% in-hospital mortality rate, a 9-13% 60-90 day mortality rate and a 
25-30% short term re-hospitalization rate (Metra et al., 2010).  As re-hospitalizations within 1 year 
are reported to reach 50%, this demonstrates the severity of the disease (Bueno et al., 2010).  Post-
discharge events could be due to renal and neurohormonal abnormalities and deterioration of 
general signs and symptoms of HF (Gheorghiade & Pang, 2009).  
The different types of AHF display varying severities, hospital readmissions, prognosis and mortality 
rates. For example, ADHF has higher hospital readmission and mortality rates and this was ascribed 
to the presence of multiple comorbidities (Adams Jr. et al., 2005). In addition, patients with acute de 
novo HF exhibited increased risk of death compared to ADHF, even though these patients were 
younger and displayed less co-morbidities (Follath et al., 2011; Nieminen et al., 2006; Tavazzi et al., 
2006). Such patients presented with lower blood pressure despite displaying higher left ventricular 
ejection fractions (Follath et al., 2011). Although evidence-based therapies for HF have been 
initiated earlier during hospitalization, the mortality, post-discharge and re-hospitalizations remain 
high. Thus such findings clearly demonstrate that this is an undeniable social burden, especially 
when considering the number of individuals affected by various AHF conditions and the resultant 
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Bringing it closer to home: 
Major reviews on the pathogenesis, epidemiology and prognosis of HF and cardiomyopathy in 
Africans were recently published that provide useful insight in this regard (Mayosi, 2007; Ntusi & 
Mayosi, 2009; Sliwa et al., 2005). For example, ADHF is the most common primary diagnosis in 
patients with heart disease admitted to African hospitals (Damasceno et al., 2007; Sliwa et al., 2008). 
Moreover, while AHF is a disease of the elderly (mean age 70-72 years) in western countries (Adams 
Jr. et al., 2005; Nieminen et al., 2006), the situation is quite different for Africa where it strikes at a 
mean age of 52 years (Ogah et al., 2015; Sliwa & Mayosi, 2013). Registries of higher income 
countries also reveal that women with AHFS are generally older than men (Fonarow et al., 2009; 
Galvao et al., 2006; Nieminen et al., 2008; Tsuchihashi-Makaya et al., 2011).However, Sub-Saharan 
African women are on average younger and more prone to de novo AHF compared to men (Ogah et 
al., 2015). The substantial difference in AHF prevalence in young persons (20-29 year old age group) 
is also alarming (Figure 1.1). Cardiomyopathies in Africa pose a particular threat as it imposes on 
individuals already plagued by famine and other diseases. Furthermore, the resource-poor 
environment lacks specialized equipment needed for accurate diagnosis and limited, if any, 
accessibility to potentially lifesaving interventions are available. AHF therefore strikes the African 
homes of young mothers and breadwinners, thus further disrupting already dire household 
situations (Sliwa & Mayosi, 2013). 




 Major differences are also evident in terms of ADHF epidemiological data (Sliwa & Mayosi, 2013), 
i.e. between the Sub-Saharan “The Sub-Saharan Africa Survey of Heart Failure” (THESUS-HF) registry 
(Damasceno et al., 2012), the North-American “Acute Decompensated Heart Failure National 
Registry” (ADHERE) registry (Adams Jr. et al., 2005) and the European “EuroHeart Failure Survey II” 
(EHFS II) registry (Nieminen et al., 2006) (Table 1.2). 
Characteristic ADHERE registry 
(n=105,388) 




Male (%) 48 61 49 
Mean age (years) 72 70 52 
History of HF (%) 75 63 22*  
Hypertension (%) 73 63 45 
CAD (%) 57 54 7 
Diabetes (%) 44 33 11 
Renal insufficiency (%) 30 17 8 
 
Figure 1.1: Acute heart failure (AHF) prevalence in Sub-Saharan Africa by age distribution.  
Females are on average significantly younger (50.7 years old) than males (54 years old) and a 
profound sex difference exists for the 20-29 year old age group (Ogah et al., 2015). 
Table 1.2: Features of patients with acute heart failure (AHF) in the ADHERE (USA), EHFS 
(Europe) and THESUS-HF (Sub-Saharan Africa). HF: heart failure, CAD: coronary artery disease, 
ADHERE:  Acute Decompensated Heart Failure National Registry, EHFS: EuroHeart Failure 
Survey, THESUS-HF:  The Sub-Saharan Africa Survey of Heart Failure registry.  * In the last 12 
months. Table adapted from Sliwa & Mayosi, 2013.  
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While keeping the patient characteristics in mind (age difference, etiology) the in-hospital mortality 
(4%) and 6 months post-discharge mortality (18%) for the THESUS-HF registry was similar to 
European and North-American registries. This supports the assumption that once AHF strikes there is 
no bias in terms of individual patient characteristics (Damasceno et al., 2012; Sliwa & Mayosi, 2013). 
This section highlighted that African women suffering from AHFS are younger (with an exceptional 
stress on the 20-29 year old group) and are more prone to suffer from acute de novo HF.  This AHF 
type is associated with an increased risk of death with less co-morbidities.  Before this review 
examines AHF etiology in more detail, the under-representation of women in such studies will be 
discussed as the focus of this thesis is on sex differences. 
1.4 Unheard voices from the hearts of women 
The role of female-specific risk factors for CVD were emphasized in an AHA statement 
‘Cardiovascular disease in Women’ in 1997 (Mosca et al., 1997). These included arterial 
hypertension, diabetes mellitus, dyslipidemia and obesity.  It also stressed that women (sometimes 
unlike men) exhibit different frequencies and decreases in risk factors (due to interventions). 
Subsequently, in 1999 the AHA and American College of Cardiology released a scientific statement 
on the first guidelines on the prevention of cardiac disease in women (Mosca et al., 1999). This was a 
turning point as the scientific community increased the focus on risk factors in women.  For example, 
Olmsted County data (1979-2000) revealed that the survival rate of HF was lower in women 
(Braunstein et al., 2003), while less than a third was aware that CVD is the leading cause of death in 
this group. This reflected the dire lack of education in women.  When this figure increased to 46% in 
2003 (Mosca et al., 2004), multiple campaigns were launched in an effort to promote the awareness 
of CVD affecting women. For example, in 2004 the seminal work of Mosca (‘Evidence-Based 
Guidelines for Cardiovascular Disease Prevention in Women’) was published (Mosca et al., 2004). 
This was followed by the AHA’s ‘Go Red for Women’, the ESC’s ‘Women at Heart’ and the Spanish 
Society of Cardiology’s ‘Cardiovascular Disease in Women Working Group’ campaigns (Alfonso et al., 
Stellenbosch University  https://scholar.sun.ac.za
8 
 
2006; Kolovou et al., 2011). Moreover, clinical guidelines for the prevention of CVD in women were 
updated in 2007 (Mosca et al., 2007). These efforts therefore reflect an increased emphasis to better 
understand female-specific CVD, in stark contrast to previous research where this option was largely 
ignored. 
The CVD risk of females has been grossly undervalued in the past due to the misperception that 
women are protected through estrogen (Healy, 1991). However, epidemiological data showed that 
CVD burden is progressively expanding due to increasing diabetes and obesity and that HF is 
expected to increase by 25% by 2030 (Santulli, 2013). Although HF in women contributed to 35% of 
the total CVD mortality (Koelling et al., 2004; Rathore et al., 2003; Roger et al., 2011), this group has 
historically been under-represented in HF clinical trials. For example, past clinical trials enrolled only 
17%-23% women participants (Heiat et al. 2002). This has now been rectified and recent large scale 
studies recruit near equal numbers of males and females. Unfortunately, previous under-
representation in clinical trials has hampered incorporation of guidelines for the treatment of 
female-related CVD.  For example, the 2008 US guidelines on CVD (Melloni et al., 2010; Mosca et al., 
2007) are primarily based on research performed on males, while the 2008 ESC guidelines barely 
addressed gender issues (Dickstein et al., 2008; Maas et al., 2011). 
HF signs and symptoms in women can be difficult to interpret and this can lead to misdiagnosis. 
Moreover, among patients hospitalized for HF, women are more likely to have extended stays (Klein 
et al., 2011).  Although the ADHERE registry reported no sex differences in terms of in-hospital 
mortality, significant differences were noticed in treatment.  Here women received less evidence-
based therapies and often did not receive potentially lifesaving invasive testing or procedures as was 
the case for men. This trend was continued in the AHA ‘Get With The Guidelines-Heart Failure’ 
registry (Galvao et al., 2006; Hernandez et al., 2007; Shin et al., 2012). However, women who did 
receive therapies were usually prescribed suboptimal doses (Klein et al., 2011).  
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As discussed, the lack of uniformity regarding the definition of AHF has led to contradicting data 
especially for mortality and survival. For example, some studies established that women have a 
better survival rate (Adams Jr. et al., 1999; Deswal & Bozkurt, 2006; Ghali et al., 2003; Levy et al., 
2002; Martinez-Sellés et al., 2003; O'Meara et al., 2007; Rathore et al., 2003; Roger et al., 2004; 
Simon et al., 2001; Taylor et al., 2006), while others reported mortality rates comparable to those 
for men (Al Suwaidi et al., 2012; De Maria et al., 1993; Galvao et al., 2006; Nieminen et al., 2008; 
Opasich et al., 2000; Opasich et al., 2004).  
Even though women have less CVD risk in pre-menopause compared to age-matched men, this 
difference is no longer evident five years post-menopause (Harman, 2006; Hayward et al., 2000). In 
addition, although chronic heart failure (CHF) incidence (Ho et al., 1993) is lower in women, the risk 
of mortality is higher (Johnson, 1994; Wittnich et al., 2013).  Thus the concept of the “double edged 
sword” emerges, i.e. although women appear to be “protected” against CVD, they tend to fare far 
worse if an insult actually does occur.  
It becomes clear then that past under representation of women has resulted in a significant effect 
on the forward momentum of scientific advancement. It is therefore crucial that researchers include 
both sexes (whether it is clinical or animal studies) in planned research studies. The emphasis will 
now shift to a more comprehensive review of AHF etiology and presentation. A general review of 
this condition will initially be covered and thereafter the attention will shift to AHF in women as this 
is the focus of this laboratory-based study. 
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1.5 The sources, co-conspirators and presentation of the failing heart 
Co-morbidities may act as an underlying disease(s) or it may serve as a trigger for AHF. It not only 
influences clinical manifestations and prognosis, but also contributes to pathology. Five categories of 
AHF etiology can be distinguished: (1) acute coronary syndrome, cardiomyopathies, hypertension 
and different arrhythmias; (2) Iatrogenic etiology, consisting of therapies such as cardio-toxic 
chemotherapy, beta blockers and calcium (Ca2+) channel blockers; (3) metabolic etiology such as 
diabetes mellitus and thyroid abnormalities; (4) infiltration, that includes among others, amyloidosis 
and sarcoidosis and (5) other that can include a wide variety including diet, valvular disease and 
peripartum cardiomyopathy (Laribi et al., 2012). 
According to the ADHERE and EHFS II registries, the large epidemiological contributions were 
coronary artery disease (CAD), hypertension and diabetes (Adams Jr. et al., 2005; Nieminen et al., 
2006). For another study comparing European and US data, the contribution of hypertension and 
diabetes for all AHF individuals was 59.4% and 44.6%, respectively (Karasek et al., 2012).  As 
underlying disease and trigger events, CAD contributed 71% and 36.1% respectively, while 
hypertension contributed 11% and 21.3%, respectively. This mimics the African context where AHF 
affects younger patients and factors most likely to contribute would include hypertension, diabetes 
and obesity.  Interestingly, ischemic heart disease has the lowest etiology contribution within the 
African context (Damasceno et al., 2012; Sliwa & Mayosi, 2013).  
Data from registries (developing world) show that women with ADHF tend to be older, present with 
more severe HF and display increasingly frequent signs and symptoms of HF, lower quality of life and 
worse impairment of functional capacity (Deswal & Bozkurt, 2006; Galvao et al., 2006; Koelling et al., 
2004; Levy et al., 2002; Roger et al., 2004). This therefore demonstrates the importance of 
investigating AHF in women. 
There are remarkable differences in AHF-related symptoms between men and women. Women are 
more likely to present with preserved ejection fraction as a result of hypertension and diabetes.  
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They also present with higher systolic blood pressure and ejection fraction on admission. In addition, 
they are less likely to present with CAD and ischemic etiology. By contrast, men are usually 
diagnosed with systolic HF as a result of ischemia and previous myocardial infarctions. Thus men are 
also more likely to be burdened with CAD and impaired left ventricular function (Adams Jr. et al., 
2005; Al Suwaidi et al., 2012; Klein et al., 2011; Nieminen et al., 2008; O'Meara et al., 2007; Owan et 
al., 2006; Regitz-Zagrosek et al., 2007). Of note, increased total cholesterol levels are found in 
female AHF patients of all ages (Spinarova et al., 2012). Moreover, there are also differences in 
terms of left ventricular remodeling where women display more severe hypertrophy in smaller 
hearts (an intrinsic sex difference), while the men exhibit more dilation and fibrosis due to pressure 
overloads (Fliegner et al., 2010; Petrov et al., 2010). As these results demonstrate, AHF has distinct 
characteristics in men and women and it is therefore shortsighted to simply extrapolate the results 
of male-based studies to females.  
1.5.1 Diabetes 
Diabetes can be present in up to 35%-40% of AHF cases. However, with right ventricular AHF it is 
present in only 24.5% of cases (Spinarova et al., 2012). Co-morbidities-and risk factors do not 
completely explain the compelling and independent role that diabetes plays as a CVD risk factor (De 
Simone et al., 2010; Horwich & Fonarow, 2010). For example, diabetes has an independent 
association with death (from any cause) for HF patients (Martínez-Sellés et al., 2012). Moreover, 
despite intensive treatment regimens diabetic AHF patients possess a higher in-hospital mortality 
rate than their non-diabetic counterparts (Parissis et al., 2012). Type 2 diabetes is a stronger risk 
factor for CVD in women than in men (Becker et al., 2003) and here females display a higher mean 
systolic blood pressure and increased cholesterol and hypertension are also more frequent. Their 
cardiovascular risk profile is worse and evidence shows that they reach therapeutic goals less often 
(Kautzky-Willer et al., 2010). In agreement, fatal ischemic heart disease risk is 50% higher in female 
type 2 diabetic persons (Huxley et al., 2006), while the Framingham study revealed that HF was 
several times higher in the diabetic women versus male counterparts (Kannel et al., 1974). To 
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summarize, diabetes is a particularly strong and deadly risk factor for HF in women (Bibbins-
Domingo et al., 2004; Roger et al., 2011). However, it is not the only culprit and obesity plays an 
equally strong role when discussing HF etiologies. 
1.5.2 Obesity 
The American Medical Association’s policy recognized obesity as a disease in June 2013 (Ryan & 
Braverman-Panza, 2014). The prevalence of extreme obesity rose by 2.7% (2000-2010), representing 
a 70% increase in the United States population. In addition, extreme obesity is 50% higher in women 
compared to men. Obesity is defined as a chronic, complex and multifactorial condition that arises 
from a positive energy imbalance over time that is influenced by genetic and environmental factors. 
Obesity-related inflammation is linked to CVD onset as it is an important contributing factor to heart 
diseases (Wang & Nakayama, 2010). It is also a key risk factor for the development of hypertension 
and CAD that both contribute to HF etiology. In fact, obesity may be an independent predictor for HF 
as it elicits dire effects on cardiac structure and left ventricular systolic pressure while diastolic 
function is also compromised (Lavie et al., 2009; Lavie et al., 2013). For patients with CHF, obesity is 
prevalent in 70% of women versus less than half of men (Pyöräiä et al., 2004). Women are also at 
increased risk of death for even modest weight gain in their childhoods (Hu et al., 2004), while the 
Framingham Heart Study demonstrated that there was a graded increase in HF risk in both men and 
women for all body mass index (BMI) categories. A BMI increase for every 1kg/m2 is correlated with 
a higher HF risk by 7% in women and 5% in men (Kenchaiah et al., 2002). The duration of obesity is 
also significant as HF prevalence rates can exceed 70% after 20 years and 90% after 30 years of 
obesity (Alpert et al., 1997). A graded pattern arises when AHF patients are divided into BMI 
quartiles: as BMI increases the patients tend to be younger, display more diabetes and hypertension, 
higher left ventricular ejection fractions; for the fourth quartile (highest BMIs) more tend to be 
female (Clark et al., 2011; Daniels et al., 2006; Fonarow et al., 2007; Zapatero et al., 2012). HF-
related mortality due to obesity likely depends on the presence of left ventricular dysfunction 
(Gustafsson et al., 2005). The effect of malnutrition on HF is also an important consideration in 
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developing countries such as South Africa as malnourished HF patients have an increased in-hospital 
mortality and high risk of readmission after 30 days (Zapatero et al., 2012). 
In summary, AHFS has received limited attention to date and limitations of previous study designs 
have made it difficult to derive meaningful sex-based comparisons. What is clear is that Africans 
present with AHF at a younger age during their productive years and that such women suffer at a 
much younger age than their male counterparts.  Acute instances of de novo AHF occurring more 
frequently in women are associated with an increased risk for death and although it does not need 
multiple co-morbidities to reach this status, females are again at a disadvantage. Women also suffer 
from diabetes and obesity more than their male counterparts putting them at higher risk for heart 
insults and the associated consequences. In addition, malnutrition and obesity occur commonly in 
African women. The rhetorical question therefore remains:  why were women so misrepresented in 
past clinical trials and why is the understanding of AHF pathology so neglected? As the focus of this 
thesis is also on metabolism the next section of this introduction will briefly highlight normal cardiac 
metabolism and thereafter AHF pathology will be discussed.  
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1.6 Mechanics of the flourishing heart 
The amount of adenosine triphosphate (ATP) that the mammalian myocardium can store is low 
especially when considering that the heart needs to sustain basal metabolism, ionic homeostasis and 
cardiac contraction in order to pump 7,000 liters of blood daily (Soukoulis et al., 2009). To meet 
these demands there is a complete turnover of the myocardial pool  every 10 seconds (Neely & 
Morgan, 1974)  and the heart cycles 6 kg of ATP daily (Neubauer, 2007). This explains why ATP 
consumed and generated daily is more than fifteen times the heart’s own weight (Ingwall, 2002)! 
Such high demands for energy emphasizes the omnivorous properties of the mammalian heart - it 
can utilize fatty acids (FAs), glucose, lactate and ketone bodies as energy substrates. The relative 
contribution to ATP production at any time is tightly controlled and regulated in this exceptionally 
plastic process that also includes the interdependence of substrates.   
For the normal heart that is well perfused and oxygenated (in the absence of pathology) 60-80% of 
ATP production is contributed by FA β-oxidation (FAO) and the remainder is supplied by 
carbohydrate (glucose and lactate) catabolism and a small portion from the oxidation of ketone 
bodies (Bing et al., 1954; Neely & Morgan, 1974; Opie, 1968; Opie, 1969). This is all dependent on 
the availability of oxygen, as glycolysis and glucose oxidation (GO) uses six oxygen molecules to 
produce 31 ATP molecules, while FAO uses 23 oxygen molecules to produce 105 molecules of ATP. 
Thus although FAO is  an abundant source of energy it is also an inefficient one as more oxygen is 
used per ATP molecule produced compared to GO. In addition, the FAO cycle produces both FADH2 
(1, 5-dihydroflavin adenine dinucleotide) and NADH (nicotinamide adenine nucleotide), whereas GO 
generates only NADH that is directly linked to ATP production at complex 1 of the electron transport 
chain (ETC). FADH2 skips complex 1 and so transfers less protons across the ETC making it less 
efficient in terms of ATP production (Lopaschuk et al., 2010). 
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1.6.1 Fatty acid β-oxidation 
The free FAs designated for FAO (Figure 1.2) are usually bound to albumin, can be contained in a 
chylomicron triacylglycerol (TAG) or in a very-low-density lipoprotein (VLDL) in circulation. FAs can 
cross the cardiomyocyte membrane into the cytosol by simple diffusion or by CD36-mediated 
transport, fatty acid-transporter protein (FATP) or fatty acid-binding proteins (FABP). After uptake, 
fatty acyl-CoA synthase (FACS) esterifies FAs to fatty acyl-CoA that potentially has two fates: a) it can 
be esterified to form TAG complex lipids (bound for storage, an endogenous source of FAs), or b) 
carnitine palmitoyltransferase- (CPT) 1 can transfer the acyl group to carnitine. Acylcarnitine then 
enters mitochondria via acylcarnitine translocase (CT) where CPT-2 converts it back to fatty acyl-CoA 
that can either be cleaved by mitochondrial thioseterase (MTE) to long-chain FA ions (FA-) that exit 
via UCP-3 or enters the FAO cycle.  Four key enzymes are involved in FAO namely acyl-CoA 
dehydrogenase, enoyl-CoA hydratase, 3-OH-acyl CoA dehydrogenase and 3-keotacyl-CoA thiolase (3-
KAT) (Figure 1.3). This cycle produces NADH, FADH2 and acetyl-CoA - the latter entering the 
tricarboxylic acid (TCA) cycle. The resultant NADH and FADH2 feed into and drive the ETC to produce 
ATP (discussed later) that is exported to the cytosol via adenine nucleotide translocase (ANT) which 
forms part of the mitochondrial permeability transition pore (MPTP). It is crucial that FAO be tightly 
controlled and here malonyl-CoA exerts allosteric inhibition over CPT-1. This is only the downstream 
result of the “fuel sensor” AMP (adenosine 3', 5'-monophosphate)-activated protein kinase (AMPK), 
that exerts the main control over cardiac metabolic regulation. When there is an increase/decrease 
in energy demand,  metabolic stress, ATP depletion or a decrease in the creatine/phosphocreatine 
(Cr/PCr) ratio, AMPK will either stimulate or inhibit acetyl-CoA carboxylase (ACC) to manipulate 
levels of malonyl-CoA in order to meet metabolic demand (Lopaschuk et al., 2010).  




Figure 1.2: Fatty acid β-oxidation in a nut shell.   Fatty acids enter cardiomyocytes via 
diffusion through the CD36/FATP/FABP transporters where in the cytosol fatty acyl-CoA 
synthase (FACS) converts it to fatty acyl-CoA. This can a) be esterified to triacylglycerol (TAG) 
or b) carnitine palmitoyltransferase (CPT)-1 transfers an acyl group to carnitine.  
Carnitinetransferase (CT) shuttles the acylcarnitine into the mitochondrion where CPT-2 
transfers it back to fatty acyl-CoA to enter the fatty acid β-oxidation spiral to produce acetyl- 
CoA to enter the TCA cycle. Resultant FADH2/NADH enters the electron transport chain to 
produce ATP. The “fuel sensor” AMP-activated protein kinase (AMPK) exerts control over 
acetyl-CoA carboxylase (ACC) to manipulate levels of malonyl-CoA in order to meet 
metabolic demands. FATP: fatty acid-transporter protein, FABP: fatty acid-binding protein, 
MTE: mitochondrial thioseterase, MCD: malonyl-CoA decarboxylase, MPTP: mitochondrial 
permeability transition pore, UCPs: uncoupling proteins, MIM: mitochondrial inner 
membrane, MOM: mitochondrial outer membrane, FA-: fatty acid anions, TCA: tricarboxylic 
acid, ADP: adenosine 5′-diphosphate ATP: adenosine 5′-triphosphate, FADH2: 1, 5-
dihydroflavin adenine dinucleotide, NADH: nicotinamide adenine nucleotide, AMP: 
adenosine 3', 5'-monophosphate, H+: proton/hydrogen ion , ΔμH
+: change in electrochemical 
gradient. Image adapted from Lopaschuk et al., 2010. 








Figure 1.3: Mitochondrial fatty acid β-oxidation spiral. The four enzymes occur with varying 
fatty acid chain length specificities and have different isoforms. A fatty-acyl chain that is two 
carbons shorter and acetyl-CoA (destined to enter the TCA cycle) are produced by one cycle of 
the FA β-oxidation spiral. FADH2: 1, 5-dihydroflavin adenine dinucleotide, NADH: nicotinamide 
adenine nucleotide, H2O: water. Image adapted from Lopaschuk et al., 2010. 
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1.6.2 Glucose oxidation and the Randle cycle 
Glucose is transported into the cytosol after the recruitment of glucose transporter-1 (GLUT-1) and 
GLUT-4 from the intracellular compartments. AMPK can also intervene in glycolysis as it can trigger 
GLUT-4 translocation to enhance glucose uptake. Subsequently, glucose is phosphorylated to 
glucose-6-phosphate (G-6-P) by hexokinase I and/or hexokinase II and phosphofructokinase-1 (PFK-
1) catalyzes the reaction to pyruvate. Pyruvate can be anaerobically converted to lactate or it can be 
transported into mitochondria to undergo oxidation by pyruvate dehydrogenase (PDH) to form 
NADH (feeds into the ETC) and acetyl-CoA designated for the TCA cycle (Lopaschuk et al., 2010).  
Philip Randle and colleagues were the first to describe the reciprocal relationship between FA and 
carbohydrate metabolism. Since the 1960s, this has been simply referred to as the “Randle cycle” 
(Figure 1.4) (Garland et al., 1963; Randle et al., 1963; Randle et al., 1964). This effect lends plasticity 
to cardiac metabolism for meeting fuel demand and supply. FAO can inhibit GO (pyruvate) in two 
ways. Firstly, increased acetyl-CoA produced by the FAO cycle can activate pyruvate dehydrogenase 
kinase (PDHK), that will phosphorylate and inactivate PDH. This leads to backflow in the system 
resulting in glucose conversion to lactate and associated protons. Secondly, increased acetyl-CoA 
entering the TCA cycle can also elevate citrate levels that can inhibit cytosolic PFK-1, thereby leading 
to lowered glucose utilization. 
Conversely, GO can also inhibit FAO in two ways: a) 3-KAT (last FAO enzyme) is sensitive to inhibition 
from increased acetyl-CoA (from GO) and b) elevated acetyl-CoA from GO can be converted to 
acetylcarnitine by carnitine acetyl transferase (CAT). Cytosolic CAT can convert this into cytosolic 
acetyl-CoA that is metabolized to malonyl-CoA by ACC, thereby exerting an inhibitory effect on CPT-1 
(Lopaschuk et al., 2010).  
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Figure 1.4: The Randle cycle.  In order to provide plasticity to cardiac metabolism for exceptional 
dynamic demands and supplies there is a reciprocal relationship between fatty acid and carbohydrate 
metabolism. Fatty acid β-oxidation (FAO) can inhibit carbohydrate metabolism in two ways. The 
increased acetyl-CoA produced by the mitochondrial FAO spiral can either act indirectly on pyruvate 
dehydrogenase (PDH) (1) or it can translate to citrate produced that feeds back to inhibit 
phosphofructokinase-1 (PFK-1) (2). Conversely, increased acetyl-CoA produced by glucose metabolism 
can also inhibit FAO by either targeting the sensitive 3-keotacyl-CoA thiolase (3-KAT) enzyme in the 
mitochondrial FA β-oxidation spiral (3) or by translating into cytosolic acetylcarnitine that indirectly acts 
on malonyl-CoA to inhibit carnitine palmitoyltransferase-1 (CPT-1) (4). GLUT-4: glucose transporter-4, G-
6-P: glucose-6-phosphate, F-6-P: fructose-6-phosphate, G-3-P: glyceraldehyde-3-phosphate, LDH: lactate 
dehydrogenase, MCT: monocarboxylate transporter, PDHP: pyruvate dehydrogenase phosphatase, 
PDHK:  pyruvate dehydrogenase kinase, NADH: nicotinamide adenine nucleotide, CO2: carbon dioxide, 
CAT:  carnitine acetyl transferase, CT:  acylcarnitine translocase, ACC: acetyl-CoA carboxylase, MCD: 
malonyl-CoA decarboxylase, FACS: fatty acyl-CoA synthase, FATP: fatty acid-transporter  protein, FABP: 
fatty acid-binding proteins, TCA: tricarboxylic acid, CTP: citrate transport protein, MIM: mitochondrial 
inner membrane, MOM: mitochondrial outer membrane. Image adapted from Lopaschuk et al., 2010. 




1.6.3 Electron transport chain 
ATP is generated in mitochondria by the high energy reducing equivalents (NADH and FADH2) from 
the TCA cycle (GO and FAO) that are passed along proteins in the mitochondrial inner membrane 
(MIM) by a series of redox reactions (Figure 1.5).  At complex IV oxygen accepts the hydrogen 
molecule to form water, but more importantly this reaction produces energy so that other protons 
are extruded into the intermembrane space from complex I, III and IV. The resultant electrochemical 
gradient drives complex V (ATP synthase) to phosphorylate adenosine 5′-diphosphate (ADP) to ATP. 
However, under normal physiological conditions electron flow is not always tightly coupled to ATP 
generation with some energy being lost as heat. Here uncoupling proteins (UCPs), ANT and non-
specific membrane slippage contribute to non-ATPase related proton leaks from the inter-
mitochondrial membrane space into the matrix.  However, this is a protective feedback mechanism 
and is sometimes referred to as “uncoupling to survive”.  Reverse electron transport at complex I 
(NAD+ is reduced back to NADH) and electron leaks are natural phenomena occurring within the ETC. 
Here electrons do not reach the end of the chain to form water, but rather exit early at complex I 
and III to form superoxide (SO2∙
-). This natural production of reactive oxygen species (ROS) 
exacerbates proton leaks and studies found that a decrease in proton gradient due to uncoupling 
can attenuate SO2∙
- production and reverse electron transport (Schwarz et al., 2014). However, when 
uncoupling becomes dysregulated it may contribute to pathology. 
The important role of cardiac metabolism in energy production is abundantly clear and the focus will 
now shift to AHF pathology with some reference to this context. However, distinct clinical 
presentations of males and females will initially be discussed, where after the focus will shift to 
hemodynamic alterations and molecular events. 






Figure 1.5: Mitochondrial respiratory/electron transfer chain.  Reducing equivalents NADH and 
FADH2 from GO and FAO are passed to and through (via  coenzyme Q and cytochrome c 
shuttles) the electron transport chain as high energy loaded electrons and  these electrons 
release energy as it undergoes redox reactions at the copper and iron centers of the individual 
complexes in the chain. Hydrogen ions are extruded into the inter-membrane space from the 
matrix due to related conformational changes. The availability of oxygen is a rate-limiting step, 
as it is the terminal acceptor of energy depleted electrons. The electron gradient drives ATP 
synthase to phosphorylate ADP to ATP.  FADH2: 1, 5-dihydroflavin adenine dinucleotide, NADH: 
nicotinamide adenine nucleotide, H2O: water, O2: oxygen, ADP: adenosine 5′-diphosphate , ATP: 
adenosine 5′-triphosphate, UCPs:  uncoupling proteins, MPTP: mitochondrial permeability 
transition pore, TCA: tricarboxylic acid, I-V:the five protein complexes of the electron transport 
chain, CoQ: coenzyme Q/ubichinone, CyC: cytochrome c, H+: proton/hydrogen ion, MIM: 
mitochondrial inner membrane, MOM: mitochondrial outer membrane. Image adapted from 
Schwartz et al., 2014. 




1.7 Pathology of acute heart failure 
AHF pathology can be sub-divided into two categories (Table 1.3). Here acute decompensated 
(cardiac) failure is characterized by a milder and more gradual nature whereby symptom worsening 
presents. The presence of pulmonary edema is infrequent, while symptoms such as jugular vein 
congestion, peripheral edema, poor peripheral perfusion and renal and hepatic dysfunction are 
frequent. Such patients are usually younger males with normal/low range blood pressure with on-
going myocardial injury (ischemia) as a precipitating factor. By contrast, acute cardiovascular 
(hypertensive) failure is a rapidly progressive disorder that is characterized by extreme and acute 
pulmonary edema and dyspnea. Such patients are usually women that present with high blood 
pressure, preserved ejection fraction and hypertension - this form is common for de novo AHF 
(Cotter, et al., 2008; Phan et al., 2012).  




Sex  Usually younger males  Usually women  
Common for de novo AHF 
Progression Milder and more gradual symptom 
worsening presents (days) 
Extreme and acute: a rapidly 
progressive disorder  (hours) 
Precipitating factor On-going myocardial injury (ischemia)  Hypertension 
Main mechanism of 
onset 
↓ Contractility and renal 
hypoperfusion 
↑ Afterload 
Main symptom Fatigue Dyspnea 
Main sign(s) Peripheral edema, jugular venous 
stasis, hepatomegaly 
Extreme and acute pulmonary 
edema, dyspnea, Rales 
Systolic blood 
pressure 




Left ventricular filling 
pressure 
May be reduced by 
low cardiac output 
High 
Cardiac output Low Normal or high 
 
This review will focus on the female AHF phenotype as it is the main interest of this thesis. The 
proposed pathology encompasses the most important symptoms whereby AHF females present, 
Table 1.3: Classifications of acute heart failure (AHF). Males and females in the clinical setting 
present with two different classifications of AHF.  Adapted from Metra et al., 2010.  




namely fluid overload and dyspnea, left ventricular (diastolic) failure, left ventricular preserved 
ejection fraction and high systolic blood pressure. Thereafter co-morbidities (obesity and diabetes) 
will be discussed - these parameters will be separately described but as such components are 
intertwined none of them can easily be considered in isolation.  
1.7.1 Hemodynamics 
Poor contractility is often present during AHF together with a resultant low cardiac output and 
decreased plasma volume. Pathways such as the renin-angiotensin-aldosterone-system (RAAS) and 
adrenergic and inflammatory pathways are activated to try and increase the plasma volume. 
However, fluid retention can be exacerbated by pharmacological treatment, non-compliance and 
diet. Although mechanisms such as B-type natriuretic peptide (BNP) try to restore euvolemia, fluid 
retention and accumulation persists (Pandit et al., 2011). As mentioned previously, AHF patients are 
mainly hospitalized for dyspnea and not for low cardiac output. Pulmonary edema and congestion 
are the main mechanisms causing dyspnea (Metra et al., 2010). 
Pulmonary edema arises when the colloid osmotic pressure (provided by plasma proteins) is 
exceeded by intravascular pressure (hydrostatic force) (Figure 1.6). Fluid from the intravascular 
space is then forced into the alveoli and this increases resistance in the airways and renders the lung 
incompliant, so leading to difficulty with breathing and increased cardiac effort (Haydock & Cowie, 
2010). Pulmonary congestion is pulmonary venous hypertension or increased pulmonary capillary 
wedge pressure that results in pulmonary interstitial and alveolar edema (Gheorghiade & Pang, 
2009). 
A potential mechanism whereby this may occur is that fluid may be redistributed from the periphery 
to the pulmonary system. However, this is not the only cause as pulmonary congestion/edema and 
increased pulmonary capillary pressure can also arise due to vasoconstriction, particularly when 
diastolic dysfunction is present. Venoconstriction results in greater right heart venous return and in 
combination with failing ventricles causes increased end diastolic pressures in both right and left 




ventricles. Arterial vasoconstriction results in increased afterload in the left ventricle with a 
subsequent decrease in stroke volume. The exact trigger for such excessive vasoconstriction has not 
been fully clarified, however, inflammation and neurohormonal activation are favored as potential 
mediators (Colombo et al., 2008; Metra et al., 2010). Pulmonary congestion may also be caused by 
an acute increase in blood pressure (afterload) in the presence of diastolic dysfunction (Cotter et al., 
2002; Cotter et al., 2008) and by an increase in left ventricular diastolic pressure. It can also occur 
indirectly via activation of neurohormones and by remodeling (Gheorghiade et al., 2006).  
Pulmonary capillary wedge pressure (high left side pressures) can cause increased systemic venous 
pressure (at the high right atria) that can also contribute to cardio-renal syndrome (Damman et al., 
2007; Núñez et al., 2015). West and colleagues (2010) postulate that dyspnea more likely results 
from incompatible information within the controls of the respiratory system.  They propose that 
patients perceive a mismatch between the afferent sensation (mechanical receptors in the chest 
wall, lungs and airways, and chemoreceptors in the blood) and efferent motor activity (in the brain 
that descends down into the diaphragm and supporting respiratory muscles) (West et al., 2010). In 
summary, dyspnea (a key characteristic of AHF) arises due to rapid dysregulation of cardiac 
pressures and associated compensatory mechanisms that may arise.  
Venous congestion is starting to gain credibility as a primary contributor to ADHF, rather than being 
considered a secondary consequence. Fluid redistribution and accumulation are two mechanisms 
proposed for venous congestion pathogenesis. Neurohormonal [increased levels of endothelin-1 (ET-
1), angiotensin II (AII) and norepinephrine] and endothelial activation [increased levels of vascular 
cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1), interleukin-1β (IL-
1β), IL-6 and tumor necrosis factor-alpha (TNF-α)] in AHF increases oxidative stress (OS), 
inflammation and vasoconstriction (Colombo et al., 2015). 






Endothelial cells are activated by biomechanical forces due to wall stress (circumferential or shear) 
and/or hydrostatic pressure. These cells then phenotypically switch from a quiescent to a 
vasoconstricted, pro-inflammatory, pro-oxidant activated state.  Biomechanical stress to endothelial 
cells causes increased ROS production and associated endothelial nitric oxide synthase (eNOS) and 
inducible nitric oxide synthase (iNOS) up regulation and activity. Increased ROS can either interact 
with the elevated nitric oxide (NO) levels to produce reactive nitrogen species (RNS), or ROS can 
Figure 1.6: Hemodynamic pathophysiology of systemic and pulmonary edema. HF: heart 
failure, DNV: distended neck veins, RAAS:  renin-angiotensin-aldosterone-system, LAP: left atrial 
pressure, LVEDP: left ventricular end diastolic pressure, PAP: pulmonary arterial pressure, 
PCWP, pulmonary capillary wedge pressure. Image adapted from Hummel et al., 2015.  




oxidatively degrade NO thereby leading to vasoconstriction. It is also possible that ROS and cytokines 
can trigger the nuclear factor (NF)-κB inflammatory response that would lead to cyclo-oxygenase-2 
(COX-2) expression. This led Colombo et al. (2015) to put forward that the above-mentioned fluid 
redistribution (vascular pathway) and fluid accumulation pathway do not act in isolation, but that 
rather that there is a positive feedback system cycling between the two pathways. This results in a 
mismatch between pre- and afterload and cardiac function that leads to ADHF (Colombo et al., 
2015). 
Fluid redistribution and fluid accumulation are also linked to increased arginine vasopressin (AVP) 
release. Abnormal release of vasopressin overrides AVPs osmotic regulation and leads to additional 
water absorption so contributing to hyponatremia in AHF (Cotter et al., 2008; Pearse & Cowie, 2014; 
Verbrugge et al., 2015). AHF volume and pressure overloads (but not normal hearts) show increased 
TNF-α levels and this has received some attention - it seems TNF-α exerts its effect by inducing NO 
and/or by dampening the Ca2+ concentration during systole. TNF-α in HF-related studies has been 
associated with premature death, effects on β-adrenergic receptors and left ventricular remodeling 
and contractile dysfunction (Chen et al., 2008).  
Left ventricular diastolic dysfunction is regularly associated with a combination of two mechanisms 
(Laribi et al., 2012). Firstly, reduced left ventricular dispensability occurs together with the 
associated pulmonary diastolic blood pressure (PDBP) that is upstream of increased left ventricular 
end diastolic pressure. These are, however, a consequence of intrinsic muscle impairment (i.e. 
ventricle rigidity due to diabetes) and/or left ventricular remodeling that frequently results in 
pressure overload (systolic blood pressure). For the second mechanism there is altered ventricular 
filling due to relaxation time elongation in situations of hypertension and concentric left ventricular 
remodeling. This would occur during fluid overload or arrhythmias in which case the filling time is 
decreased and the resultant (inadequate) filling leads to increased pressure upstream and finally to a 
reduced ejection fraction (Laribi et al., 2012).  




Left ventricular failure is a vicious cycle where initial compensatory mechanisms aimed at temporary 
relief exacerbates pathology in the long run. With left ventricular failure, decreased renal perfusion 
activates RAAS that initially assists in maintaining cardiac output but is detrimental in the long run. 
RAAS is responsible for increased vasoconstriction (initially maintains vital organ perfusion), sodium 
(Na+) and water reabsorption and retention to enhance ventricular preload and also for interstitial 
fibrosis. These mechanisms all have the important outcomes of causing vasoconstriction, eccentric 
ventricular hypertrophy, Na+ retention and myocardial fibrosis. Aldosterone is also responsible for 
eccentric ventricular hypertrophy, Na+ retention and fibrosis in addition to coronary vasculopathy 
and cytokine activation. Left ventricular failure also triggers arterial baroreceptors to detect the 
reduced cardiac output and so initiates increased sympathetic activation by increasing 
norepinephrine levels. This sympathetic intervention leads to enhanced contractility, heart rate and 
wall stress. Myocardial hypertrophy occurs as a compensatory mechanism with the aim to preserve 
the wall stress as the ventricle dilates. However, this causes ventricular remodeling that feeds back 
to the start of the chain reaction to exacerbate the initial left ventricular failure. Ventricular dilation 
and volume expansion occurs in an attempt to increase ventricular preload, a compensatory 
mechanism based on the Frank-Starling mechanism. Increased diastolic filling and stretch results in a 
more forceful contraction therefore increased stroke volume and cardiac output (Haydock & Cowie, 
2010; Krum & Abraham, 2009).  
Left ventricular and arterial stiffness is common in patients with preserved ejection fraction. Such 
individuals are extremely sensitive to even a remote rise in volume (preload and afterload) as they 
generally exhibit high diastolic pressures in small diastolic volumes. Thus a slight increase in volume 
could have one of two consequences or a combination thereof: a) a robust increase in left 
ventricular end diastolic pressure and b) an elevation in relative afterload causes afterload mismatch 
that significantly slows left ventricular active relaxation. This “mismatch” refers to a discrepancy 
between the increasing afterload and impaired systolic performance. This results in increased left 
ventricular end diastolic pressure and reduced cardiac output. Slowing of relaxation leads to the 




cardiac pressures transferring back to the pulmonary system; the pulmonary venous pressure in turn 
is transferred back to the alveoli and in this way contributes to pulmonary edema (Cotter et al., 
2008; Phan et al., 2012).  
The elevated systolic blood pressure occurring in AHF female patients can have one of two roles in 
pathology. Here it can exacerbate an already dire situation by undue vasoconstriction and increased 
afterload. But as this is more common in women with preserved left ventricular ejection fraction, it 
may well be a by-product of the pre-existing AHF via neurohormonal and cardiac activity (Metra et 
al., 2010). 
In summary, dyspnea or pulmonary congestion arises in response to erratic cardiac pressures and 
the resulting activation of compensatory mechanisms, whereas systemic or venous congestion is 
caused by a mismatch between pre- and afterload.  Left ventricular failure is the pathological 
outcome of prolonged compensatory mechanisms and left ventricular diastolic dysfunction is the 
combined result of left ventricular reduced dispensability and altered ventricular filling. Lastly, 
patients with preserved ejection fraction are exceptionally sensitive to small increases in volume as 
this results in pre- and afterload mismatch thereby fueling the vicious cycle. Co-morbidities (obesity 
and diabetes) will now be discussed – bear in mind that these should ideally not be considered in 













1.7.2 Molecular effects of co-morbidities 
1.7.2.1 Obesity 
Being saddled with obesity can result in far-reaching and varied effects, including cardiac structure 
and function, neurohormonal and cellular effects and both central and peripheral hemodynamics 
(Lavie et al., 2013). Excess body weight correlates proportionately and positively with total blood 
volume and cardiac output (Alexander & Alpert, 1998; Alpert, 2001). Increased left ventricular stroke 
volume and work is responsible for the higher cardiac output and work (Alpert, 2001). Left 
ventricular failure and associated diastolic dysfunction is common in obese patients (Alexander, 
1964; Lavie et al., 2009), while in the presence of hypertension it was found that concentric 
hypertrophy predominates (Alpert et al., 1998; Messerli et al., 1983a; Messerli et al., 1983b). Lavie 
et al., 2013 proposed that excessive adipose accumulation leads to increased fat-free mass and 
decreased systemic vascular resistance, followed by higher circulating blood volume, left ventricular 
stroke volume and cardiac output. In parallel, there is no perceivable change in heart rate. Left 
ventricular enlargement, together with hypertension result in increased wall stress causing left 
ventricular hypertrophy.  Mild/inadequate hypertrophy leads to left ventricular systolic dysfunction 
while severe/adequate hypertrophy results in left ventricular diastolic dysfunction. The excessive 
adipose accumulation observed could also result in sleep apnea, while obesity hypoventilation 
syndrome leads to hypoxia and/or acidosis that culminates in pulmonary arterial hypertension (and 
increased cardiac output) that causes right ventricular hypertrophy and enlargement. Left 
ventricular failure can also operate on a feedback basis to cause pulmonary venous hypertension 
leading to pulmonary arterial hypertension resulting in right ventricular failure. Neurohormonal 
changes associated with obesity are insulin resistance and hyperinsulinemia, leptin insensitivity and 
hyperleptinemia, reduced adiponectin, sympathetic nervous system activation, activation of RAAS 
and overexpression of peroxisome proliferator-activator receptor (PPAR) (Lavie et al., 2013).  




Adipocyte endocrinology as a new research field only really gained momentum after 1994 when 
Zhang and colleagues found that adipocytes produced the hormone leptin (Zhang et al., 1994). Thus 
it is now clear that adipose tissue is not a mere energy reservoir but an active endocrine organ with 
far-reaching effects.  Obesity can therefore now be linked to CVD via its inflammatory role with 
inflammatory cytokines (produced by adipocytes and macrophages) secreted when macrophages 
are activated due to abnormal levels of lipids, FAs and cytokines.  Leptin, adiponectin, TNF-α, IL-1 
and IL-6 make up the inflammation-related adipokines, while pro-coagulant substances include 
plasminogen activator inhibitor−1 (PAI-1). Vasoactive substances include leptin, angiotensinogen 
and endothelin. Various modulators that may contribute to insulin resistance are also secreted by 
adipocytes, e.g. FAs, TNF-α and resistin (Wang & Nakayama, 2010). In obese individuals macrophage 
accumulation (Weisberg et al., 2003) and activation result in  inflammatory cytokine secretion (Fried 
et al.,1998) that reaches the liver via the portal circulation and leading to hepatic inflammation 
(Tarakçioglu et al., 2003). This in turn can induce a systemic inflammatory response that together 
with the effects of hypertension, diabetes and hypercholesterolemia can trigger endothelial 
dysfunction. Subsequently, there is the release of a variety of mediators and surface proteins, 
vascular tone changes and increased fibrinolysis and coagulation. With the additive effects of 
obesity-induced systemic OS this ultimately results in atherosclerosis - a key risk factor for 











In situations of hemodynamic disruption e.g. AHF there will be serious consequences as kidney 
function is highly dependent on the hemodynamics of a patient. Venous pressure, hypotension, 
neurohormonal activation and renal hypoperfusion are all part of an interconnected web whereby 
AHF causes kidney dysfunction (Metra et al., 2010). This can occur in the absence of CAD and here 
the left ventricle displays hypertrophy together with systolic and diastolic dysfunction - the so-called 
diabetic cardiomyopathy (DCM) (Poornima et al., 2006).    
DCM is a clinical condition where cardiovascular damage presents in diabetic patients. It is 
characterized by left ventricular hypertrophy, systolic and diastolic dysfunction and myocardial 
dilation (Voulgari et al., 2010). DCM is independent of the presence of ischemic heart disease and 
hypertension, although hypertension frequently co-exists and accelerates the underlying functional 
pathology. DCM is an exceptional condition with far-reaching influences and intertwined pathology, 
of which the full discussion lies outside the scope of this review (Poornima et al., 2006; Voulgari et 
al., 2010).  The three hallmarks of DCM, namely obesity, insulin resistance and hyperglycemia will be 
briefly covered in the following paragraphs. 
Obesity (increased FAs and triglycerides [TG]) is a predisposition for type 2 diabetes, dyslipidemia 
and hypertension. Higher FA production by the adipose tissue due to increased leptin, sympathetic 
innervation and TNF-α is implicated in lipotoxicity, apoptosis, insulin resistance and myocardial 
contractile dysfunction. Increased FAs can lead to insulin resistance by activation of atypical protein 
kinase C (PKC) that impairs insulin transduction through the insulin receptor substrate-1 (IRS-1) and 
the phosphatidylinositol 3-kinase (PI3-K) pathway (Kim et al., 2001). FAs can also prevent the 
activation of protein kinase B (AKT-1) through up regulation of the phosphatase and tensin homolog 
deleted on chromosome 10 (PTEN) (Schwartzbauer & Robbins, 2001). The reaction between the 
palmitoyl-CoA (an intracellular FA intermediate) and ceramide can result in lipotoxicity (lipid-induced 
apoptosis) (Unger & Orci, 2000; Zhang et al., 2001). Myocardial contractility can also be directly 




altered by FAs though ATP-sensitive potassium channel (KATP) channel opening (Unger & Orci, 2000).  
Obesity is also marked by reduced levels of adiponectin (insulin-sensitizing modulator) and may 
therefore contribute to insulin resistance onset (Yamauchi et al., 2001). Insulin resistance is 
associated with elevated levels of C-reactive protein (CRP) (a marker of the acute phase of 
inflammation) and this is associated with increased DCM risk (Festa et al., 2000; Ridker et al., 2000). 
The catastrophic relationship between over nutrition (obesity) and cardiac insulin resistance can 
loosely be divided into four cellular events (Figure 1.7). It is noteworthy that the described 
pathological situations all revolve around the phosphorylation of serine residues of IRS-1. This 
decreases phosphorylation of tyrosine on IRS-1, association with PI3-K (p85 subunit) and it triggers 
its proteasome–dependent degradation (Aroor et al., 2012).  
Insulin resistance results in compensatory hyperinsulinemia, another hallmark of diabetes that can 
trigger multiple pathways that can lead to cardiac hypertrophy. The PI3-K/AKT-1 pathway stimulates 
one of two paths in order to increase the nuclear transcription of the hypertrophy program, i.e. it 
can deactivate glycogen synthases kinase-3β (GSK-3β) (Morisco et al., 2005) or activate the 
mammalian target of rapamycin (mTOR) (Khamzina et al., 2005). Hyperinsulinemia may also enhance 
AKT-1 activation through increased stimulation of the sympathetic nervous system via protein kinase 
A (PKA) and calcium-calmodulin dependent kinase (CaMK) (Morisco et al., 2005). In order to increase 
the nuclear transcription of the hypertrophic response, Rho and Ras can be prenylated (directly or 
indirectly) via the p38 mitogen-activated protein kinase (MAPK) pathway (Wang et al., 2004). Of 
note, it is simplistic to only implicate hyperinsulinemia in the onset of cardiac hypertrophy. Insulin 
resistance disrupts multiple systems that interact to cause, among others, myocardial cell death, 
contractile dysfunction, attenuated ATP production and decreased cardiac efficiency. Eventually the 
heart succumbs to the demands placed on it and fails (Figure 1.8) (Aroor et al., 2012).  
 





Figure 1.7: Cellular events as obesity (over nutrition) contributes to impaired insulin signaling. 
(1) Over nutrition results in increased levels and uptake of fatty acids, diacylglycerol (DAG) and 
ceramide accumulates that phosphorylates serine of insulin receptor substrate-1 (IRS-1). 
Hyperglycemia can also trigger the phosphorylation of IRS-1, activate protein kinase C (PKC) and 
upregulate angiotensin II. Excess glucose and amino acids both activate the mammalian target of 
rapamycin (mTOR)/S6 kinase (S6K). (2) Dysregulation of adipocyte function increases secretion of 
inflammatory markers such as interleukin-6 and tumor necrosis factor-alpha  (TNF-α) that 
activate mitogen-activated protein kinase, PKC, mTOR/S6K and IRS-1 degradation mediated by 
suppressor of cytokine signaling-3. (3) Through renin-angiotensin-aldosterone-system (RAAS) 
activation, aldosterone and AngII activate nicotinamide adenine dinucleotide phosphate (NADPH) 
oxidase complexes to generate radical oxygen species (ROS) that stimulate isoenzymes, MAPK 
and S6K, all able to phosphorylate IRS-1. It is also suggested that cross talk exists between RAAS 
and mTOR/S6K. (4) Mitochondrial stress acts through serine phosphorylation of IRS-1. ER stress is 
proposed to contribute via MAPK C-Jun N-terminal kinase (JNK) activation. ERK-1/2: extracellular 
signal-regulated kinase-1/2, PI3-K: phosphatidylinositol 3-kinase, AKT-1: protein kinase B, PKC: 
protein kinase C, GLUT-4: glucose transporter-4, AMPK: adenosine 3', 5'-monophosphate-
activated protein kinase, FATP: fatty acid-transporter protein, PPAR-α: peroxisome proliferator 
activated receptor- alpha, MCT: monocarboxylate transporter, CPT-1/2: palmitoyltransferase-1/2, 
FA-: fatty acid anions, ADP: adenosine 5′-diphosphate, ATP: adenosine 5′-triphosphate, UCPs: 
uncoupling proteins, MPTP: mitochondrial permeability transition pore, H+: proton/ hydrogen 
ion, ΔμH
+: change in electrochemical gradient, MIM: mitochondrial inner membrane, MOM: 
mitochondrial outer membrane. Image adapted from Aroor et al., 2012.   









Figure 1.8: Dysfunctional roads to heart failure due to insulin resistance and associated 
oxidative stress. Insulin resistance and all its cofactors converge to cause heart failure by mainly 
targeting calcium handling in the sarcoplasmic reticulum (SR), flexibility of cardiac metabolism, 
mitochondrial and endothelial function. RAAS: renin-angiotensin-aldosterone-system, TNF-α: 
tumor necrosis factor-alpha, IL-6: interleukin-6, Ca2+: calcium, ER: endoplasmic reticulum, RyR:  
ryanodine receptors, NCX: Na+/Ca2+ exchanger, SERCA-2a: sarco(endo)plasmic reticulum calcium-
ATPase-2a, PPAR-α:  peroxisome proliferator activated receptor- alpha, PDHK-4: pyruvate 
dehydrogenase kinase-4, ROS: radical oxygen species, eNOS: endothelial nitric oxide synthase, 
NO:  nitric oxide, ET-1: endothelin-1, ATP: adenosine 5′-triphosphate. Image adapted from Aroor 
et al., 2012.   




Hyperglycemia leads to increased GO and production of mitochondrial SO2∙
- in mitochondria 
(Nishikawa et al., 2000). Hyperglycemic-induced injury can be mediated by alternative pathways that 
are activated when glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is inhibited by poly (ADP-
ribose) polymerase (PARP) in response to SO2∙
- -mediated deoxyribonucleic acid (DNA) damage. 
Glucose is subsequently diverted away from glycolysis into non-oxidative glucose pathways (NOGPs) 
i.e. advanced glycation end products (AGEs), hexosamine biosynthetic pathway (HBP), polyol and 
PKC pathway. This can lead to hypertrophy, increased ventricular stiffness, impaired filling and 
relaxation and prolonged Ca2+ transients by mechanisms involving collagen crosslinking, altered 
function and expression of ryanodine receptors (RyR) and sarco(endo)plasmic reticulum calcium-
ATPase-2 (SERCA-2) and increases in extracellular matrix (Bidasee et al., 2003; Clark et al., 2003; 
Herrmann et al., 2003; Wakasaki et al., 1997). The effects of AGEs can be direct and also be 
mediated through specific receptors (RAGE) to activate TNF-α, VCAM-1, NF-κB, and interleukin that 
contribute to the inflammatory component of pathology (Ban & Twigg, 2008). Thus hyperglycemia 
activates multiple pathophysiological mechanisms (Mapanga & Essop, 2015) that eventually 
contributes to the characteristic pathology found with DCM (Dei Cas et al., 2015) (Figure 1.9).  
Although DCM occurs independently of hypertension, these commonly co-exist in a synergistic 
manner and as a result there are shared pathologic pathways. For example, dyslipidemia 
(characteristic of DCM) also plays a key role in hypertension.  Low-density lipoprotein (LDL) 
ultimately exacerbates and promotes vasoconstriction as the oxidized form suppresses endothelial 
NO production, thereby stimulating constriction. In addition, vasorelaxation is impaired by 
hypertriglyceridemia (Goode et al., 1995). 
This overview briefly provided a synopsis of the key hallmarks of DCM, namely obesity, insulin 
resistance and hyperglycemia.   The central theme arising from this discussion is the significant, 
causative role played by altered metabolism. The next (short) section will summarize clinical data 




regarding the contributions of altered cardiac energy status due to conditions such as obesity, 




Figure 1.9: Characteristic pathological pathways activated by hyperglycemia in diabetic 
cardiomyopathy (DCM). Hyperglycemia has direct and indirect effects on the myocardium. Most 
notably is the decreased glucose oxidation (GO) and increased glucose flux into non-oxidative 
glucose pathways (NOGPs) that result in multiple pathologies. GLUT: glucose transporter, VEGF: 
vascular endothelial growth factor, PPAR-α: peroxisome proliferator activated receptor- alpha, 
PDH: pyruvate dehydrogenase, FA: fatty acid, FAO: fatty acid oxidation, Ca2+: calcium, RAAS: 
renin-angiotensin-aldosterone-system, DAG/PKC: diacylglycerol/protein kinase C, NO: nitric 
oxide, HBP: hexosamine biosynthetic pathway, SERCA: sarco(endo)plasmic reticulum calcium-
ATPase, eNOS: endothelial nitric oxide synthase, Bcl-2: B-cell lymphoma-2, BAD: Bcl-2-associated 
death promoter, NADH+: nicotinamide adenine nucleotide, GSH: glutathione, TNF-α: tumor 
necrosis factor-alpha, MPTP: mitochondrial permeability transition pore, RyR: ryanodine 
receptors, Na+/K+: sodium/potassium, AGE:  advanced glycation end products, LDL: low-density 
lipoprotein, HDL: high-density lipoprotein. Image adapted from Dei Cas et al., 2015. 




1.7.3 Metabolism of the failing heart  
Females are known to have enhanced cardiac work, lower efficiency, greater myocardial blood flow 
and higher oxygen consumption (Chareonthaitawee et al., 2001; Herrero et al., 2005). In parallel, 
they display higher myocardial FA utilization and oxidation but lower glucose utilization (Desrois et 
al., 2004; Peterson et al., 2007; Peterson et al., 2008). Here the greater percentage body fat ensures 
increased FA release into circulation and therefore greater myocardial FA delivery likely contributes 
to such metabolic differences (Mittendorfer, 2005). Substrate competition (FAs vs. glucose) may 
explain the lower glucose utilization in females although the role of sex hormones should not be 
overlooked. Here studies demonstrated that estrogen decreases GO, gluconeogenesis and 
glycogenolysis, but increases FAO in skeletal muscle and the liver (Kendrick & Ellis, 1991; 
Mittendorfer, 2005). Estrogen may also increase cardiac oxygen consumption by uncoupling 
mechanisms (Peterson et al., 2007; Peterson et al., 2008). Whatever the explanation, such metabolic 
differences become even more apparent in pathological conditions (HF, hypertrophy, diabetes and 
obesity) that affect cardiac metabolism. 
Diabetes and obesity are conditions where insulin resistance occurs and both involve alterations to 
myocardial FA and glucose metabolism, cardiac steatosis and phosphate energy metabolism (Table 
1.4) (Iozzo, 2010). Moreover, FA metabolism is positively correlated to BMI and insulin resistance for 
females (but not males). Glucose availability is lowered by the interaction of myocardial blood flow 
and oxygen consumption – obesity and female gender are independent predictors for both (Knuuti 
et al., 2001; Peterson et al., 2004; Peterson et al., 2008). With especially type 2 diabetes and obesity, 
peripheral insulin resistance increases plasma FA levels thereby leading to higher FA delivery to the 
myocardium and thus increased FA uptake and oxidation. GLUT expression and insulin-mediated 
glucose transport are both decreased under such circumstances (Boudina & Abel, 2007; Young et al., 
2002). Type 2 diabetes and obesity are also characterized by cardiac stenosis that further 
exacerbates the metabolic shift by providing additional FAs (Kankaanpää et al., 2006; McGavock et 




al., 2007; Rijzewijk et al., 2008; Szczepaniak et al., 2003). Moreover, insulin resistance and obesity 
result in significant declines of the phosphocreatine/ATP (PCr/ATP) ratio (Perseghin et al., 2007). 














↓ → ↑ ↓ ↑ ↓ → 
Obesity ↓→  ↑ ↑ ↑ ↓ ↓ 
Diabetes        
Type 1 ↓ → ↑  ↑ ↓→ ↓ 
Type 2  ↓ ↑→ ↑   ↓ 
Hypertension        
- Hypertrophy  ↑→   ↑ → → 
+ Hypertrophy  ↑→ ↓  → ↓ ↓ 
+ Dysfunction   ↓  → ↓ ↓ 
Heart failure        
Coronary* ↓ ↓ ↑  ↓→ ↓ ↓ 
Idiopathic ↑ ↓→ ↓ ↓ ↓→ ↓ → 
 
We will now focus on the last component contributing to cardiac energy metabolism, i.e. the 
differences between males and females. Please note that this section will only cover the effects on 
cardiac metabolism as sex differences in pharmacokinetics and dynamics is a vast field and lies 
outside the scope of this review.    
  
Table 1.4: Derangement in myocardial substrate metabolism.  Pathologic states mediate 
damage by alterations of substrate availabilities to the myocardium. GU: glucose uptake, FAU: 
fatty acid uptake, TG: triglycerides, PCr/ATP: phosphocreatine/ATP, ↑: increased, ↓: decreased, 
→: normal. * non-ischemic, non-dysfunctional regions. Table from Iozzo, 2010.  




1.8 Effects of sex hormones 
Dr. Sliwa points out that it is important to distinguish between sex and gender, even in molecular 
studies. Sex is the biological variations between men and women, i.e. the relative differences of sex 
hormones and different X and Y chromosome gene expressions (Regitz-Zagrosek, 2012).  Sex steroids 
cause a wide variety of genes to respond in a sexually dimorphic way. For example, estrogens can 
cause the up- or down-regulation of genes in especially males, while the same is true for androgens. 
By contrast, gender encompasses the social and cultural differences between men and women, i.e. 
stress- and lifestyle- associated differences. Factors such as acceptance of invasive procedures, 
nutritional choices and gender-based exercise behavior have important consequences for gender-
specific disease states (Regitz-Zagrosek, 2012). Although this review acknowledges the important 
role of gender in CVD, the focus will be solely on sex as the biological actions of sex steroids can be 
independent regulators in cardiac metabolism and function (Wittnich et al., 2013).   
The tenacious nature of sex differences in the clinical presentation of HF leads to the conclusion that 
a lot may be due to fundamental sex differences in cardiac physiology. Multiple clinical- and animal-
based studies have therefore set out to investigate such differences in resting cardiac function (Ben-
Sira & Sagiv, 1997; Beyer et al., 2001; Capasso et al., 1983; Convertino, 1998; Haykowsky et al., 1998; 
Leblanc et al., 1998; Lerner & Kannel, 1986; Merz et al., 1996; Younis et al., 1990). However, some of 
the data generated were contradictory and led to the conclusion that significant results were 
reflective not of inherent performance differences, but rather due to load differences.  As a result 
some investigated isometric and isotonic contractions while controlling for pre- and afterload and 
found that there are no inherent sex differences (Capasso et al., 1983).  Thus the end results do not 
differ, but in essence it comes down to how the heart achieves its end parameters (Wittnich et al., 
2013). To further elucidate this, research also focused on sex differences in terms of cardiac 
excitation-contraction coupling and associated Ca2+ handling (Parks & Howlett, 2013). For example, 
comparative research work concentrated on contractile functional differences (Curl et al., 2001; 




Farrell et al., 2010; Howlett, 2010; Schwertz et al., 2004; Vizgirda et al., 2002) and ovariectomy 
studies reported on Ca2+ transients,  myofilament, sarcoplasmic reticulum (SR) Ca2+ sparks, SR Ca2+ 
content, Ca2+ current, diastolic Ca2+ and Na+/Ca2+ exchanger (NCX) currents (Bupha-Intr et al., 2007; 
Fares et al., 2012; Kravtsov et al., 2007; Ma et al., 2009; Wattanapermpool & Reiser, 1999). It is clear 
that estrogen is not solely responsible for all such discrepancies. However, its unique role cannot be 
overlooked as it responds to signals of environmental, genetic and non-genetic origin (Konhilas & 
Leinwand, 2007). For the purpose of this review, the focus will not be on electrical and contractile 
effects of estrogen, but rather on its impact on metabolism, e.g. why healthy young human females 
utilize less glucose and more oxygen than age-matched male counterparts (Peterson et al., 2007). 
Skeletal muscle studies showed that estrogen decreased GO, gluconeogenesis and glycogenolysis, 
while it elevated FAO (Campbell & Febbraio, 2001). If this applies to the myocardium then it means 
that females rely more on FAO together with higher myocardial oxygen utilization. This reflects 
previous findings to explain the “double-edged sword” theory that follows estrogens’ role in the 
heart (Wittnich et al., 2013). Here estrogen offers advantage under well-oxygenated and perfused 
states, while the opposite is true during situations of oxygen deprivation where glucose utilization 
predominates (more ATP per oxygen).  
Studies done on PPAR-α knock-out animals where CPT-1 was inhibited (Djouadi et al., 1998) and 
where lipoprotein lipase (LPL) was overexpressed (Nöhammer et al., 2003) demonstrate that 
females are better adapted to utilize FA and that they are also protected against increased FA levels  
compared to males (Konhilas, 2010). This ties in with data that show that larger VLDL particles with 
more triglycerides are secreted by female livers (Magkos et al., 2007). In addition, VLDL production is 
higher in women but also VLDL-TG clearance (Mittendorfer et al., 2003), meaning that basal lipolysis 
is upregulated providing increased plasma FAs for utilization (Nielsen et al., 2003; Spriet, 2002). This 
explains the higher LPL activity that is typically found in women (Farese et al., 1991; Spriet, 2002). 




Interestingly, LPL activity in adipose tissue and plasma is decreased by estrogen (Price et al., 1998; 
Urabe et al., 1996).  
Estrogen also phosphorylates and thereby activates AMPK in many tissues, including adipose and the 
myocardium (Arad et al., 2007; D'Eon et al., 2005). AMPK acts to increase FA uptake and oxidation 
and also enhances glucose transport and glycolysis. It seems plausible that during stressful 
conditions, females take advantage of this metabolic state to increase circulating levels of fuel 
substrates. Estrogen also phosphorylates and activates the insulin-like growth factor 1 signaling 
pathway (Kahlert et al., 2000; Richards et al., 1996). PI3-K is activated by this pathway together with 
the downstream phosphorylation of AKT-1, a central regulator of glucose metabolism (Kandel & Hay, 
1999). Conversely, estrogen can decrease glucose utilization in the myocardium by upregulating 
nitric oxide synthase (NOS). With NO overproduction leading to a decrease in AMPK-mediated GLUT-
4 cell surface translocation via the second messenger cyclic guanosine monophosphate (Sharkey et 
al., 1999; Skavdahl et al., 2005). Estrogen is also the sole modulator known to affect ATP synthesis at 
complex 1 within the ETC (Rattanasopa et al., 2015). It is not known how estrogen controls this 
balancing act in terms of cardiac energy metabolism and even less data exist regarding how results 
are affected in various pathological situations in patients with different clinical characteristics. To 
complicate matters even further, estrogen is not the only mediator in females although it dominates 
the follicular phase of the menstrual cycle.  However, during the luteal phase progesterone plays a 
more predominant role.   
Evidence is mounting that the protective effects of both estrogen and progesterone are rapid and 
non-genomic (Pang, Dong, & Thomas, 2015). Estrogen has received most attention while studies on 
the effects of progesterone are limited so far. However, some found that physiologically high levels 
of progesterone in both males and females are associated with increased CHF prevalence (Nilsson et 
al., 2009). Mechanistic studies of progesterone revealed contradictory findings owing to 
supraphysiological levels tested and the nature of diseased tissue studied (Cheng et al., 2012; 




Nakamura et al., 2007). These studies reported on Na+ efflux, Ca2+ uptake, action potential duration 
(Mendoza & De Mello, 1974) and force of contraction (Sitzler et al., 1996). The autonomic function 
has also been implicated in progesterone studies, i.e. systole duration is reduced upon progesterone 
exposure (Fuenmayor et al., 2000; Re et al., 1986). The first clues of progesterone’s role in energy 
metabolism only emerged more recently, i.e. mediating its effects via the progesterone receptor-α, 
to subsequently activate PI3-K/AKT-1 and MAPK in addition to increased eNOS activity and NO 
production (Pang et al., 2015; Simoncini et al., 2004).      
This concludes the underlying pathology section of this review.  The reader will note that there is no 
set understanding of AHF specific pathology, the best that can be done is to review the pathologic 
mechanisms of underlying etiologies. At present the nature of the “switch” that determines whether 
the heart will develop CHF, ADHF or acute de novo AHF remains unclear. 
The focus will now shift to current biomarkers and generic treatment of AHF, where after the 
emphasis will move to metabolism-derived therapies.  
  




1.9 Treatment of acute heart failure 
1.9.1 Biomarkers 
Despite the alarmingly poor understanding of its pathology, there has been a rapid accumulation of 
knowledge and understanding of the clinical presentation and characterization of AHF during the last 
few years (investigation into different characteristics between AHF and CHF patients only became 
“popular” since 2005). The increasing number of patients, the cost and sheer burden on health 
systems demand earlier diagnosis, improved risk stratification and treatment that is more cost 
effective. Moreover, the acute nature of this condition means that utilization of biomarkers remains 
a very useful tool for improved diagnosis (Maisel & Choudhary, 2012).   
Research efforts reflect this as hundreds of articles were published in this regard during the last few 
years (started gaining momentum from around 2007). Current biomarkers include BNP, N-terminal 
of the prohormone brain natriuretic peptide (NT-proBNP), cystatin C, neutrophil gelatinase-
associated lipocalin (NGAL), CRP, urinary albumin/creatinine ratio (UA/CR), galectin-3, suppression 
of tumorigenicity (ST2), L-type FABP (L-FABP), β-trace protein (β-TP), kidney injury molecule-1 (KIM-
1), procalcitonin, surfactant proteins, s100-B protein, adrenomedullin (MR-proADM),creatinine, 
blood urea nitrogen (BUN), IL-6, IL-10, IL-18, and TNF-α (Damman et al., 2012; Di Somma et al., 2012; 
Maisel & Choudhary, 2012; McCullough & Jefferies, 2015; Teichman et al., 2015). Although the use 
of biomarkers aims to achieve fast diagnosis, prognosis, therapeutic solutions and rapid discharge 
rates, a recent review reminded of the importance of patient history and physical examination 
(Schuetz et al., 2015). The significance of a patient’s overall gestalt (unified whole), rather than blind 
adherence to laboratory results was also emphasized. Patients suffer from hospital-acquired 
venipuncture, anemia and worrying hemoglobin levels as a result of bungles and repeats of “daily 
labs” (daily sample [blood, urine etc.] collections and ensuing laboratory testing). In addition, the 
test methodology, limitations, variations, interferences, false negatives and/or false positives are 
completely intertwined and can sometimes be misunderstood, leading to inaccurate conclusions. 




Thus it is the clinician’s responsibility to make a humane and educated treatment decision based on 
all research and observations.  
1.9.2 Current treatments 
As for any acute onset event, diagnosis and treatment is mostly carried out in parallel (Table 1.5). 
During this process the close monitoring of patients is of outmost importance as any change in 
condition may require rapid implementation of a different treatment regimen. For further treatment 
of suspected/confirmed AHFS, the immediate goal is to improve symptoms and to stabilize the 
hemodynamic condition. Equally important is the pre- and post-discharge care of such patients 
(McKelvie et al., 2012; McMurray et al., 2012; Nieminen et al., 2005).  
AHF patients are treated with basic therapy consisting mainly of loop diuretics, vasodilators, opioids 
and oxygen (Table 1.6). However, the generic nature of such interventions show that current 
therapies are not tailored/designed specifically for AHF. Alternative treatment modalities were 
recently proposed but were generally unsuccessful as it did not lower re-hospitalization rates or 
improve patient outcomes (Hummel et al., 2015). However, the crucial issue remains the ongoing 
failure to develop AHF-specific therapies  
Here a key issue is patient heterogeneity and plurality in terms of AHFS (Felker et al., 2010; Voors & 
Veldhuisen, 2012). There are similar signs/symptoms from a cluster of related diseases and yet this 
umbrella term contains subdivisions wherein parameters present differently. Thus it is unrealistic to 
expect one treatment to suit all. In addition, background or “standard therapy” varies extensively 
among studies – if it is indeed reported and it should be borne in mind that AHF treatment is 
routinely adjusted depending on patient progress. Natural disease history is also rarely reported and 
the limited information makes it hard to perform comparative studies. The inclusion criteria for 
studies are also variable, qualitative and subjective and hence the diagnosis often varies between 
hospitals, regions and studies. For example, inclusion of patients in trials that are not actually 
suffering from AHF dilutes the potential effects of the drugs being tested. Knowledge, understanding 




and implementation of intervention and treatment timing, duration and “therapeutic windows” are 
also suboptimal as are experimental endpoints. The choice of hard and/or soft endpoints and the 
general consensus around primary endpoints is of course also a critical study design issue. 
Regulatory requirements and approval of drugs and studies also greatly affect the design of 
international studies.  
 
Initial assessment 
History and physical examination, blood pressure, respiratory frequency, chest x-ray, ECG, 
echocardiography and/or NT-proBNP, blood-gas analysis, laboratory tests (including troponin, 
complete blood count, electrolytes, renal parameters, TSH, albumin, blood glucose). 
Simultaneous specific assessment Acute treatment 
Hypoxemia, hyperventilation, hypoventilation Oxygen; non-invasive  or invasive ventilation 
Life-threatening arrhythmia or 
bradycardia 
Electric cardioversion, external 
pacemaker 
Blood pressure <85 mmHg or shock Inotropic agents, vasopressors, 
mechanical circulatory support 
Acute coronary syndrome Coronary reperfusion, antiplatelet agents, 
anticoagulation 
Acute mechanical cause/severe valvular 
disease 











Table 1.5: Parallel assessment and treatment of acute heart failure.  Acute diagnostic 
assessment is based on the unique clinical presentation of each patient. ECG: 
electrocardiography, NT-proBNP: N-terminal of the prohormone brain natriuretic peptide, TSH: 
thyroid stimulating hormone. Table from Hummel et al., 2015.  




Pharmacological therapy:  
Acute management 
Other pharmacological therapies are used like 
anticoagulants and vasopressin V2-receptor 
antagonists. However these come with 
contraindications and uncertain or extreme 
adverse side effects. 
Oxygen: Utilized to treat hypoxemia (SpO2 
<90%). Important to prevent end-organ 
dysfunction and multiple organ failure. 
Diuretics: Administered in the presence of fluid 
retention symptoms (peripheral and/or 
pulmonary edema). This leads to a decrease in 
extracellular fluid volume, plasma, total body 
water and sodium. This ultimately leads to 
reduced left and right ventricle filling pressures 
in addition to reduced edema. 
Pharmacological therapy:  
After stabilization 
ACE-inhibitors:  Achieves its hemodynamic effect 
through decreased AII and bradykinin level 
increases. This results in general and total 
decreases in peripheral vascular resistance. 
Opiates: Administered to patients with dyspnea 
associated anxiety and distress. They induce 
venodilation (reduced preload), mild arterial 
dilation and also serve to reduce sympathetic 
drive or heart rate. 
Mineralocorticoid (aldosterone) receptor 
antagonists and Digoxin (anti-arrhythmia drug): 
Advised on the condition that there are no 
contra-indications involved. 
Vasodilators: Of most use to hypertensive 
patients. They increase stroke volume and lower 
preload and afterload. 
Beta-blockers: Can limit infarct size and reduce 
arrhythmias and pain. 
Inotropes: Administered as a last resort and with 
much caution. These patients have drastically 
low cardiac output, to the point of 
hypoperfusion of vital organs. These are 
hypotensive “shocked” patients. 
Non-pharmacological/non-device therapy 
Non-invasive ventilation such as NIPPV and CPAP 
do relief dyspnea and it also improves some 
physiological measurements such as oxygen 
saturation. However if a patient is experiencing 
symptoms such as respiratory failure (acidosis 
and hypoxemia) and diminished consciousness, 
then endotracheal intubation must be utilized. 
Mechanical circulatory support devices include 
intra-aortic balloon pumps to support circulation 
before surgical corrections and ventricular assist 
devices. Ultrafiltration (venovenous isolated) can 
be used to remove fluid when patients are 
resistant and/or unresponsive to diuretics. 
Vasopressors: Epinephrine and norepinephrine 
are administered only in case of emergencies (to 
sustain life) where a patient is in life threatening 
hypoperfusion after diuretics and inotropes have 
failed. They redeploy the cardiac output from 
the extremities to the vital organs and raise the 
blood pressure. 
Dopamine: Have inotropic and vasoconstrictor 
effects at high doses and at low doses has renal 
arterial vasodilator (selective) effects. 
 
  
Table 1.6: Untailored treatment for acute heart failure (AHF).  Treatment of AHF can be divided 
into two categories, namely pharmacological (acute management and after stabilization) and 
non-pharmacological/non-device therapy. SpO2: arterial oxygen saturation, ACE: angiotensin 
converting enzyme, AII: angiotensin II, NIPPV: non-invasive positive pressure ventilation, CPAP: 
continuous positive airway pressure. Table adapted from McKelvie et al., 2012; McMurray et al., 
2012; Nieminen et al., 2005. 




1.10 Movement towards metabolic-mediated therapies 
The relative contribution of fuel substrates to ATP production is tightly controlled/regulated and this 
plastic process includes the interdependence of substrates. Here shifts in substrate selection and 
utilization can occur rapidly and multiple times a day depending on changing situations, availability 
of substrates and/or hormone changes.  
Cardiac function and efficiency is strongly reliant on the relative contributions of FAO. For example, 
if a pathologic state disrupted such homeostasis it would alter cardiac metabolism, function and 
efficacy into a spiral towards cardiac injury. This is not a new concept and the first description of the 
so-called Randle effect was already published in 1961 (Garland et al., 1963; Randle et al., 1963; 
Randle et al., 1964). Thus an intriguing question emerges regarding the failure of hemodynamically-
related drugs (previously discussed) and whether targeting cardiac metabolism/energetics may 
instead provide novel therapeutic opportunities.  
Such ‘’metabolic’’ drugs mainly fall into one of four categories based on specific target sites. The first 
group is targeted at the availability of circulating FAs: glucose-insulin-potassium therapy (GIK), β-
adrenoceptor antagonists and PPAR-α agonists. The second group targets the uptake of 
mitochondrial FA: etomoxir (CPT-1 inhibitor), perhexiline (CPT-1 inhibitor) and malonyl-CoA 
decarboxylase inhibitors. The third group targets mitochondrial FAO: trimetazidine (TMZ) (discussed 
next) is a 3-KAT inhibitor and ranolazine (multiple sites of action). The last group targets the PDH 
complex and GO: PDHK inhibitors (Jaswal et al., 2011). 
The reader will notice the focused attention on only glucose and FA metabolism. This is because in 
the absence of pathology, 60-80% of ATP production is generated from FAO, while the remainder is 
derived from carbohydrate (glucose and lactate) and also from ketone bodies (Bing et al., 1954; 
Neely & Morgan, 1974; Opie, 1968; Opie, 1969).  A critical consideration to keep in mind is that the 
aim is not to completely shift or force cardiac metabolism to a sole substrate, but rather to restore 
homeostasis and metabolic plasticity.  




1. 11 Trimetazidine 
Studies investigating the therapeutic use of metabolic moderators have yielded inconsistent data, 
although it emerges that TMZ holds the most clinical promise (Tuunanen & Knuuti, 2011) as it is the 
most prescribed metabolic modulator and is available in more than eighty countries around the 
globe (Folmes et al., 2005). This anti-anginal drug is a partial inhibitor of the last enzyme of FAO, i.e. 
3-KAT. TMZ shifts cardiac metabolism to GO via the Randle cycle (Kantor et al., 2000; Lopaschuk et 
al., 2003). However, it has lately emerged that TMZ’s positive effects can also be due to other 
mechanisms (Parkhomenko & Gurjeva, 2014) that include an impact on inflammatory and 
endothelial function, proton reduction and effects on the MPTP. Thus the beneficial effects of TMZ 
are far reaching as further discussed below. 
TMZ showed positive clinical effects in patients with recurrent/stable angina where they showed 
improved exercise test duration, total workload, time to 1 mm ST segment duration and time to 
angina onset. Such patients also required decreased nitrate consumption and exhibited a lower 
number of angina attacks (Hu et al., 2011; Ribeiro, 2012; Ruzyllo et al., 2004; Szwed, 2004).   Within 
the context of ischemic reperfusion injury, TMZ displays effects on signaling pathways, ROS (Kutala 
et al., 2006), opening of the MPTP, the permeability of the mitochondrial membrane, OS, caspase-3 
activity, apoptotic and necrotic cell loss (Argaud et al., 2005), inflammatory cascades (Kuralay et al., 
2006), neutrophil accumulation and neutrophil-mediated injury (Tritto et al., 2005; Williams et al., 
1993), pro-survival AKT-1 enzyme, p38 MAPK (Khan et al., 2010) and eNOS (Di Napoli et al., 2007). 
Patients present with reduced dispersion of the Q-T interval and heart rate variability and a large 
myocardial infarction registry reported improved survival and reduced new incidents of 
myocardial infarction with TMZ (Kim et al., 2013). The employment of percutaneous angioplasty that 
accompanies myocardial ischemia treatment is also reduced (Polonski et al., 2002) with TMZ 
treatment. Patients show reduced pressure overload fibrosis via the nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase-ROS-connective tissue growth factor signaling pathway 




(Liu et al., 2010).  Here TMZ did not act via the expected FAO reduction, but rather by decreased 
proton production, i.e. decreasing glycolysis, recoupling glycolysis and GO and also by tempering 
acidosis (Liu et al., 2002; Liu et al., 1996; Saeedi et al., 2005). CAD patients treated with TMZ 
displayed a 30% greater survival rate versus controls (El-Kady et al., 2005) and here it seems the 
inflammatory system is targeted with reduced CRP, TNF-α and nitrite levels (Kuralay et al., 2006). In 
patients with idiopathic dilated cardiomyopathy improvements in walk tests and left ventricular 
contractility were noted, i.e. displaying lower B-type BNP levels (Zhao et al., 2013). Other studies 
also found reduced FAO, increased GO and favorable changes in ejection fraction, high-density 
lipoproteins (HDL) and insulin resistance was observed (Tuunanen et al., 2008; Zhao et al., 2013).  
Beneficial effects of TMZ have been found for unspecified, ischemic and non-ischemic HF.  Patients 
experience improved quality of life, New York Heart Association (NYHA) class, exercise tolerance, 
metabolic shift (FAO to GO), PCr/ATP ratio, whole body insulin sensitivity, ejection fraction, left 
ventricular diastolic function, left ventricular end diastolic volume, regional myocardial wall motion 
(at rest and stressed), functional capacity and endothelial function. Moreover, reduced mortality, 
hospitalizations and BNP levels have been documented (Gao et al., 2011; Jaswal et al., 2011; Ribeiro, 
2012; Tuunanen & Knuuti, 2011). There is also evidence that TMZ reversed left ventricular 
remodeling and limits the inflammatory response (Di Napoli et al., 2005; Fragasso et al., 2006).  Of 
note, a study on HF in rabbits found that TMZ’s benefits where not due to expected FAO outcomes, 
but instead due to mitochondrial cardio protective effects.  Here it lowered electron leaks from 
complex 2 in the ETC, improved the function of complex 1, uncoupled mitochondrial NOS (reducing 
ROS) and decreased the likelihood of MPTP opening (Dedkova et al., 2013). Thus the picture 
emerges that TMZ acts on multiple levels and thus raises the question whether it may offer 
therapeutic value for AHF patients.  





 ADHF is the most common primary diagnosis in heart disease patients admitted to African hospitals. 
Moreover, African women suffering from AHFS are younger, with significant stress on the 20-29 year 
old group and also more prone to suffer from acute de novo HF. This type of AHF is also associated 
with increased risk of death compared to other forms.  In addition, co-morbidities such as diabetes 
and obesity further complicate the picture.  In light of this bleak scenario the optimization of cardiac 
metabolism and especially TMZ emerges as a novel and worthy therapeutic option to investigate for 
the treatment of AHF. 
1.13 Hypothesis and aims 
For this study, we hypothesized that TMZ, a partial FAO inhibitor, offers cardio protection during 
AHF under normal and obese-related diabetic conditions and we further propose that the estrous 
cycle will influence such cardio protection. 
The aims of this study were: (1) to establish a de no AHF mouse model; (2) to test whether simple 
filtering could replace the gold standard dialysis method; (3) to identify and establish the four phases 
of the estrous cycle in the female mice; and (4) to evaluate the therapeutic value of TMZ under 
normal and obese-related diabetic conditions in both male and female mouse hearts subjected to a 
unique ex vivo model of AHF. We also tested the influence of the different phases of the estrous 
cycle (follicular and luteal) on the efficacy TMZ and assessed whether there were any sex differences 
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2.1 Animals and ethics statement 
 
Animals were treated in agreement with the Guide for the Care and Use of Laboratory Animals of 
the National Academy of Science (National Institutes of Health publication No. 85-23, revised 1996). 
This study was executed with the approval of the Animal Ethics Committees of Stellenbosch 
University (South Africa) (Addendum A). 
For the experimental procedure, 102 male and female diabetic (db/db) mice (12-14weeks) and their 
lean non-diabetic littermates (db/+) were purchased from Jackson Laboratories (Bar Harbor, Maine, 
United States). Animals were divided into 17 groups as set out in Table 2.1. Mice were housed six per 
cage in the animal housing facility under standard conditions and had ad libitum access to water and 
standard chow. 
Allocation of Animals 
Filter versus dialysis experiments Filter Dialysis 
Lean males n=6 n=6 
Acute heart failure experiments Control CAHF treated RAHF treated 
Obese males n=6 n=6 n=6 
Obese females n=6 n=6 n=6 
Lean males n=6 n=6 n=6 
Lean females (follicular phase) n=6 n=6 n=6 
Lean females (luteal phase) n=6 n=6 n=6 
 
  
Table 2.1: Group allocations. CAHF: critical acute heart failure, RAHF: recovery acute 
heart failure. 




2.2 Vaginal cytology 
 
The estrous cycle of females (12-14 weeks old) was determined by vaginal smear cytology or “wet 
smears” as previously described (Caligioni, 2009; Long & Evans, 1922; Marcondes et al., 2002; Wood 
et al., 2007). Because group-housed female mice do not display reliable regular estrous cycling 
(MacDonald et al., 2014; Whitten, 1958), bedding from young male mice were placed in the female 
cages a minimum of 5 days prior to performing estrous phase determination. Vaginal secretion was 
collected by inserting a pipette tip filled with 10 µl normal saline into the vaginal opening, taking 
care not to insert it too deep as to cause harm to the female. The saline was injected and the vaginal 
flush was collected in the same tip which was then transferred to a clean glass slide (Labstar frosted 
microscope slides, Lasec Laboratory Solution Provider, Cape Town, South Africa). The unstained 
material was viewed under a light microscope (YS 100, Nikon Co., Chiyoda, Tokyo, Japan) (without 
use of condenser lens) under 4x, 10x and 40x objective lenses. Three distinct cell types were present, 
namely epithelial cells (round and nucleated), cornified epithelial cells (irregular in shape, absence of 
a nucleus) and leukocytes (black, small and round). The ratio or proportion of such in the vaginal 
flush was used to determine estrous cycle phases. Proestrus was characterized by the predominance 
of epithelial cells; estrus by the majority of cornified epithelial cells; metestrus by the presence of a 
mixed cell type dominated by leukocytes and diestrus by the bulk of leukocytes.  
  




2.3 Testing filter versus dialysis 
 
Due to the sensitive nature of the ex vivo perfused mouse heart, perfusates containing bovine serum 
albumin (BSA) should be purified. Traditionally, researchers utilize the dialysis method but this is an 
expensive and time consuming method.  In light of this, we aimed to test whether filtering the 
perfusates would deliver comparative results.  
We excised (intramuscular injection of ketamine (100 mg/kg) and xylazine (5 mg/kg) (obtained from 
the animal facility manager) and perfused 12 lean male non-diabetic (db/+) mouse hearts at 
constant 100 cmH2O perfusion pressure for 30 minutes with Krebs-Henseleit buffer (Addendum B) 
with 10 mM/L glucose (#G7528, Sigma-Aldrich Co. LLC., St. Louis, Missouri, United States) and 1.2 
mM/L palmitic aid (#P0500, Sigma-Aldrich Co. LLC., St. Louis, Missouri, United States) bound to 3% 
BSA (BSA Fraction V, Roche Ltd., Basel, Switzerland) as previously described (Lopaschuk & Barr, 
1997). The buffer of the dialysis group (n=6) was dialyzed (#68100, SnakeSkin Dialysis Tubing [23µm], 
Thermo Fisher Scientific Inc., Waltham, Massachusetts, United States) overnight according to the 
stipulated protocol while for the filter group (n=6) we filtered the buffer through a low protein 
binding filter (Durapore Polyvinylidene fluoride [PVDF] 0.22 µm, Merck Millipore Co., Darmstadt, 
Germany) using the plastic structure of a bottle top vacuum filter (#431118, Corning Inc., New York, 
United States) and a vacuum pump (2522C-02, Welch, Niles, Illinois, United States) on the day of 
perfusion.   
  




 2.4 Acute heart failure retrograde Langendorff heart perfusion 
 
The mouse ex vivo Langendorff retrograde perfusion model of de novo AHF was adapted from a rat 
model previously set up (Deshpande et al., 2014; Deshpande, 2013; Deshpande et al., 2010; Opie et 
al., 2010).  
2.4.1 Perfusing mouse hearts 
 
Male and female mice (immediately following estrous phase determination) were anesthetized by 
an intramuscular injection of ketamine (100 mg/kg) and xylazine (5 mg/kg), the hearts rapidly 
excised and mounted on a cannula connected to the modified Langendorff retrograde perfusion 
model - flow from the stabilization phase was immediately commenced. The left atrial appendage 
was cut off and a deflated self-made balloon constructed from cling wrap (connected to a distilled 
water [dH2O]-filled catheter [Portex Jackson cat catheter with luer connection, 4F, Smiths Medical 
International Ltd., Kent, United Kingdom]) was placed into the left ventricle via the mitral valve. 
Using an insulin syringe connected to the pressure transducer (Stratham MLT 0380/D, AD 
Instruments Inc., Bella Vista, New South Wales, Australia) compatible with the PowerLab System 
ML410/W (AD Instruments Inc., Bella Vista, New South Wales, Australia), the balloon was inflated to 
fill the left ventricle.  A pacer (self-made) was connected to the right atrial appendage of the heart 
and set to 400 bpm. A buffer filled reservoir - correlating to each phase - was raised around the 
excised heart to maintain the heart at a stable temperature of 37.5˚C. The PowerLab System was set 
to record the following functional parameters: left ventricular end diastolic pressure (LVEDP), left 
ventricular end systolic pressure (LVESP), left ventricular developed pressure (LVDevP) [calculated as 
LVESP-LVEDP], heart rate, rate pressure product (RPP) calculated as [heart rate x LVDevP] and 
(dp/dt)max (an index of myocardial contraction velocity) [calculated as pressure difference in 
mmHg/time in sec]. 
 




2.4.2 Rationale of the model 
 
Each of the three phases (discussed below) was maintained for 25 minutes, for a total protocol 
duration of 75 minutes. The model consists of three phases, namely (1) stabilization, (2) critical acute 
heart failure (CAHF), and (3) recovery acute heart failure (RAHF) (Figure 2.1). Each phase can be 
independently induced by cut-off stop cocks at the other reservoirs. The buffer for all three phases 
was based on standard mouse Krebs-Henseleit buffer, with deviations only in glucose and FA 
concentrations (Addendum B). All buffers were gently gassed with 95% O2/5% CO2 (#801068-RC-A, 
AFROX, Gauteng, South Africa) for 20 minutes prior to perfusion and for the duration of the 
experiment. The system consists of a series of double-jacketed glass reservoirs connected by piping. 
A water bath (HAAKE SC100 & S3, Thermo Fisher Scientific Inc., Waltham, Massachusetts, United 
States) constantly circulates heat-controlled water through the outer jacket of the system to 
maintain the perfusate temperature in the reservoirs at 37.5 °C.   
Stabilization phase:  
 
This phase is solely to stabilize the heart and to achieve baseline functional parameters. It also 
functions to flush the heart of any residual blood that could introduce metabolites into the model, 
potentially affecting the function.  This phase is perfused at 100 cmH2O perfusion pressure with 
glucose (10 mM/L) as the sole substrate. Hearts that do not achieve a stable heart rate of 400 ± 20 
beats per minute (bpm) and a left ventricular developed pressure of >20 mmHg were excluded from 
the study.  
Critical acute heart failure phase (CAHF): 
 
This phase mimics the state of hypotension that patients with AHF suffer and also aims to simulate 
the shift in substrate utilization (GO toward FAO) found with HF and under ischemic conditions. For 
this reason this phase is perfused at a reduced perfusion pressure of 20 cmH2O and the glucose 
concentration is decreased to 2.5 mM/L, while introducing 1.2 mM/L FA (palmitic acid [the most 




abundant FA in human tissues] conjugated to 3% BSA) into the buffer (Oliveira et al., 2015). This 
phase was allowed to continue without any pacing in order for the heart to fail ‘naturally’ - a patient 
will not experience stable heart rates during this phase. 
Recovery acute heart failure (RAHF) phase: 
 
The perfusion pressure is restored back to 100 cmH2O and the pacer (unchanged from 400 bmp 
setting during stabilization) is turned on again to mimic a recovering patient who has been 
hemodynamically stabilized. Glucose concentrations are also restored to 10 mM/L baseline 
condition, with the high FA content (1.2 mM/L) being maintained in the recovery buffer, to give the 
recovering heart a choice in terms of metabolic fuel substrate utilization during this recovery stage.  
 
Figure 2.1: Schematic representation of the modified retrograde Langendorff model to 
induce acute heart failure (AHF). 




2.5 Treatment with trimetazidine 
 
Control groups were allowed to go through the full protocol without any intervention. Treated 
groups received TMZ (5 µM) (#653322, Sigma-Aldrich Co. LLC., St. Louis, Missouri, United States) in 
the perfusate in either the CAHF or RAHF stage for the full duration of the phase. The therapeutic 
dose was selected based on mean plasma TMZ concentrations in a clinical study (Barré et al., 2003) 




Figure 2.2: Schematic representation of treatment regime. 




2.6 Producing murine ventricular balloons for the Langendorff heart perfusion 
 
Aortic retrograde perfusion in the Langendorff mode is a widely used technique in both academia 
and in the industry. Intrinsic rhythmic contraction can be maintained for hours in order to measure 
functional parameters of heart function by means of a dH2O-filled balloon that is inserted into the 
left ventricle of the excised and mounted heart. Traditionally, the rat is employed for this technique 
and manufactured latex balloons are commercially available for hearts or alternatively it can be 
easily prepared by the researcher. This is, however, not the case when utilizing mice hearts for 
Langendorff perfusions as there are no commercially available balloons.  Moreover, manufacturing a 
ventricular balloon that is small enough and made from a thin material that has adequate tensile and 
elastic properties has been a challenge (Miller & Wright, 2011), especially in South Africa.  We 
therefore set out to manufacture our own mouse ventricular balloons that would: 1) be 
appropriately sized (including tubing); 2) be free from sharp edges (due to material bunching); 3) fill 
and form to the contours of the ventricle (highly flexible); 4) be made from a thin, highly compliant 
and non-elastic material that can accurately transmit functional data to the fluid in the balloon and 
5) have high linear frequency response (appropriate transducer, tubing and attachments) (Liao et al., 
2012).   
2.6.1 Optimization of ventricular balloons 
 
We prepared and tested ventricular balloons constructed from multiple materials.  Here latex-based 
balloons (constructed from condom tips and dental dams) were a) too thick and elastic (not in 
compliance with the requirements set out above) and b) when inflated yielded perfectly round 
balloons that would not fill nor transmit pressures from the bottom tip of the ventricle (inadequate 
ventricular filling).  By contrast, balloons constructed from multiple different types of plastic 
sheeting yielded irregular shaped balloons with sharp edges (non-compliant material) that caused 
damage to the ventricle.  We subsequently decided to adapt a fluid silicone method (Miller & 
Wright, 2011) where pins were dipped into molten caramelized sugar to form a stem and teardrop 




that was left to dry. This was then dipped into fluid silicone (silicone mold star 16, SM420 and 
SM421, amt composites, Maitland, Cape Town, South Africa) to form a silicone balloon over the 
candy and once dried was removed by placing it into warm water to melt the candy. Although the 
precise shape/size of such balloons was easily controlled, the balloon was still too thick and 
incompliant.  An additional approach was thereafter assessed i.e. we utilized commercial food wrap 
(‘’cling film’’) and prepared the balloons following the instructions of ADInstruments 
(http://cdn.adinstruments.com/adi-web/techniques/TN-BalloonCatheter.pdf). Although this 
resulted in an improvement on the previous plastic sheeting balloons, it still yielded irregular and 
sharp edged balloons.  
2.6.2 Constructing ventricular balloons for mouse heart perfusions 
 
For accurate measurement of ventricular pressures, the ventricular balloon (and tubing) should be 
small enough, void of any damaging corners, should occupy the full shape of the ventricle and must 
accurately relay cardiac pressures into the fluid contained within the balloon (Addendum C). We 
eventually found the best method of constructing murine ventricular balloons to be: 1) pre-
stretched industrial grade cling film; 2) 5-0 silk suture replaced with “invisible thread” (available from 
any craft store) and 3) commercially available cat catheters (size F4) as a replacement for common 
plastic tubing. 
The first step was to cut a small piece of cling wrap (approximately 3 x 3 cm). Using a size 13 knitting 
needle held upright with the point to the top, the cling wrap was slowly pulled 1-2 cm over the point 
of the needle. We found holding the cling wrap in close proximity to the needle shaft a good strategy 
as this helps to not only stretch the cling wrap to its maximum but also to “shape” it better. The cling 
wrap was then slowly and gently removed from the knitting needle. With the catheter attached to 
the syringe, degassed distilled dH2O was sucked into the syringe while making sure there were no air 
bubbles in the catheter. The tip of the dH2O-filled catheter was then placed into the cone shape, 
leaving a space of at least 5 mm between the tips of the cling wrap cone and the catheter. The 




invisible thread was then neatly wrapped and tied off around the catheter: we left a tail of thread at 
the back (syringe side) and started winding from the tip of the catheter upward for about 1 cm. The 
starting point of the “coil” was close to the tip of the catheter – max 1 mm distance.  We knotted-off 
sufficiently to prevent leaks and winding should be done neatly to avoid repeated overlap of thread. 
There should be no openings between successive coils. In addition, the winding should also be tight 
enough to prevent leaks, however, winding too tightly could also pinch close the catheter. The 
resulting inflated and dH2O filled balloon should not only be a teardrop shape, but more importantly 
there should be no sharp edges or corners on the balloon.  There should be absolutely no air bubbles 
in the balloon or the catheter, if there is it can be removed by repeated inflating and deflating while 
flicking the catheter and/or syringe in the upright position. Throughout making the balloons, 
additional care should be taken not to kink the catheter as this influences the functional readings. 
  




2.7 Blood and tissue collection 
 
Blood was collected from the thoracic cavity after excision of the heart and centrifuged (Spectrafuge 
24D, Labnet International, Inc., Edison, New Jersey, United States) at 3000 rpm (828 x g) for 15 
minutes in order to collect the serum. After the cessation of the RAHF phase the left ventricles of 
hearts were snap frozen in liquid nitrogen and all samples stored at -80˚C for future use. 
2.8 Analysis 
2.8.1 Evaluation of serum levels of estradiol and progesterone 
 
Commercially available enzyme-linked immunosorbent assays (ELISA) were used to assess hormonal 
concentrations of estradiol (DE4399, Demeditec Diagnostics, Kiel, Germany) and progesterone 
(DEV9988, Demeditec Diagnostics, Kiel, Germany) in serum. The assay procedures were carried out 
as stipulated in the instructions provided. Both kits were solid phase ELISAs that are based on 
competitive binding principles. In short, the microtiter wells are coated with an antibody directed to 
each hormone, respectively. The unknown amount of hormone that is present in each sample 
competes with horseradish peroxidase conjugated estradiol or progesterone for binding to the 
coated antibody. The unbound conjugates are washed off after incubation, meaning that the bound 
peroxidase conjugate is reversely proportional to the hormone level in the sample. Addition of the 
substrate solution allows for colorimetric evaluation of hormone concentrations in the sample. Both 
kits contained standards from which to produce a standard curve in order to determine final 










2.8.2 Evaluation for protein expression levels 
 
Protein determination for 3-KAT and PDH were performed by Western Blot analysis (refer to 
Addendum D for complete protocol). In short, left ventricular tissues from each treatment group 
were homogenized and resuspended in RIPA (modified RadioImmunoPrecipitAtion) buffer.  After 
centrifugation, the whole fractions were used to determine the total protein concentration using the 
Bradford method (Bradford, 1976). Sample (six samples per group to make a total of 90 samples) 
preparations  (50µg per well) were run on 12% 1 mm sodium dodecyl sulfate polyacrylamide gel 
electrophoresis gels (SDS-PAGE), supplemented with 0.5% v/v trichloroethanol (TCE) (#T54801, 
Sigma-Aldrich Co. LLC., St. Louis, Missouri, United States). The addition TCE to the gels allow us to 
utilize the Bio-Rad Stain-Free technology. The separated proteins were electrophoretically 
transferred to PVDF membranes (Trans-Blot Turbo Transfer System Transfer Pack, Bio-Rad 
Laboratories Inc., Hercules, California, Unites States) using the Bio-Rad Trans-Blot Turbo Transfer 
system V1.02 (Bio-Rad Laboratories Inc., Hercules, California, Unites States). Protein standards 
(#1610377 Precision Plus Dual Xtra Prestained and #1610396, Precision Plus Protein Unstained, Bio-
Rad Laboratories Inc., Hercules, California, Unites States) were run in each gel. The blots were 
blocked in Tris-buffered saline-Tween-20 (TBS-T) supplemented with 5% fat free milk (Parmalat, 
Stellenbosch, South Africa). Blots were incubated overnight at 4°C with the various primary 
antibodies at 1:1,000 dilutions in TBS-T. Primary antibodies used were 3-KAT mouse (Anti-ACAA1, 
#Ab110289, Abcam plc., Cambridge, United Kingdom) and PDH rabbit (#2784 Cell Signaling 
Technology Inc., Danvers, Massachusetts, United States). Membranes were washed in TBS-T before 
incubation for 1 hour with either 1:8,000 anti-mouse IgG, HRP-linked  secondary antibody (#7076S, 
Cell Signaling Technology Inc., Danvers, Massachusetts, United States) or 1:4,000 anti-rabbit IgG, 
HRP-linked secondary antibody (#7074S, Cell Signaling Technology Inc., Danvers, Massachusetts, 
United States) diluted in TBS-T. Blots were treated with Enhanced Chemi-Luminescence (ECL) (Bio-
Rad Clarity Western ECL substrate, Bio-Rad Laboratories Inc., Hercules, California, Unites States) 




reagents and the required proteins were detected using the Bio-Rad Chemidoc MP Imaging system 
(Bio-Rad Laboratories Inc., Hercules, California, Unites States). Quantification of protein expression 
was analyzed using Image Lab Software Version 5.0 (#170-9690, Bio-Rad Laboratories Inc., Hercules, 
California, United States). Blots were normalized to total protein as stipulated in the Bio-Rad Stain-
Free technology protocols that is included in Addendum D. 
2.9 Statistical analysis 
 
Data are expressed as mean ± standard error of the mean (SEM). Data was analyzed using either a 
one-way or two-way analysis of variance (ANOVA) where appropriate, followed by a Bonferroni 
post-hoc test (GraphPad Prism v5, San Diego, California, United States). A value of p<0.05 was 
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3.1 Characterizing the estrous cycle 
 
We initially set out to determine whether the different stages of the estrus cycle could be identified, 
namely the follicular (proestrus and estrus) and luteal phases (metestrus and diestrus). Thereafter 
we assessed whether such phases corresponded with the expected hormonal fluctuations of 
estradiol and progesterone. Here the follicular phase should be characterized by high estradiol 
levels, whereas in the luteal phase, progesterone levels are expected to predominate.  
 
Slides prepared from mice in the proestrus phase showed a predominance of nucleated epithelial 
cells and occasionally some cornified cells and/or leukocytes were present (Figure 3.1). In the estrus 
phase there was a predominance of cornified squamous epithelial cells that are easily identifiable by 
its irregular shape and granular cytoplasm. The metestrus phase is characterized by the presence of 
mixed cell types although a predominance of leukocytes occurs, while the diestrus phase is 
Figure 3.1: Stages of the estrus cycle characterized by vaginal cytology. The phases are 
characterized by the ratio of cells that are present. Indicated are nucleated epithelial cells (E), 
cornified squamous epithelial cells (C) and leucocytes (L). Images represent the vaginal flush of 
lean females under 4x and 10x magnification. 




completely dominated by exceptionally dense depositions of leukocytes (Figure 3.1). While all four 
phases were detected in lean females, obese females did not undergo any follicular phases. 
Average levels of estradiol and progesterone in serum of lean female mice showed no statistical 
differences for any of the phases (Figure 3.2). Obese males and females and lean male sera were 
also tested but did not show any statistical significant differences (data not shown).  
Figure 3.2: Average estradiol and progesterone levels in serum of lean female mice throughout 
the estrus cycle. (A) Estradiol (B) Progesterone (n=6).  
 




3.2 Comparing the filter and dialysis method 
 
The dialysis method to prepare conjugated fatty acids: serum albumin preparations are 
routinely used for heart perfusion studies. However, this method is time consuming 
(requires overnight stirring) and also costly. We therefore set out to test whether a 
simplified protocol (filtering) could achieve the same results and thus potentially replace 
the classic dialysis method. 
For the duration of the experiment, the dialysis group displayed increases in both RPP and 
(dp/dt)max (p<0.05) versus the filter group that stayed constant (Figure 3.3 A). Moreover, at 
the cessation of the experiment the dialysis group exhibited a higher (dp/dt)max (p<0.05) 
(Figure 3.3 B) and a moderately lower heart rate (Figure 3.3 C) (p<0.01) compared to the 
filter group. The dialysis group also showed a higher LVDevP, although this was not 
statistically significant (Figure 3.3 D). A decrease in LVEDP for the filter group was noted 
between the groups at the last time point (Table 3.1). No differences in LVESP were 
observed (Table 3.1).  
 
 
Figure 3.3: Characterization and comparison of the filter and dialysis method in lean male 
mice. (A) RPP (B) (dp/dt)max (n=6). Significance is expressed as *p<0.05 versus dialysis 25-30 min. 
RPP: rate pressure product, (dp/dt)max: index of myocardial contraction velocity, min: minutes. 





Thus these data demonstrate the filtering method to be equally useful for fatty acid conjugations 
and hence was employed for all the perfusion experiments completed in this study. 
 Filter versus dialysis method 
(start of experiment) 
Filter versus dialysis method 







































































































98.87    
± 0.20 




95.59    
± 0.58 



























   
  
Figure 3.3: Characterization and comparison of the filter and dialysis method in lean male 
mice. (C) Heart rate (D) LVDevP (n=6). Significance is expressed as **p<0.01 versus dialysis 25-30 
min. LVDevP: left ventricular developed pressure, min: minutes. 
Table 3.1: Characterization and comparison of the filter and dialysis method in lean male mice. 
Data are expressed as a percentage of baseline (n=6). Significance is expressed as *p<0.05; 
**p<0.01 versus dialysis 25-30min, ###p<0.001 versus filter start and $p<0.05 versus dialysis 
start. RPP: rate pressure product, (dp/dt)max: index of myocardial contraction velocity, LVDevP: 
left ventricular developed pressure, LVEDP: left ventricular end diastolic pressure, LVESP: left 
ventricular end systolic pressure, min: minutes, ns: not significant. 




3.3 Establishing the ex vivo mouse model of acute heart failure 
 
The rapid switch in our perfusion system from the baseline/stabilization phase to the CAHF phase 
(reflecting de novo AHF) resulted in a drastic decrease in both RPP (p<0.001) and (dp/dt)max 
(p<0.001) (Figure 3.4). Switching from the CAHF to the RAHF phase (reflecting partial recovery) 
resulted in modest increases for RPP (p<0.001) and (dp/dt)max (p<0.01) (Figure 3.4, Table 3.2). 
However, the resultant recovery in the RAHF phase was still statistically lower than the initial 
baseline for both RPP (p<0.001) and (dp/dt)max (p<0.001).  
 
There were no significant changes in heart rate between the phases, although there was a definite 
tendency for higher heart rates in the CAHF phase compared to the baseline. Heart rate during the 
RAHF phase was also slightly elevated compared to baseline (not significant), reflecting that the 
heart has sustained some damage even though there is some recovery (Table 3.2).  
LVEDP decreased following the switch from baseline to CAHF (p<0.01) and subsequently increased 
during the RAHF phase compared to CAHF (p<0.001). There was a tendency for the LVEDP to be 
higher during RAHF compared to baseline, although this was not significant (p>0.05). The LVESP 
followed a similar pattern, although it was significantly lower during RAHF versus the initial baseline 
(p<0.05) (Table 3.2). 
Figure 3.4: RPP and (dp/dt)max in establishing the ex vivo mouse model of acute heart failure 
(AHF) in lean male mice. Data is expressed as a percentage of baseline (n=6).  Data represents 
the last ten minutes of each phase. Significance is expressed as **p<0.01; ***p<0.001 versus 
CAHF and ###p<0.001 versus RAHF. RPP: rate pressure product, (dp/dt)max: index of myocardial 
contraction velocity, CAHF: critical acute heart failure, RAHF: recovery acute heart failure. 




Parameters Baseline vs. 
CAHF 
CAHF Phase 





(% of Baseline) 






3.12 ± 0.62 *** 
 






2.97 ± 0.88 ** 
 






274.70 ± 81.42 ns 
 






6.40 ± 4.12 ns 
 






65.06 ± 6.89 *** 
 






46.47 ± 5.75 *** 
 






Table 3.2: Establishing the ex vivo mouse model of acute heart failure (AHF) in lean male mice. 
Data from the CAHF and RAHF phases were normalised to baseline (assume 100%) and therefore 
CAHF and RAHF phase data are expressed as a percentage of baseline (n=6). Data represents the 
last ten minutes of each phase. Significance is expressed as **p<0.01; ***p<0.001 versus CAHF 
and #p<0.05; ###p<0.001 versus RAHF. RPP: rate pressure product, (dp/dt)max: index of 
myocardial contraction velocity, LVDevP: left ventricular developed pressure, LVEDP: left 
ventricular end diastolic pressure, LVESP: left ventricular end systolic pressure, CAHF: critical 
acute heart failure, RAHF: recovery acute heart failure, ns: not significant. 




3.4 Effects of trimetazidine treatment with acute heart failure 
 
Results will be discussed by first focusing on heart function during the CAHF phase, thereafter data 
for the RAHF phase will be discussed. It is important to note that the CAHF phase perfusion data are 
expressed as CAHF/Baseline (%), (using the RAW values obtained, see Addendum E) reflecting by 
what percentage the heart’s function changes in relation to baseline. Similarly, the RAHF phase data 
are expressed as RAHF/CAHF (%), i.e. the “recovery” of heart function from the CAHF phase.  
3.4.1 Acute heart failure: males 
3.4.1.1 CAHF phase 
 
The model results in a profound decline in RPP and (dp/dt)max in control lean males, i.e. to 3.1% and 
3.0%, respectively (Figure 3.5). Lean males treated with TMZ during the CAHF phase showed no 
significant changes for RPP, (dp/dt)max or any of the other parameters assessed (Figure 3.5, Table 
3.3). Control obese males also displayed a robust decrease in RPP and (dp/dt)max. Obese males 
showed a significant, yet negligible increase for RPP with TMZ treatment during the CAHF phase. 
However, none of the other parameters showed significant changes, except for an increase in 
LVDevP, a reflection of the increased RPP (Figure 3.5, Table 3.4). 
 
Figure 3.5 Effect of trimetazidine (TMZ) treatment during the CAHF phase on RPP and 
(dp/dt)max of lean and obese males. (A) RPP (B) (dp/dt)max (n=6). Data represents the last ten 
minutes of the CAHF phase and is expressed as a percentage of baseline. Significance is expressed 
as *p<0.05 versus control obese males. RPP: rate pressure product, (dp/dt)max: index of 
myocardial contraction velocity, CAHF: critical acute heart failure. 




TMZ treatment of lean males during CAHF 
Treatment group RPP  
(%) 





Control 3.12 ± 0.63 ns 2.97 ± 0.88 ns 6.40 ± 4.12 ns 
TMZ at CAHF 3.48 ± 0.28 2.32 ± 0.26 0.87 ± 0.09 







Control 274.74 ± 81.42 ns 65.06 ± 6.89 ns 46.47 ± 5.75 ns 
TMZ at CAHF 407.79 ± 16.88 82.65 ± 4.68 55.40 ± 3.30 
 
TMZ treatment of obese males during CAHF 
Treatment Group RPP 
(%) 





Control 1.89 ± 0.29  
* 
1.89 ± 0.32 ns 0.49 ± 0.07  
* TMZ at CAHF 3.42 ± 0.49 2.56 ± 0.37 0.86 ± 0.12 
Treatment group Heart rate 
(%) 





Control 382.43 ± 11.68 ns 88.31 ± 3.07 ns 62.29 ± 5.08 ns 
TMZ at CAHF 401.55 ± 22.64 76.20 ± 5.19 56.83 ± 4.85 
 
 
There were no significant differences when comparing lean and obese males for the CAHF phase, 
although there was a tendency for the control obese males to have lowered RPP and (dp/dt)max. 
However, control obese males displayed a higher LVEDP (p<0.05). TMZ treatment during the CAHF 
phase eliminated differences in LVEDP that were evident in control males (Figure 3.5, Table 3.5). 
 
 
Table 3.3 Effect of trimetazidine (TMZ) treatment during the CAHF phase (lean males) (n=6). 
Data represents the last ten minutes of the CAHF phase and is expressed as a percentage of 
baseline.  RPP: rate pressure product, (dp/dt)max: index of myocardial contraction velocity, 
LVDevP: left ventricular developed pressure, LVEDP: left ventricular end diastolic pressure, 
LVESP: left ventricular end systolic pressure, CAHF: critical acute heart failure, Sig.: significance, 
ns: not significant. 
Table 3.4 Effect of trimetazidine (TMZ) treatment during the CAHF phase (obese males) (n=6).  
Data represents the last ten minutes of the CAHF phase and is expressed as a percentage of 
baseline. Significance is expressed as *p<0.05 versus control. RPP: rate pressure product, 
(dp/dt)max: index of myocardial contraction velocity, LVDevP: left ventricular developed pressure, 
LVEDP: left ventricular end diastolic pressure, LVESP: left ventricular end systolic pressure, CAHF: 
critical acute heart failure Sig.: significance, ns: not significant. 




Comparing TMZ treatment for lean vs. obese males during CAHF 
 Control TMZ during CAHF 
Parameters Lean Obese Sig. Lean Obese Sig. 
RPP 
 (%) 
3.12 ± 0.63 1.89 ± 0.29 ns 3.48 ± 0.28 3.42 ± 0.49 ns 
(dp/dt)max  
(%) 
2.97 ± 0.88 1.89 ± 0.32 ns 2.32 ± 0.26 2.56 ± 0.37 ns 
Heart rate  
(%) 
274.74 ± 81.42 382.43 ± 11.68 ns 407.79 ± 16.88 401.55 ±2 2.64 ns 
LVDevP 
(%) 
6.40 ± 4.12 0.49 ± 0.07 ns 0.87 ± 0.09 0.86 ± 0.12 ns 
LVEDP 
(%) 
65.06 ± 6.89 88.31 ± 3.07 * 82.65 ± 4.68 76.20 ± 5.19 ns 
LVESP  
(%) 
46.47 ± 5.75 62.29 ± 5.08 ns 55.40 ± 3.30 56.83 ± 4.85 ns 
 
 
3.4.1.2 RAHF phase 
 
The control lean males showed a respective 5.6-fold and 6.4-fold increase for RPP and (dp/dt)max 
from the previous CAHF phase. TMZ treatment initiated during the CAHF phase did not make any 
difference in terms of functionality. However, when TMZ treatment was initiated during the RAHF 
phase, this strongly improved RPP and (dp/dt)max values compared to both control and the CAHF 
treated lean males. Here data revealed an impressive 3.2-fold increase in RPP between RAHF-treated 
and control lean males (p<0.001) and a similar 2.9-fold increase (p<0.001) versus CAHF-treated lean 
males. The other significant parameters that increased included (dp/dt)max and LVDevP (Figure 3.6, 
Table 3.6).  
Table 3.5 Comparing the effect of trimetazidine (TMZ) treatment during the CAHF phase (lean 
and obese males) (n=6). Data represents the last ten minutes of the CAHF phase and is expressed 
as a percentage of baseline. Significance is expressed as *p<0.05 versus lean males. RPP: rate 
pressure product, (dp/dt)max: index of myocardial contraction velocity, LVDevP: left ventricular 
developed pressure, LVEDP: left ventricular end diastolic pressure, LVESP: left ventricular end 
systolic pressure, CAHF: critical acute heart failure, Sig.: significance, ns: not significant. 





The obese males exhibited a similar pattern as for the lean males and recovered similarly during the 
RAHF phase. Moreover, TMZ treatment initiated during the RAHF phase also significantly improved 
RPP and (dp/dt)max for the obese males (Figure 3.6, Table 3.7). 
When performing comparative analysis for the RAHF phase, there was a tendency for TMZ-treated 








Figure 3.6 Effect of trimetazidine (TMZ) treatment during the RAHF phase on RPP and 
(dp/dt)max of lean and obese males. (A) RPP (B) (dp/dt)max (n=6). Data represents the last ten 
minutes of the RAHF phase and is expressed as a fold recovery from the previous CAHF phase. 
Significance is expressed as **p<0.01; ***p<0.001 versus TMZ at RAHF lean males and #p<0.05; 
##p<0.01 versus TMZ at RAHF obese males. RPP: rate pressure product, (dp/dt)max: index of 
myocardial contraction velocity, CAHF: critical acute heart failure, RAHF: recovery acute heart 
failure. 




TMZ treatment of lean males during RAHF 
Treatment group RPP  
(%) 





Control 568.43 ± 71.91 *** 
*** 
 
640.47 ± 184.14 *** 
** 
1259.06 ± 485.90 *** 
*** TMZ at CAHF 616.08 ± 91.27 1077.15 ± 184.60 2204.29 ± 355.33 
TMZ at RAHF 1806.94 ± 245.55 2435.16 ± 253.84 6025.70 ± 654.65 







Control 210.13 ± 127.11 ns 201.85 ± 36.57 ns 211.06 ± 43.49 ns 
TMZ at CAHF 28.26 ± 1.48 160.23 ± 9.38 170.36 ± 11.07 
TMZ at RAHF 29.74 ± 2.23 158.26 ± 18.72 171.80 ± 24.07 
 
TMZ treatment of obese males during RAHF 
Treatment group RPP 
(%) 





Control 724.78 ± 124.26 * 
** 
763.84 ± 132.18 ** 
** 
2411.10 ± 458.16 ** 
TMZ at CAHF 492.12 ± 122.78 624.06 ± 122.29 1678.49 ± 470.27 
TMZ at RAHF 1430.89 ± 221.17 1744.19 ± 249.20 4522.35 ± 742.07 
Treatment group Heart rate 
(%) 





Control 31.75 ± 2.85 ns 142.48 ± 10.43 ns 147.98 ± 11.77 ns 
TMZ at CAHF 30.17 ± 2.62 158.98 ± 15.10 164.74 ± 16.48 





Table 3.6 Effect of trimetazidine (TMZ) treatment during the RAHF phase (lean males) (n=6).  
Data represents the last ten minutes of the RAHF phase and is expressed as a percentage of 
CAHF. Significance is expressed as **p<0.01; ***p<0.001 versus TMZ at RAHF. RPP: rate pressure 
product, (dp/dt)max: index of myocardial contraction velocity, LVDevP: left ventricular developed 
pressure, LVEDP: left ventricular end diastolic pressure, LVESP: left ventricular end systolic 
pressure, CAHF: critical acute heart failure, RAHF: recovery acute heart failure, Sig.: significance, 
ns: not significant. 
Table 3.7 Effect of trimetazidine (TMZ) treatment during the RAHF phase (obese males) (n=6).  
Data represents the last ten minutes of the RAHF phase and is expressed as a percentage of 
CAHF. Significance is expressed as *p<0.05; **p<0.01 versus TMZ at RAHF. RPP: rate pressure 
product, (dp/dt)max: index of myocardial contraction velocity, LVDevP: left ventricular developed 
pressure, LVEDP: left ventricular end diastolic pressure, LVESP: left ventricular end systolic 
pressure, CAHF: critical acute heart failure, RAHF: recovery acute heart failure, Sig.: significance, 
ns: not significant. 




Comparing TMZ treatment of lean vs. obese males during RAHF 
  Control  
 Lean Obese Sig. 
RPP  
(%) 
568.43 ± 71.91 724.78 ± 124.26 ns 
(dp/dt)max  
(%) 
640.47 ± 184.14 763.84 ± 132.18 ns 
Heart rate  
(%) 
210.13 ± 127.11 31.75 ± 2.85 ns 
LVDevP 
(%) 
1259.06 ± 485.90 2411.10 ± 458.16 ns 
LVEDP 
(%) 
201.85 ± 36.57 142.48 ± 10.43 ns 
LVESP  
(%) 
211.06 ± 43.49 147.98 ± 11.77 ns 
 TMZ at CAHF TMZ at RAHF 
 Lean  Obese Sig. Lean  Obese Sig. 
RPP  
(%) 














Heart rate  
(%) 














160.23 ± 9.38 158.98 ± 15.10 ns 158.26 ± 18.72 141.43 ± 9.98 ns 
LVESP  
(%) 







Table 3.8 Comparing the effect of trimetazidine (TMZ) treatment during the RAHF phase (lean 
and obese males) (n=6). Data represents the last ten minutes of the RAHF phase and is expressed 
as a percentage of CAHF. RPP: rate pressure product, (dp/dt)max: index of myocardial contraction 
velocity, LVDevP: left ventricular developed pressure, LVEDP: left ventricular end diastolic 
pressure, LVESP: left ventricular end systolic pressure, CAHF: critical acute heart failure, RAHF: 
recovery acute heart failure Sig.: significance, ns: not significant. 




3.4.1.3 Summary  
 
The ex vivo AHF model results in a profound decrease in heart function during the CAHF phase that is 
moderately improved during the RAHF phase. Generally, TMZ treatment during the CAHF phase did 
not result in significant improvement for lean and obese hearts although there was a small but 
significant increase in RPP for obese males. During the RAHF phase lean and obese hearts improve 
without treatment. However, TMZ treatment during this phase resulted in a robust increase in 




















3.4.2 Acute heart failure: females 
 
Females were divided into the two main stages of the estrus cycle, namely the follicular and luteal 
phase. However, obese females experienced stasis in the luteal phase. Thus we initially focused on 
differences between the phases of the lean animals followed by a comparison of lean and obese 
females (luteal phases).   
3.4.2.1 Lean follicular vs. lean luteal 
3.4.2.1.1 CAHF phase 
 
Control lean follicular females displayed significantly lower RPP and (dp/dt)max versus the initial 
baseline. Treatment of lean follicular females with TMZ in the CAHF phase resulted in a non-
significant decrease in RPP, although the detrimental decrease in (dp/dt)max was significant (p<0.05) 
(Figure 3.7, Table 3.9). Of note, the relative degree of these changes (even though significant) are 
very minimal. No changes were found for any of the other parameters (Table 3.9). 
Control lean luteal females showed similar patterns for RPP and (dp/dt)max with and without TMZ 
treatment initiated during the CAHF phase (Figure 3.7, Table 3.10).  
 
 
Figure 3.7: Effect of trimetazidine (TMZ) treatment during the CAHF phase on RPP and 
(dp/dt)max of lean females (follicular and luteal phase). (A) RPP (B) (dp/dt)max (n=6). Data 
represents the last ten minutes of the CAHF phase and is expressed as a percentage of baseline. 
Significance is expressed as *p<0.05 versus control follicular females. RPP: rate pressure 
product, (dp/dt)max: index of myocardial contraction velocity, CAHF: critical acute heart failure. 




TMZ treatment of lean females (follicular) during CAHF 
Treatment group RPP 
(%) 





Control 3.65 ± 1.18 ns 2.20 ± 0.36  
* 
1.42 ± 0.53 ns 
TMZ at CAHF 1.64 ± 0.29 1.25 ± 0.19 0.47 ± 0.14 
Treatment group Heart rate 
(%) 





Control 370.14 ± 42.40 ns 79.33 ± 4.02 ns 63.26 ± 4.62 ns 
TMZ at CAHF 390.47 ± 34.75 88.56 ± 9.22 69.06 ± 8.36 
 
 
TMZ treatment of lean females (luteal) during CAHF 
Treatment group RPP 
(%) 





Control 3.17 ± 0.93 ns 2.11 ± 0.54 ns 1.26 ± 0.57 ns 
TMZ at CAHF 1.63 ± 0.27 1.40 ± 0.29 0.47 ± 0.06 
Treatment group Heart rate 
(%) 





Control 326.97 ± 36.00 ns 65.49 ± 4.01 ns 46.76 ± 3.93 ns 
TMZ at CAHF 347.26 ± 30.05 78.67 ± 9.69 57.91 ± 8.55 
 
When comparing lean follicular and lean luteal control females in the CAHF phase, no differences 
were observed for the functional parameters RPP and (dp/dt)max.  However, differences were found 
for LVEDP and LVESP. Here lean follicular control females exhibited a moderately higher LVEDP 
(p<0.05) and LVESP (p<0.05). TMZ-treated lean females showed similar responses, although 
differences in the LVESP and LVEDP were no longer evident (Figure 3.7, Table 3.11). 
 
Table 3.9: Effect of trimetazidine (TMZ) treatment during the CAHF phase (lean follicular 
females) (n=6). Data represents the last ten minutes of the CAHF phase and is expressed as a 
percentage of baseline.  Significance is expressed as *p<0.05 versus control follicular females. 
RPP: rate pressure product, (dp/dt)max: index of myocardial contraction velocity, LVDevP: left 
ventricular developed pressure, LVEDP: left ventricular end diastolic pressure, LVESP: left 
ventricular end systolic pressure, CAHF: critical acute heart failure, Sig.: significance, ns: not 
significant. 
Table 3.10: Effect of trimetazidine (TMZ) treatment during the CAHF phase (lean luteal females) 
(n=6). Data represents the last ten minutes of the CAHF phase and is expressed as a percentage 
of baseline. RPP: rate pressure product, (dp/dt)max: index of myocardial contraction velocity, 
LVDevP: left ventricular developed pressure, LVEDP: left ventricular end diastolic pressure, LVESP: 
left ventricular end systolic pressure, CAHF: critical acute heart failure, Sig.: significance, ns: not 
significant. 




Comparing TMZ treatment for lean follicular vs. lean luteal females  during CAHF 
 Control TMZ at CAHF 
Parameters Follicular Luteal Sig. Follicular Luteal Sig. 
RPP  
(%) 
3.65 ± 1.18 3.17 ± 0.93 ns 1.64 ± 0.29 1.63 ± 0.27 ns 
(dp/dt)max  
(%) 
2.20 ± 0.36 2.11 ± 0.54 ns 1.25 ± 0.19 1.40 ± 0.29 ns 
Heart rate  
(%) 
370.14 ± 42.40 326.97 ± 36.00 ns 390.47 ± 34.75 347.26 ± 30.05 ns 
LVDevP 
(%) 
1.42 ± 0.53 1.26 ± 0.57 ns 0.47 ± 0.14 0.47 ± 0.06 ns 
LVEDP 
(%) 
79.33 ± 4.02 65.49 ± 4.01 * 88.56 ± 9.22 78.67 ± 9.69 ns 
LVESP  
(%) 
63.26 ± 4.62 46.76 ± 3.93 * 69.06 ± 8.36 57.91 ± 8.55 ns 
 
 
3.4.2.1.2 RAHF phase 
 
Control lean follicular females showed a respective 8.4-fold and 16.2-fold increase in RPP and 
(dp/dt)max from the previous CAHF phase (Figure 3.8). We noted a delayed treatment effect of TMZ 
in lean follicular females during the RAHF phase. Here we previously found that treatment initiated 
during the CAHF phase negatively affected functional parameters when measured at CAHF phase 
(Figure 3.7). However, the same females now display a robust increase in RPP (p<0.05) that is 2.4-
fold higher (and LVDevP 2.8 fold higher) compared to control females when assessed during the 
RAHF phase. Analysis of (dp/dt)max did not mirror the significance, although it followed the same 
pattern as for RPP (Figure 3.8, Table 3.12).  
Table 3.11: Comparing the effect of trimetazidine (TMZ) treatment during the CAHF phase (lean 
follicular and luteal females) (n=6). Data represents the last ten minutes of the CAHF phase and 
is expressed as a percentage of baseline.  Significance is expressed as *p<0.05 versus lean 
follicular females. RPP: rate pressure product, (dp/dt)max: index of myocardial contraction 
velocity, LVDevP: left ventricular developed pressure, LVEDP: left ventricular end diastolic 
pressure, LVESP: left ventricular end systolic pressure, CAHF: critical acute heart failure, Sig.: 
significance, ns: not significant. 





Control lean luteal females showed a substantial 16.9-fold and 22.6-fold increase in RPP and 
(dp/dt)max, respectively, from the previous CAHF phase.  TMZ treatment of lean luteal females during 
the RAHF phase did not result in any significant changes although there was a tendency to respond 
in a graded fashion over the different treatment groups (Figure 3.8, Table 3.13). 
When comparing follicular and luteal lean females, there were no significant differences except for 
TMZ treatment in the RAHF phase where lean luteal females displayed a high RPP (p<0.05) (Figure 






Figure 3.8: Effect of trimetazidine (TMZ) treatment during the RAHF phase on RPP and 
(dp/dt)max of lean females (follicular and luteal phase). (A) RPP (B) (dp/dt)max (n=6). Data 
represents the last ten minutes of the RAHF phase and is expressed as a fold recovery from the 
previous CAHF phase. Significance is expressed as *p<0.05 versus control lean follicular females 
and #p<0.05 versus TMZ at RAHF lean follicular females.  RPP: rate pressure product, (dp/dt)max: 
index of myocardial contraction velocity, CAHF: critical acute heart failure, RAHF: recovery 
acute heart failure. 




TMZ treatment of lean females (follicular) during RAHF 
Treatment group RPP 
(%) 





Control 839.55 ± 213.56  
* 
1624.63 ± 283.02 ns 2875.81 ± 725.74  
* TMZ at CAHF 1980.56 ± 321.98 2911.24 ± 487.59 8049.63 ± 1961.21 
TMZ at RAHF 1163.93 ± 191.79 2364.91 ± 338.16 4918.75 ± 762.73 
Treatment group Heart rate 
(%) 





Control 30.21 ± 4.14 ns 140.87 ± 9.40 ns 149.10 ± 10.88 ns 
TMZ at CAHF 27.94 ± 3.51 139.35 ± 24.49 152.26 ± 30.49 
TMZ at RAHF 23.93 ± 2.00 137.35 ± 3.71 145.29 ± 4.73 
 
TMZ treatment of lean females (luteal) during RAHF 







Control 1687.62 ± 421.02 ns 2255.71 ± 507.28 ns 6116.62 ± 1675.88 ns 
TMZ at CAHF 2021.86 ± 324.85 2685.27 ± 513.67 6202.00 ± 1064.64 
TMZ at RAHF 2519.13 ± 475.16 4060.05 ± 639.68 9475.80 ± 1807.90 
Treatment group Heart rate 
(%) 





Control 33.55 ± 4.86 ns 179.64 ± 10.82 ns 199.59 ± 13.44 ns 
TMZ at CAHF 34.18 ± 5.60 176.24 ± 43.51 194.08 ± 51.29 








Table 3.12: Effect of trimetazidine (TMZ) treatment during the RAHF phase (lean follicular 
females) (n=6). Data represents the last ten minutes of the RAHF phase and is expressed as a 
percentage of CAHF.  Significance is expressed as *p<0.05 versus control. RPP: rate pressure 
product, (dp/dt)max: index of myocardial contraction velocity, LVDevP: left ventricular developed 
pressure, LVEDP: left ventricular end diastolic pressure, LVESP: left ventricular end systolic 
pressure, CAHF: critical acute heart failure, RAHF: recovery acute heart failure, Sig.: significance, 
ns: not significant. 
Table 3.13: Effect of trimetazidine (TMZ) treatment during the RAHF phase (lean luteal females) 
(n=6). Data represents the last ten minutes of the RAHF phase and is expressed as a percentage of 
CAHF. RPP: rate pressure product, (dp/dt)max: index of myocardial contraction velocity, LVDevP: 
left ventricular developed pressure, LVEDP: left ventricular end diastolic pressure, LVESP: left 
ventricular end systolic pressure, CAHF: critical acute heart failure, RAHF: recovery acute heart 
failure, Sig.: significance, ns: not significant. 




Comparing TMZ treatment for lean follicular vs. lean luteal females  during RAHF 
  Control  
Parameters Follicular Luteal Sig. 
RPP  
(%) 
839.55 ± 213.56 1687.62 ± 421.02 ns 
(dp/dt)max  
(%) 
1624.63 ± 283.02 2255.71 ± 507.28 ns 
Heart rate  
(%) 
30.21 ± 4.14 33.55 ± 4.86 ns 
LVDevP 
(%) 
2875.81 ± 725.74 6116.62 ± 1675.88 ns 
LVEDP 
(%) 
140.87 ± 9.40 179.64 ± 10.82 ns 
LVESP  
(%) 
149.10 ± 10.88 199.59 ± 13.44 ns 
 TMZ at CAHF TMZ at RAHF 























Heart rate  
(%) 














139.35 ± 24.49 176.24 ± 43.51 ns 137.35 ± 3.71 134.06 ± 4.27 ns 
LVESP  
(%) 









Table 3.14: Comparing the effect of trimetazidine (TMZ) treatment during the RAHF phase 
(lean follicular and luteal females) (n=6). Data represents the last ten minutes of the RAHF 
phase and is expressed as a percentage of CAHF.  Significance is expressed as *p<0.05 versus 
follicular females. RPP: rate pressure product, (dp/dt)max: index of myocardial contraction 
velocity, LVDevP: left ventricular developed pressure, LVEDP: left ventricular end diastolic 
pressure, LVESP: left ventricular end systolic pressure, CAHF: critical acute heart failure, RAHF: 
recovery acute heart failure, Sig.: significance, ns: not significant. 






The data reveal that during the CAHF phase lean females (follicular and luteal) show similar 
decreases in functionality. Treatment with TMZ during CAHF results in early detrimental effects, 
although this shows a delayed positive effect later-on during the RAHF phase (lean follicular 
females). During the RAHF phase, lean luteal females show superior recovery from the previous 
CAHF phase versus follicular females. Although TMZ treatment show no significant effect for lean 
luteal females, RAHF-treated luteal females show superior functioning compared to follicular 
females. Thus it seems that luteal females possess an inherent ability to better cope with an AHF 
event and that TMZ treatment does not contribute to this.  However, lean follicular females benefit 
from TMZ treatment during the CAHF phase. 
3.4.2.2 Lean luteal vs. obese luteal 
3.4.2.2.1 CAHF phase 
 
Control obese luteal females exhibited a similar decrease to lean females for RPP and (dp/dt)max 
during the CAHF phase. TMZ treatment of obese luteal females showed the same pattern as for lean 
females with a decrease for both RPP (p<0.01) and (dp/dt)max (p<0.05) (Figure 3.9). TMZ treatment 
also resulted in a considerable increase in LVEDP (p<0.01) and LVESP (p<0.01) for obese luteal 
females (Figure 3.9, Table 3.15). 





For the CAHF phase, the only statistical difference between obese and lean luteal females was a high 
LVESP (p<0.05) found in lean control luteal females. TMZ increased the LVESP of obese females, 
thereby eliminating the difference with control animals (Table 3.16). 
TMZ treatment of obese females (luteal) during CAHF 
Treatment group RPP 
(%) 





Control 3.55 ± 0.69  
** 
2.54 ± 0.66  
* 
1.40 ± 0.55 ns 
TMZ at CAHF 1.07 ± 0.21 0.95 ± 0.21 0.32 ± 0.05 







Control 339.53 ± 48.09 ns 47.29 ± 10.60  
** 
28.88 ± 6.73  




Figure 3.9: Effect of trimetazidine (TMZ) treatment during the CAHF phase on RPP and 
(dp/dt)max (lean and obese females). (A) RPP (B) (dp/dt)max (n=6). Data represents the last ten 
minutes of the CAHF phase and is expressed as a percentage of baseline. RPP: rate pressure 
product, (dp/dt)max: index of myocardial contraction velocity, CAHF: critical acute heart failure. 
 
Table 3.15: Effect of trimetazidine (TMZ) treatment during the CAHF phase (obese luteal 
females) (n=6). Data represents the last ten minutes of the CAHF phase and is expressed as a 
percentage of baseline.  Significance is expressed as *p<0.05; **p<0.01 versus control. RPP: rate 
pressure product, (dp/dt)max: index of myocardial contraction velocity, LVDevP: left ventricular 
developed pressure, LVEDP: left ventricular end diastolic pressure, LVESP: left ventricular end 
systolic pressure, CAHF: critical acute heart failure, Sig.: significance, ns: not significant. 




Comparing TMZ treatment for lean vs. obese (luteal) females during CAHF 
 Control TMZ at CAHF 
Parameters Lean Obese Sig. Lean Obese Sig. 
RPP  
(%) 
3.17 ± 0.93 3.55 ± 0.69 ns 1.63 ± 0.27 1.07 ± 0.21 ns 
(dp/dt)max 
 (%) 
2.11 ± 0.54 2.54 ± 0.66 ns 1.40 ± 0.29 0.95 ± 0.21 ns 
Heart rate  
(%) 
326.97 ± 36.00 339.53 ± 48.09 ns 347.26 ± 30.05 335.46 ± 34.69 ns 
LVDevP 
(%) 
1.26 ± 0.57 1.40 ± 0.55 ns 0.47 ± 0.06 0.32 ± 0.05 ns 
LVEDP 
(%) 
65.49 ± 4.01 47.29 ± 10.60 ns 78.67 ± 9.69 87.69 ± 5.43 ns 
LVESP  
(%) 




3.4.2.2.2 RAHF phase 
 
The control obese females showed a much lower recovery during the RAHF phase (Figure 3.10). 
However, obese females with TMZ treatment responded favorably with a 3.3-fold increase in RPP 
(p<0.01) and a 2.3-fold increase in (dp/dt)max (p<0.05) compared to control obese females (Figure 
3.10, Table 3.17).   
When comparing lean and obese luteal females during the RAHF phase it is evident that both groups 
respond in a graded fashion; however the lean luteal females consistently displayed a superior 
improvement in heart function. Here lean control females have a substantial advantage over the 
control obese females, e.g. RPP is 3.2-fold (p<0.05) higher versus obese females. Moreover, lean 
luteal females that receive TMZ treatment during the RAHF phase displayed a higher (dp/dt)max 
(p<0.01) compared to the obese females (Figure 3.9, Table 3.18). 
Table 3.16: Comparing the effect of trimetazidine (TMZ) treatment during the CAHF phase (lean 
and obese luteal females) (n=6). Data represents the last ten minutes of the CAHF phase and is 
expressed as a percentage of baseline.  Significance is expressed as *p<0.05 versus lean females. 
RPP: rate pressure product, (dp/dt)max: index of myocardial contraction velocity, LVDevP: left 
ventricular developed pressure, LVEDP: left ventricular end diastolic pressure, LVESP: left 
ventricular end systolic pressure, CAHF: critical acute heart failure, Sig.: significance, ns: not 
significant. 






TMZ treatment of obese females (luteal) during RAHF 
Treatment group RPP 
(%) 





Control 519.68 ± 83.40  
 
** 
876.00 ± 125.34  
 
* 
1725.24 ± 397.04  
 
** 
TMZ at CAHF 1087.06 ± 199.76 1284.62 ± 211.00 3199.25 ± 743.72 
TMZ at RAHF 1722.53 ± 267.61 1984.13 ± 387.63 5400.37 ± 887.21 
Treatment group Heart rate 
(%) 





Control 38.49 ± 10.56 ns 574.86 ± 308.07 ns 521.49 ± 240.36 ns 
TMZ at CAHF 36.99 ± 3.84 140.93 ± 11.62 145.23 ± 12.91 






Figure 3.10: Effect of trimetazidine (TMZ) treatment during the RAHF phase on RPP and 
(dp/dt)max (lean and obese females). (A) RPP (B) (dp/dt)max (n=6). Data represents the last ten 
minutes of the RAHF phase and is expressed as a fold recovery from the previous CAHF phase. 
Significance is expressed as *p<0.05; **p<0.01 versus control obese females and ##p<0.01 
versus TMZ at RAHF obese females. RPP: rate pressure product, (dp/dt)max: index of myocardial 
contraction velocity, CAHF: critical acute heart failure, RAHF: recovery acute heart failure. 
Table 3.17: Effect of trimetazidine (TMZ) treatment in the RAHF phase (obese luteal females) 
(n=6). Data represents the last ten minutes of the RAHF phase and is expressed as a percentage 
of CAHF.  Significance is expressed as *p<0.05; **p<0.01 versus control. RPP: rate pressure 
product, (dp/dt)max: index of myocardial contraction velocity, LVDevP: left ventricular developed 
pressure, LVEDP: left ventricular end diastolic pressure, LVESP: left ventricular end systolic 
pressure, CAHF: critical acute heart failure, RAHF: recovery acute heart failure, Sig.: significance, 
ns: not significant. 





 Comparing TMZ treatment of lean vs. obese (luteal) females during RAHF 
  Control  
Parameters Lean Obese Sig. 
RPP  
(%) 
1687.62 ± 421.02 519.68 ± 83.40 * 
(dp/dt)max  
(%) 
2255.71 ± 507.28 876.00 ± 125.34 ns 
Heart rate 
(%)  
33.55 ± 4.86 38.49 ± 10.56 ns 
LVDevP 
(%) 
6116.62 ± 1675.88 1725.24 ± 397.04 * 
LVEDP 
(%) 
179.64 ± 10.82 574.86 ±308.07 ns 
LVESP  
(%) 
199.59 ± 13.44 521.49 ± 240.36 ns 
 TMZ at CAHF TMZ at RAHF 







































176.24 ± 43.51 140.93 ± 11.62 ns 134.06 ± 4.27 126.83 ± 7.53 ns 
LVESP  
(%) 








Table 3.18: Comparing the effect of trimetazidine (TMZ) treatment during the RAHF phase 
(lean and obese luteal females) (n=6). Data represents the last ten minutes of the RAHF phase 
and is expressed as a percentage of CAHF.  Significance is expressed as *p<0.05; **p<0.01 versus 
lean females. RPP: rate pressure product, (dp/dt)max: index of myocardial contraction velocity, 
LVDevP: left ventricular developed pressure, LVEDP: left ventricular end diastolic pressure, 
LVESP: left ventricular end systolic pressure, CAHF: critical acute heart failure, RAHF: recovery 
acute heart failure, Sig.: significance, ns: not significant. 






It is clear that the inherent ability of lean luteal females to handle an AHF event is lost with obesity. 
Here the lean control females displayed superior function and recovery from the previous CAHF 
phase and as such TMZ treatment has no further beneficial effects. Conversely, the control obese 
females start out with a limited recovery from CAHF, but with TMZ treatment during the RAHF phase 
this results in favorable effects although this is still not adequate to restore functionality to that of 



















3.4.3 Acute heart failure: males and females 
3.4.3.1 Lean 
3.4.3.1.1 CAHF phase 
 
Lean control males and follicular females displayed a decrease in RPP and (dp/dt)max (Figure 3.11). 
The only difference is the relatively small increased LVESP in the females (p<0.05), although this is no 
longer the case with TMZ treatment during the CAHF phase. TMZ treated follicular females also have 
lowered RPP (p<0.001), (dp/dt)max (p<0.01) and LVDevP (P<0.05) compared to treated lean males, 
which is consistent considering the negative effect of TMZ on females treated during CAHF. (Figure 
3.11, Table 3.19).  
 
Lean control males and luteal females exhibited an attenuation in RPP and (dp/dt)max and there were 
no differences found for the CAHF phase. As for the follicular females, TMZ-treated luteal females 
displayed a slightly lower RPP (p<0.001) and (dp/dt)max (p<0.05) compared to the lean males (Figure 
3.12, Table 3.20).  
 
 
Figure 3.11: Effect of trimetazidine (TMZ) treatment during the CAHF phase on RPP and 
(dp/dt)max of lean males and lean follicular females. (A) RPP (B) (dp/dt)max (n=6). Data 
represents the last ten minutes of the CAHF phase and is expressed as a percentage of baseline. 
Significance is expressed as *p<0.05; **p<0.01; ***p<0.001 versus TMZ at CAHF lean follicular 
females. RPP: rate pressure product, (dp/dt)max: index of myocardial contraction velocity, CAHF: 
critical acute heart failure. 




Comparing TMZ treatment for lean males vs. lean follicular females during CAHF 
 Control TMZ at CAHF 
Parameters Males Females Sig. Males Females Sig. 
RPP  
(%) 
3.12 ± 0.63 3.65 ± 1.18 ns 3.48 ± 0.80 1.64 ± 0.29 *** 
(dp/dt)max  
(%) 
2.97 ± 0.88 2.20 ± 0.36 ns 2.32 ± 0.26 1.25 ± 0.19 ** 
Heart rate  
(%) 
274.74 ± 81.42 370.14 ± 42.40 ns 407.79 ± 16.88 390.47 ± 34.75 ns 
LVDevP 
(%) 
6.40 ± 4.12 1.42 ± 0.53 ns 0.87 ± 0.09 0.47 ± 0.14 * 
LVEDP 
(%) 
65.06 ± 6.89 79.33 ± 4.02 ns 82.65 ± 4.68 88.55 ± 9.22 ns 
LVESP  
(%) 





Table 3.19: Comparing the effect of trimetazidine (TMZ) treatment during the CAHF phase 
(lean males and lean follicular females) (n=6). Data represents the last ten minutes of the CAHF 
phase and is expressed as a percentage of baseline.  Significance is expressed as *p<0.05; 
**p<0.01; ***p<0.001 versus lean males. RPP: rate pressure product, (dp/dt)max: index of 
myocardial contraction velocity, LVDevP: left ventricular developed pressure, LVEDP: left 
ventricular end diastolic pressure, LVESP: left ventricular end systolic pressure, CAHF: critical 
acute heart failure, Sig.: significance, ns: not significant. 
Figure 3.12: Effect of trimetazidine (TMZ) treatment during the CAHF phase on RPP and 
(dp/dt)max of lean males and lean luteal females. (A) RPP (B) (dp/dt)max (n=6). Data represents 
the last ten minutes of the CAHF phase and is expressed as a percentage of baseline. 
Significance is expressed as *p<0.05; ***p<0.001 versus TMZ at CAHF lean luteal females. RPP: 
rate pressure product, (dp/dt)max: index of myocardial contraction velocity, CAHF: critical acute 
heart failure. 
 




Comparing TMZ treatment for lean males vs. lean luteal females during CAHF 
 Control TMZ at CAHF 
Parameters Males Females Sig. Males Females Sig. 
RPP  
(%) 
3.12 ± 0.63 3.17 ± 0.93 ns 3.48 ± 0.28 1.63 ± 0.27 *** 
(dp/dt)max 
 (%) 
2.97 ± 0.88 2.11 ± 0.54 ns 2.32 ± 0.26 1.40 ± 0.29 * 
Heart rate  
(%) 
274.74 ± 81.42 326.97 ± 36.00 ns 407.79 ± 16.88 347.26 ± 30.05 ns 
LVDevP 
(%) 
6.40 ± 4.12 1.26 ± 0.57 ns 0.87 ± 0.09 0.47 ± 0.06 ** 
LVEDP 
(%) 
65.06 ± 6.89 65.49 ± 4.01 ns 82.65 ± 4.68 78.67 ± 9.69 ns 
LVESP  
(%) 



















Table 3.20: Comparing the effect of trimetazidine (TMZ) treatment during the CAHF phase 
(lean males and lean luteal females) (n=6). Data represents the last ten minutes of the CAHF 
phase and is expressed as a percentage of baseline.  Significance is expressed as *p<0.05; 
**p<0.01; ***p<0.001 versus lean males. RPP: rate pressure product, (dp/dt)max: index of 
myocardial contraction velocity, LVDevP: left ventricular developed pressure, LVEDP: left 
ventricular end diastolic pressure, LVESP: left ventricular end systolic pressure, CAHF: critical 
acute heart failure, Sig.: significance, ns: not significant. 




3.4.3.1.2 RAHF phase 
 
Control lean males showed a respective 5.6-fold and 6.4-fold increase in RPP and (dp/dt)max from the 
previous CAHF phase. Lean control follicular females displayed increased (though not statistically 
significant) RPP and (dp/dt)max versus the lean males. There were no other differences between 
control lean males and control lean follicular females (Figure 3.13, Table3.21).  
There was a substantial difference between males and females that were treated with TMZ during 
the previous CAHF phase. Here follicular TMZ-treated females exhibited substantially higher RPP 
(p<0.001), (dp/dt)max (p<0.001) and LVDevP (p<0.001) and this is due to the delayed treatment effect 
that was previously indicated. For the RAHF-treated animals, there were no significant differences 
(Figure 3.13, Table 3.21). Only males benefited from TMZ treatment during the RAHF phase, 




Figure 3.13: Effect of trimetazidine (TMZ) treatment during the RAHF phase on RPP and 
(dp/dt)max of lean males and lean follicular females. (A) RPP (B) (dp/dt)max (n=6). Data 
represents the last ten minutes of the RAHF phase and is expressed as a fold recovery from the 
previous CAHF phase. Significance is expressed as **p<0.01; ***p<0.001 versus TMZ at RAHF 
lean males and #p<0.05; ###p<0.001 versus TMZ at CAHF lean females. RPP: rate pressure 
product, (dp/dt)max: index of myocardial contraction velocity, CAHF: critical acute heart failure, 
RAHF: recovery acute heart failure. 




Comparing TMZ treatment for lean males vs. lean follicular females during RAHF 
  Control  
Parameters Males Females Sig. 
RPP  
(%) 
568.43 ± 71.91 839.55 ± 213.56 ns 
(dp/dt)max  
(%) 
640.47 ± 184.14 1624.63 ± 283.02 ns 
Heart rate  
(%) 
210.13 ± 127.11 30.21 ± 4.14 ns 
LVDevP 
(%) 
1259.06 ± 485.90 2875.81 ± 725.74 ns 
LVEDP 
(%) 
201.85  ±36.57 140.87 ± 9.40 ns 
LVESP  
(%) 
211.06 ± 43.49 149.10 ± 10.88 ns 
 TMZ at CAHF TMZ at RAHF 
 Males Females Sig. Males Females Sig. 
RPP  
(%) 














Heart rate  
(%) 














160.23 ± 9.38 139.35 ± 24.49 ns 158.26 ± 18.72 137.35 ± 3.71 ns 
LVESP  
(%) 
170.36 ± 11.07 152.26 ± 30.49 ns 171.80 ± 24.07 145.29 ± 4.73 ns 
 
Control lean males exhibited increased RPP and (dp/dt)max from the previous CAHF phase, while lean 
control luteal females showed a robust increase for both parameters (Figure 3.14). The latter values 
are higher (not significantly) than the recovery values for control follicular females (previously 
discussed) and contributes to the statistically significantly higher RPP (p<0.05) and (dp/dt)max 
(p<0.05) versus control lean males (Figure 3.14, Table 3.22).  
Table 3.21: Comparing the effect of trimetazidine (TMZ) treatment during the RAHF phase 
(lean males and lean follicular females) (n=6). Data represents the last ten minutes of the RAHF 
phase and is expressed as a percentage of CAHF.  Significance is expressed as ***p<0.001 versus 
lean males. RPP: rate pressure product, (dp/dt)max: index of myocardial contraction velocity, 
LVDevP: left ventricular developed pressure, LVEDP: left ventricular end diastolic pressure, 
LVESP: left ventricular end systolic pressure, CAHF: critical acute heart failure, RAHF: recovery 
acute heart failure, Sig.: significance, ns: not significant. 




   
As for follicular females, luteal females treated with TMZ during the CAHF phase displayed a higher 
RPP (p<0.01) and (dp/dt)max (p<0.05) compared to lean males. This picture emerges as a result of 
lean males only responding to TMZ treatment during the RAHF phase. However, this favorable 
response still did not provide lean males with superior heart functioning as RAHF-treated luteal 









Figure 3.14: Effect of trimetazidine (TMZ) treatment during the RAHF phase on RPP and 
(dp/dt)max of lean males and lean luteal females. (A) RPP (B) (dp/dt)max (n=6). Data represents 
the last ten minutes of the RAHF phase and is expressed as a fold recovery from the previous 
CAHF phase. Significance is expressed as *p<0.05; **p<0.01; ***p<0.001 versus TMZ at RAHF 
lean males, #p<0.05; ##p<0.01 versus TMZ at CAHF lean males and $<0.05 versus control lean 
males. RPP: rate pressure product, (dp/dt)max: index of myocardial contraction velocity, CAHF: 
critical acute heart failure, RAHF: recovery acute heart failure. 




Comparing TMZ treatment for lean males vs. lean luteal females during RAHF 
  Control  
Parameters Males Females Sig. 
RPP  
(%) 
568.43 ± 71.91 1687.62 ± 421.02 * 
(dp/dt)max  
(%) 
640.47 ± 184.14 2255.71 ± 507.28 * 
Heart rate  
(%) 
210.13 ± 127.11 33.55 ± 4.86 ns 
LVDevP 
(%) 
1259.06 ± 485.90 6116.62 ± 1675.88 * 
LVEDP 
(%) 
201.85 ± 36.57 179.64 ± 10.82 ns 
LVESP  
(%) 
211.06 ± 43.49 199.59 ± 13.44 ns 
 TMZ at CAHF TMZ at RAHF 
 Males Females Sig. Males Females Sig. 
RPP  
(%) 
616.08 ± 91.27 2021.86 ± 
324.85 
















Heart rate  
(%) 














160.23 ± 9.38 176.24 ± 43.51 ns 158.26 ± 18.72 134.06 ± 4.27 ns 
LVESP  
(%) 










Table 3.22: Comparing the effect of trimetazidine (TMZ) treatment during the RAHF phase 
(lean males and lean luteal females) (n=6). Data represents the last ten minutes of the RAHF 
phase and is expressed as a percentage of CAHF.  Significance is expressed as *p<0.05; **p<0.01; 
versus lean males. RPP: rate pressure product, (dp/dt)max: index of myocardial contraction 
velocity, LVDevP: left ventricular developed pressure, LVEDP: left ventricular end diastolic 
pressure, LVESP: left ventricular end systolic pressure, CAHF: critical acute heart failure, RAHF: 
recovery acute heart failure, Sig.: significance, ns: not significant. 






 There were no significant differences between controls during the CAHF phase. With TMZ treatment 
during the CAHF phase, lean males and females displayed decreased heart function during the CAHF 
phase. However, during the RAHF phase control females exhibited increased recovery from the 
CAHF phase, with luteal control females showing the highest recovery. All females that were treated 
with TMZ during the CAHF phase showed greater functional recovery during RAHF compared to male 
counterparts. This is due to the delayed treatment effect observed for follicular females and also due 
to males only responding to TMZ treatment during the RAHF phase. 
 





3.4.3.2.1 CAHF phase 
 
Control obese males showed RPP and (dp/dt)max values that were both 1.9% of the initial baseline 
whereas control obese females showed RPP and (dp/dt)max values that were respectively 3.6% and 
2.5% of the initial baseline. The only significant difference between control obese males and females 
was that females displayed significantly reduced pressures.  Females had moderately lower LVEDP 
(p<0.01) and LVESP (p<0.01). No differences were observed in functional parameters, but control 
obese females exhibited a tendency for higher RPP values (p>0.05) (Figure 3.15, Table 3.23). 
 
Pressure differences dissipated with TMZ treatment due to increasing pressures in the obese 
females (refer to previous data). TMZ treatment in the CAHF phase results in significant differences 
between obese males and females. Females had a significantly lower RPP (p<0.01) and (dp/dt)max 
(p<0.01) compared to obese males. This is due to the individual effects of TMZ treatment on the 
groups. Obese males positively benefit from TMZ treatment in the CAHF phase, whereas obese 
females respond negatively to the TMZ treatment (same as for lean females) (Figure 3.15, Table 
3.23). 
Figure 3.15: Effect of trimetazidine (TMZ) treatment during the CAHF phase on RPP and 
(dp/dt)max of  obese males and females. (A) RPP (B) (dp/dt)max (n=6). Data represents the last 
ten minutes of the CAHF phase and is expressed as a percentage of baseline. Significance is 
expressed as *p<0.05; **p<0.01 versus TMZ at CAHF obese females and #p<0.05 versus control 
obese males. RPP: rate pressure product, (dp/dt)max: index of myocardial contraction velocity, 
CAHF: critical acute heart failure. 




Comparing TMZ treatment for obese males vs. females  during CAHF 
 Control TMZ at CAHF 
Parameters Males Females Sig. Males Females Sig. 
RPP  
(%) 
1.89 ± 0.29 3.55 ± 0.69 ns 3.42 ± 0.49 1.07 ± 0.21 ** 
(dp/dt)max  
(%) 
1.89 ± 0.32 2.54 ± 0.66 ns 2.56 ± 0.37 0.95 ± 0.21 ** 
Heart rate  
(%) 
382.43 ± 11.68 339.53 ± 48.09 ns 401.55 ± 22.64 335.46 ± 34.69 ns 
LVDevP 
(%) 
0.49 ± 0.07 1.40 ± 0.55 ns 0.86 ± 0.12 0.32 ± 0.05 ** 
LVEDP 
(%) 
88.31 ± 3.07 47.29 ± 10.60 ** 76.20 ± 5.19 87.69 ± 5.43 ns 
LVESP  
(%) 
62.29 ± 5.08 28.88 ± 6.73 ** 56.83 ± 4.85 62.80 ± 4.86 ns 
 
  
Table 3.23: Comparing the effect of trimetazidine (TMZ) treatment during the CAHF phase 
(obese males and females) (n=6). Data represents the last ten minutes of the CAHF phase and is 
expressed as a percentage of baseline.  Significance is expressed as **p<0.01 versus obese 
males. RPP: rate pressure product, (dp/dt)max: index of myocardial contraction velocity, LVDevP: 
left ventricular developed pressure, LVEDP: left ventricular end diastolic pressure, LVESP: left 
ventricular end systolic pressure, CAHF: critical acute heart failure, Sig.: significance, ns: not 
significant. 




3.4.3.2.2 RAHF phase 
 
Control obese males and females showed increased RPP and (dp/dt)max from the previous CAHF 
phase. There were no functional parameter differences between control obese males and females. 
Both obese males and females benefited from TMZ treatment during the RAHF phase and there 










Figure 3.16: Effect of trimetazidine (TMZ) treatment during the RAHF phase on RPP and 
(dp/dt)max of obese males and females. (A) RPP (B) (dp/dt)max (n=6). Data represents the last 
ten minutes of the RAHF phase and is expressed as a fold recovery from the previous CAHF 
phase. Significance is expressed as *p<0.05; **p<0.01 versus TMZ at RAHF obese males and 
#p<0.05; ##p<0.01 versus TMZ at RAHF obese females. RPP: rate pressure product, (dp/dt)max: 
index of myocardial contraction velocity, CAHF: critical acute heart failure, RAHF: recovery 
acute heart failure. 





Comparing TMZ treatment for obese males vs. females  during RAHF 
  Control  
Parameters Males Females Sig. 
RPP  
(%) 
724.78 ± 124.26 519.68 ± 83.40 ns 
(dp/dt)max  
(%) 
763.84 ± 132.18 876.00 ± 125.34 ns 
Heart rate  
(%) 
31.75 ± 2.85 38.49 ± 10.56 ns 
LVDevP 
(%) 
2411.10 ± 458.16 1725.24 ± 397.04 ns 
LVEDP 
(%) 
142.48 ± 10.43 574.86 ± 308.07 ns 
LVESP  
(%) 
147.98 ± 11.77 521.49 ± 240.36 * 
 TMZ at CAHF TMZ at RAHF 
 Males Females Sig. Males Females Sig. 
RPP  
(%) 
492.12 ± 122.78 1087.06 ± 
199.76 







624.06 ± 122.29 1284.62 ± 
211.00 





Heart rate  
(%) 














158.98 ± 15.10 140.93 ± 11.62 ns 141.43 ± 9.98 126.83 ± 7.53 ns 
LVESP  
(%) 
164.74 ± 16.48 145.23 ± 12.91 ns 147.96 ± 12.18 132.12 ± 9.01 ns 
 
Table 3.24: Comparing the effect of trimetazidine (TMZ) treatment during the RAHF phase 
(obese males and females (n=6). Data represents the last ten minutes of the RAHF phase and is 
expressed as a percentage of CAHF.  Significance is expressed as *p<0.05 versus obese males. 
RPP: rate pressure product, (dp/dt)max: index of myocardial contraction velocity, LVDevP: left 
ventricular developed pressure, LVEDP: left ventricular end diastolic pressure, LVESP: left 
ventricular end systolic pressure, CAHF: critical acute heart failure, RAHF: recovery acute heart 
failure, Sig.: significance, ns: not significant. 




3.4.4 Summary of perfusion results  
 
Although there were statistical differences found during the CAHF phase, these were of such small 
magnitude that it can be considered negligible. Control animals did not differ greatly in terms of the 
decline in functional parameters (Table 3.25), but some patterns emerged for the TMZ-treated 
groups. Here lean males showed no response to treatment while the obese counterparts benefited 
from TMZ treatment. However, TMZ treatment initiated during the CAHF phase was detrimental to 
lean and obese females early on at the end of the CAHF phase before RAHF. 
For the RAHF phase, males displayed a maximum recovery of 19% (dp/dt)max without any 
interventions. Lean females showed enhanced functional recovery without treatments, with 
follicular females recovering to 31% (RPP) and luteal females to 54% (RPP) of baseline. However, 
this inherent coping mechanism of the lean luteal females is lost with obesity as such animals 
reached less than half of this recovery (19%, RPP) 
Control animals 
 CAHF  
(% of Baseline) 
RAHF 




 RPP (dp/dt)max RPP (dp/dt)max RPP (dp/dt)max 
Lean males 3.1  3.0  17.36 19.2 5.6-fold 6.4-fold 
Obese males 1.9  1.9  13.68 14.44 7.2-fold 7.6 fold 
Lean follicular 
females 
3.7  2.2  31.08 35.64 8.4-fold 16.2-fold 
Lean luteal females 3.2  2.1  54.08 47.46 16.9-fold 22.6-fold 
Obese females 3.6  2.5  18.72 22.00 5.2-fold 8.8-fold 
 
Table 3.25: Comparing the effects of the ex vivo acute heart failure (AHF) model on control 
groups (n=6). The first RAHF column estimates the improvement as a percentage of the initial 
baseline (CAHF percentage x fold improvement in RAHF). RPP: rate pressure product, (dp/dt)max: 
index of myocardial contraction velocity, CAHF: critical acute heart failure, RAHF: recovery 
acute heart failure. 




Lean and obese males responded favorably to TMZ treatment initiated during the RAHF phase 
compared to controls and animals treated during the CAHF phase. Obese females also benefited 
from TMZ treatment during the RAHF phase. Lean females exhibited a differential treatment 
response profile, i.e. lean follicular females showed a delayed TMZ treatment effect later-on, during 
the RAHF phase. However, lean luteal control females (displayed an inherent ability to) recovered 
remarkably from CAHF, while TMZ treatment had no significant effects during the RAHF phase.  
These data show that there were no differences between lean and obese males, while lean females 
are at a clear functional recovery advantage over lean males. Here the luteal group displayed 
superior functional improvement and this is likely due to an innate coping mechanism. However, 








3.5 3-KAT and PDH expression 
 
Treatment with TMZ during either of the phases showed no effect on 3-KAT nor PDH expression in 
any of the groups (Figure 3.17 and 3.18). 
 
 
Figure 3.17: Effect of trimetazidine (TMZ) treatment on 3-KAT expression during the RAHF 
phase. (A) Lean males (B) Obese males (C) Lean follicular females (D) Lean luteal females (E) 
Obese females.  









Figure 3.18: Effect of trimetazidine (TMZ) treatment on PDH expression during the RAHF 
phase. (A) Lean males (B) Obese males (C) Lean follicular females (D) Lean luteal females (E) 
Obese females.   
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AHF – the lesser known “sister” of HF - is a complex clinical syndrome that varies extensively in 
terms of clinical presentations and pathophysiologic mechanisms underlying it (Metra et al., 2010). 
ADHF is the most common primary diagnosis in heart disease patients admitted to African hospitals 
(Damasceno et al., 2007; Sliwa et al., 2008). Moreover, African women suffering from AHFS are 
younger, with significant stress on the 20-29 year-old group, and are more prone to suffer from 
acute de novo HF (Ogah et al., 2015; Sliwa & Mayosi, 2013). This type of AHF is also associated with 
increased risk of death compared to other forms (Follath et al., 2011; Nieminen et al., 2006; Tavazzi 
et al., 2006), while co-morbidities such as diabetes and obesity further complicate the picture.  In 
light of this bleak scenario, the optimization of cardiac metabolism emerges as a potentially novel 
therapeutic option for AHF treatment.   For this study, we hypothesized that TMZ (partial FAO 
inhibitor) offers cardio protection during AHF under normal and obese-related diabetic conditions 
and that this may be influenced in a sex-dependent manner.  The aims of this study were: (1) to 
establish a de no AHF mouse model; (2) to test whether simple FA-albumin filtering could replace 
the gold standard dialysis method; (3) to identify and establish the four phases of the estrous cycle 
in female mice; and (4) to evaluate the therapeutic value of TMZ under normal and obese-related 
diabetic conditions in both male and female mouse hearts subjected to a unique ex vivo model of 
AHF. We also tested the influence of the different phases of the follicular and luteal phases of the 
estrous cycle on TMZ efficacy and whether such treatment may be influenced in a sex-dependent 
fashion. 
The main findings of this study are: (1) that our perfusion system resulted in significant decreases in 
both functional and pressure parameters during the CAHF phase, reflecting de novo AHF.  Moreover, 
our model reflected partial recovery in the RAHF phase with modest increases in functional and 
pressure parameters although this was still significantly lower than baseline values; (2) the filtering 
FA-albumin method was useful and even marginally better than the gold standard dialysis method 




usually employed for Langendorff perfusion perfusates;  (3) that lean (db/+) females showed normal 
estrous cycle phases namely proestrus, estrus (follicular phase), metestrus and diestrus (luteal 
phase). Obese females (db/db) did not, however, undergo the follicular phases (proestrus and 
estrus) and we did not find any differences in serum concentrations of estradiol and progesterone 
for any of the groups studied; and (4) TMZ treatment resulted in negligible changes to functional 
parameters during the CAHF phase, but significant results were obtained in terms of recovery 
function during the RAHF phase. Lean and obese males responded equally well to TMZ treatment.  
However, lean females (follicular and luteal phases) responded in distinct fashion, while obesity 
influenced females’ response to TMZ administration. Due to the unique response pattern of the 
different estrous phases, sex differences were present only in lean groups.    
4.1.1 Aim 1: Establish the de novo acute heart failure mouse model 
In establishing our ex vivo mouse model of AHF, we based and modified the system on a previous 
acutely under perfused rat heart model (Deshpande et al., 2014; Deshpande, 2013; Deshpande et 
al., 2010) where AHF was simulated by decreasing coronary perfusion pressure.  This model is 
representative of hypotensive AHF patients who present with hypoperfusion, cardiogenic shock and 
low blood pressure (Filippatos & Zannad, 2007; Laribi et al., 2012; Nieminen et al., 2005). Lower 
pressure upon admission is inversely correlated with in-hospital mortality (Gheorghiade et al., 2006). 
In agreement with the original Deshpande model, de novo AHF is induced in the isolated heart by 
decreasing the perfusion pressure from 100 cm to 20 cmH2O and by altering metabolic substrates in 
the perfusate in order to 1) simulate circulating metabolite conditions of HF patients and 2) promote 
the upregulation of FA utilization during heart failure. We therefore introduced elevated FA (1.2 
mM/L palmitic acid conjugated to 3% BSA) (Aasum & Larsen, 1997; Lopaschuk & Barr, 1997) and 
decreased the glucose concentration from 10 to 2.5 mM/L (Stanley & Chandler, 2002). Our perfusion 
system resulted in profound decreases in both functional and pressure parameters during the CAHF 
phase reflecting de novo AHF (Figure 3.4 and Table 3.2). The recovery phase is similarly manipulated 
by restoring the perfusion pressure back to 100 cmH2O, restoring glucose to baseline levels (10 




mM/L) and by maintaining the high FA content. Our model reflected partial recovery during the 
RAHF phase (Figure 3.4 and Table 3.2) with modest increases in functional and pressure parameters 
that were still significantly lower than baseline values.  A potential critique of this model may be the 
low recovery in functional parameters achieved.  However, we are of the opinion that this model 
(with relatively weak recovery) is appropriate considering that hypoperfused patients with 
cardiogenic shock who have received hospital care display the highest cumulative mortality, 
reaching 53% and this is attributed to a high in-hospital mortality (Harjola et al., 2010). Therefore a 
model that reaches a relatively high functional recovery would be irrelevant in studying a disease 
with such a deadly outcome.  
4.1.2 Aim 2: Fatty acid-albumin filtering versus the gold standard dialysis method 
When simulating the effects of high FA availability in a Langendorff isolated heart perfusion system, 
conjugated FAs are bound to BSA and here the dialysis method is routinely employed (Belke et al., 
1999; Chatham et al., 1999; Gelinas et al., 2008; Khairallah et al., 2004; Lopaschuk & Barr, 1997; Ruiz 
et al., 2015) to minimize the contributions from impurities and contaminants in the conjugated 
perfusate.  This method is, however, time-consuming and costly and we therefore decided to 
evaluate whether a simplified protocol, i.e. filtering (to remove the impurities and contaminants) 
would deliver comparable results. Our data revealed that the filtering method is equally useful, and 
even marginally better, than the gold standard dialysis method (Figure 3.3 and Table 3.1). This is 
supported by Gross (2009) who stated that dialysis is useful in a recirculating system where the 
heart contributes metabolic waste and if continued for a long period may result in metabolic 
“poisoning” of the system (Gross, 2009). It therefore stands to reason that in a non-circulating and 
relatively short protocol, the use of dialysis is not warranted. On the contrary, filtration of the 
perfusing buffer remains of the utmost importance as microaggregate impurities and/or salt 
precipitations can obstruct blood vessels (Gross, 2009; Ross-Ascuitto et al., 1987; Ruiz et al., 2015). 
Researchers may opt to utilize inline filters directly following the buffer reservoirs in the system or 
buffers can be filtered by vacuum filtering on the day of use. Of note, low protein binding filters 




must be utilized in order to prevent altering the composition of the perfusates. In summary, we 
found that filtering delivers more stable data over the duration of the experiment, with no changes 
in functional parameters.  Moreover, it was a faster and more cost-effective method to apply in our 
laboratory.  The filtering method was therefore employed for all perfusion experiments completed 
in this study.  
4.1.3 Aim 3: Identify and establish the four phases of the estrous cycle in female mice 
In order to evaluate whether the estrous cycle may impact on TMZ efficacy during an AHF event, we 
initially identified the different phases of the estrous cycle by vaginal cytology (Caligioni, 2009; 
Marcondes et al., 2002). The short estrous cycle (lasting 4-5 days) makes the mouse an ideal model 
to investigate influences of the reproductive cycle.  After exposing the females to male pheromones 
to ensure regular cycling (MacDonald et al., 2014; Whitten, 1958), the lean (db/+) females showed 
normal estrous cycle phases (Figure 3.1) namely proestrus, estrus (follicular phase), metestrus and 
diestrus (luteal phase).  However, obese females (db/db) did not undergo the follicular phases 
(proestrus and estrus), but rather displayed metestrus and diestrus  acyclicity, a phenomenon 
common in this transgenic mouse strain (Bates et al., 2003; Johnson & Sidman, 1979; Robertson et 
al., 2010).  Leptin is an adipokine that is secreted by adipose tissue and its function is critical to body 
weight and composition, insulin sensitivity and reproduction (Leibel et al., 1997). It also functions as 
a feedback signal or “fat reporter” (Wurtman, 1996) to the nervous system to regulate energy 
homeostasis and serves as an index of stored energy in the body (Maffei et al., 1995). When leptin 
feedback is interrupted (Montague et al., 1997), a state of negative energy balance is sensed despite 
actual energy stores available, causing hyperphagia (primarily by increased meal sizes) (de Jong-
Nagelsmit et al., 1986), attenuated energy expenditure (Yen & Acton, 1972) and a decreased ability 
to utilize stored energy (Gao & Horvath, 2008). Leptin receptor deficiencies result in obesity and 
insulin resistant diabetes (Coleman, 1978), both states of energy turmoil. There is a strong 
hypothalamic link between energy balance and reproduction (Hill et al., 2008) and parallel cross talk 
with estrogen (Gao & Horvath, 2008) that leads to reproduction abnormalities.  




In addition, we also evaluated whether such phases corresponded with the expected hormonal 
fluctuations of estradiol and progesterone in serum. Here we found no differences in estradiol and 
progesterone levels between the four phases of the estrous cycle in lean females (Figure 3.2), nor 
between animal groups including obese females and lean/obese males (data not shown).  Past 
studies reported a very specific pattern in that the follicular phase is dominated by estradiol as it 
increases throughout proestrus and reaches a maximum at the onset of ovulation in estrus (Fata et 
al., 2001; Walmer et al., 1992; Wood et al., 2007).  Moreover, the luteal phase is dominated by 
progesterone. Our non-significant results could be explained by a lack of sensitivity of commercial 
ELISA kits as these have been shown to be lacking in accuracy, sensitivity and reliability (Haisenleder 
et al., 2011; Handelsman et al., 2011). In addition, analytical assessments of sex steroids are 
generally difficult to accurately and consistently measure (Bielohuby et al., 2012; McNamara et al., 
2010; Parks & Howlett, 2013).  Both liquid chromatography–tandem mass spectrometry (LC–MS/MS) 
(McNamara et al. 2010) and gas chromatography–tandem mass spectrometry (GC–MS/MS) 
(Haisenleder et al., 2011) assays are ideal as these provide exceptional accuracy, sensitivity, 
specificity and capability. Of note, although we were unable to accurately detect such differences in 
animals here studied, it should be borne in mind that such physiological differences do indeed 
manifest.  
4.1.4 Aim 4: Evaluate the therapeutic value of TMZ under various conditions 
In order to pursue our last aim, we decided to not only evaluate the recovery (RAHF phase) as is 
typically done, but to also assess heart function during the ‘’assault’’ or CAHF phase.  Here mice did 
not differ significantly in terms of the decline in functional parameters (Table 3.25) during the CAHF 
phase. However, TMZ treated hearts showed small, although statistically significant differences in 
functional parameters during the CAHF phase (Table 3.25). We speculate that such alterations are 
due to the length of the phase and that if it was continued any longer then such hearts would not 
have recovered at all. A shorter phase could possibly induce less damage and could deliver statistical 




results of a larger magnitude.  The functional assessment during the RAHF phase produced more 
compelling results.  
Our results showed that lean and obese males recovered in a similar manner (Figure 3.6) at both 
treatment time points, i.e. TMZ treatment during the CAHF and RAHF phases, respectively.  Groups 
receiving TMZ during the CAHF phase showed no statistical differences in heart function during their 
recovery (Table 3.6 & 3.7) and was expected (Figure 4.1) as TMZ treatment during the CAHF phase 
would partially inhibit 3-KAT and consequently increase glucose utilization (Banach et al., 2008; 
Dezsi, 2014; Huqi et al., 2015; Kantor et al., 2000; Lopaschuk et al., 2003; Marzilli & Huqi, 2011). 
However, during the CAHF phase glucose available for utilization is exceptionally low and TMZ 
treatment shifts metabolism away from the only plentiful metabolite that is available to the heart at 
this point. Treatment during the RAHF phase, however, resulted in significant functional recovery 
(Table 3.6 and 3.7). Metabolic therapies (e.g. TMZ) are extensive areas of research and been 
successful for CVD treatment with the latter attributed to the promotion of glucose utilization 
restoring homeostasis and alleviating the detrimental effect of increased FAO (Banach et al., 2008; 
Fang et al., 2012; Fragasso et al., 2008; Lopaschuk, 2001; Lopaschuk et al., 2003; Sabbah & Stanley, 
2005).  For example, TMZ increased mechanical heart function in db/db mice by attenuating FAO-
mediated lipotoxicity and oxidative stress, and also suppressing and preventing the development of 
DCM (L et al., 2010; Ussher et al., 2014). This was confirmed in obese humans, where TMZ improved 
myocardial efficiency by decreasing FAO (Bucci et al., 2012). Our results also demonstrate that 
obesity does not influence TMZ efficacy for AHF treatment in male mice (Figure 3.6 and Table 3.8).  
 





Lean females in the two different phases of the estrous cycle responded in unique ways (Figure 3.8). 
Here lean follicular females recovered optimally when treated with TMZ during the CAHF phase, 
unlike when there was no significant recovery when the hearts were treated during the RAHF phase 
(Table 3.12). The lean luteal females were the only group to exhibit inherent superior functional 
recovery and was also the only group that was not significantly affected by TMZ treatment for any of 
the treatment time points (Table 3.13).  This led us to conclude that this treatment difference may 
be due to the effect of sex hormones, i.e. the follicular phase (dominated by estrogen) and the luteal 
phase (characterized by progesterone) (MacDonald et al., 2014; Walmer et al., 1992; Wood et al., 
2007).  However, our ELISA results did not reflect this.  The lean follicular females was the only group 
to show significant recovery when TMZ was administered during the CAHF phase.   As previously 
discussed, our model shifts metabolism towards FAO during CAHF, but TMZ treatment would 
Figure 4.1: Acute heart failure (AHF) ex vivo model – the principle.  FAs: fatty acids, FAO: Fatty 
acid β-oxidation. 




encourage less desirable utilization of glucose (Figure 4.1) that is severely decreased.  An explanation 
of the beneficial effects of TMZ could be that estrogen increases FAO and decreases glucose 
utilization (Campbell & Febbraio, 2001), thus allowing the myocardium to utilize the high FAs during 
this phase.  In support, females seem to be better adapted to utilize FA and may also be protected 
against increased FA levels compared to males (Konhilas, 2010).  
Our results revealed that the lean luteal females did not respond to TMZ treatment. Research in sex 
differences in pharmacokinetics and pharmacodynamics (Soldin & Mattison, 2009; Soldin et al., 
2011) demonstrated that increased sex hormones in women can alter hepatic enzyme activities 
leading to fluctuations in drug accumulation and/or elimination. Drug metabolism can be altered 
during the latter stages of the luteal phase as estrogen is a substrate for CYP3A (Bigos et al., 2009; 
Soldin et al., 2011). This may explain the lack of response to TMZ in our model as the 
biotransformation of TMZ is speculated to involve isoenzymes of CYP3A (Jackson et al., 1996; Simon 
et al., 1997). The findings generated in this study also demonstrate that lean luteal females have an 
inherent “coping mechanism” to better handle the AHF event, despite the lack of response to TMZ 
treatment. This may be attributed to the protective effects of progesterone on the cardiovascular 
system (Prior, 2014), e.g. it can assist in cardiac repair by enhancing fibroblast regeneration and 
differentiation (Dubey et al., 1998).  Moreover, progesterone displays greater counter-regulatory 
responses in response to adrenergic stimulae (Moldovanova et al., 2008), it can antagonize 
vasoconstriction (Barbagallo et al., 2001), is associated with increased blood flow (Mather et al., 
2000) and can decrease arrhythmias and the risk of sudden cardiac death (Odening et al., 2012). We 
propose that any of these factors could influence the apparent innate protection observed in the 
lean luteal females.  Intriguingly, this inherent cardio protection is lost with obesity in luteal females 
across all the treatment groups (Figure 3.10 and Table 3.18). Obese females exhibited the same 
treatment pattern as their lean counterparts, but at lower values (Figure 3.10 and Table 3.17).  
Furthermore, obese luteal females responded to TMZ treatment the same as the males and 
benefitted only when it was added during the RAHF phase. We speculate that the treatment effect 




in females may be affected by the degree of obesity as obese female mice displayed a 20% increase 
in body weight compared to 10% for males (Bates et al., 2003). In addition, specific sex differences in 
body fat content and protein binding have been shown to affect distribution of drugs (Ochs et al., 
1981; Soldin & Mattison, 2009). 
Our results revealed that sex differences in TMZ efficacy as a therapy for AHF is only present in lean 
groups (Figure 3.13 & 3.14 and Table 3.21 & 3.22). There were no differences in functional recovery 
between obese males and females (Figure 3.16 and Table 3.24), showing that obesity is detrimental 
to both sexes. Sex differences are present between the lean males, and both follicular and luteal 
lean females. Sex differences in pharmacokinetics and pharmacodynamics is an exceptionally 
common and prevailing phenomenon and has resulted in a vast research field (Bigos et al., 2009; 
Soldin & Mattison, 2009; Soldin et al., 2011). In summary, differences arise due to sex differences in 
drug absorption (gastric and hepatic enzyme activities, transporter proteins, and handling of drugs 
or metabolites), drug distribution (body fat composition and cardiac output), drug metabolism 
(cytochrome P450 group, hepatic and extra-hepatic metabolism) and drug elimination. We propose 
that the distinct sex differences found in the two estrus phases may be due to varying treatment 
patterns as a result of sex hormone differences.    
To our knowledge we are the first group to demonstrate a sex difference in the therapeutic value of 
TMZ (Vitale et al., 2013) and to specifically show an involvement of the estrous cycle in this process. 
Moreover, as far as we are aware this is the first study to investigate this within the context of AHF 
(Belardinelli & Purcaro, 2001; Di Napoli et al., 2005). 
Western Blot analysis of protein expression of 3-KAT and PDH did not reveal any alterations with 
TMZ treatment (Figure 3.17 & 3.18). Previous perfusion studies evaluated enzyme activity (Kantor et 
al., 2000; Lopaschuk et al., 2003) of these enzymes and found positive results. However, the 
Lopaschuk et al. (2003) study was conducted on normal male Sprague-Dawley rats and the 
concentration of TMZ used was 100 µM (we used 5 µM).  In addition, Kantor et al. (2000) also 




utilized normal male Sprague-Dawley rats and perfused with relatively low palmitic acid levels (0.4 
mM, compared to 1.2 mM employed by this study) bound to BSA.  Others reported changes in 
expression levels, although this was for a chronic model of TMZ treatment (8 weeks) for 
streptozotocin-diabetic rats (Onay-Besikci et al., 2007). We believe that the discrepancies in drug 
and FA concentration and the choice of animal model (rats versus mice; type 1 versus type 2 
diabetes) may account for such differences.   Additionally, the short drug exposure (25 minute 
perfusion phase) may also explain why it is too early to detect changes in myocardial protein 
expression.  




4.2 Conclusion  
 
AHFS has received limited attention to date and limitations of previous study designs make it 
difficult to derive meaningful sex-based comparisons. The generic nature of interventions show that 
current therapies are not tailored/designed specifically for AHF. The optimization of cardiac 
metabolism (especially TMZ) emerges as a novel and worthy therapeutic option to investigate for 
the treatment of AHF. We have successfully established a novel ex vivo mouse AHF model and also 
shown that the less costly and more time-effective filtering method can replace dialyses in 
Langendorff perfusions. We confirmed that obese females (db/db) display metestrus acyclicity and 
diestrus acyclicity.  We showed that TMZ elicits negligible effects on heart function during the CAHF 
phase, but that it results in significant recovery for both males and obese females when 
administered during the RAHF phase. Sex differences are also present in with such therapy as the 
estrous cycle influences the therapeutic utility of TMZ.    
  




4.3 Limitations and future research 
 
Although we demonstrated that females respond to an AHF insult in a unique way in this pilot study, 
our model only mimics the subset of AHF that males are more prone to suffer (by hypoperfusion) 
(Table 1.3).  Future work should focus on setting up two models of AHF, one for each classification of 
AHF that each gender is more prone to experience. Additionally, this study could not investigate how 
obese females in the follicular phase would respond. Future studies could also include investigation 
into the two remaining sex hormones (follicle stimulating hormone and luteinizing hormone) and 
females could be divided into all four phases of the estrous cycle.  
Our current perfusion model only utilized two exogenous substrates (palmitate and glucose) to 
mimic the metabolic alteration during a cardiac insult and thus neglecting the effects of other energy 
sources namely lactate, pyruvate and ketone bodies.  Furthermore, the relative substrate 
contributions (and how altered) should be ascertained.  Future studies should not only investigate 
fuel substrate oxidation, but also uptake and esterification in addition to enzyme activity and 
expression.  
Future work could progress towards an in vivo model of AHF where cardiac failure is rapidly induced 
in a known and characterized manner. Live 3D imaging could also be performed on animals to 
evaluate cardiac function during the assault and during recovery phases.  Ideally, future work should 
utilize a diet-induced obesity/diabetic model as this is more plausible and clinically relevant.  Our 
model also represented an assault in extreme obese and diabetic states that are untreated for 
diabetes.  Thus future studies should include groups to represent treated diabetic individuals as this 
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Krebs-Henseleit buffer for mouse heart - stabilization phase 
 
Stock solutions: Concentrated (500x or 1000x) solutions are made up and stored in the fridge. 
Working solutions and final concentrations: On the day of use, alliquates from the stock solutions 
are diluted to the final working buffer (final concentrations).  
Stock solutions for mouse Krebs: 
Reagents can be purchased from Sigma-Aldrich Co. LLC., St. Louis, Missouri, United States. 
Potassium chloride (KCl) (#P9333) (2.01 M): stock = 150 g in 1 L, add 10 ml to the 5 L 
Monosodium phosphate (NaH2PO4)(#S8282) (1.16 M): stock = 140 g in 1 L, add 5 ml to the 5 L 
Disodium ethylenediaminetetraacetic acid (EDTA.2H2O) (#D2900000) (0.5 M): stock = 190 g in 1 L, 
add 5 ml to the 5 L 
Magnesium chloride (MgCl2).6H2O (#M2670) (2.5 M): stock = 240 g in 1 L, add 5 ml to the 5 L 
Calcium chloride (CaCl2).2H2O (#C5080) (3.3 M): stock = 370 g in 1 L, add 5 ml to the 5 L 
* Sodium chloride (NaCl); Sodium bicarbonate (NaHCO3) 
 5 Liter 4 Liter 2 Liter 
Final concentrations: Measure ½-¾ of final volume distilled H2O accurately into flask 
then weigh out and add: 




27.58 g   13.79 g 
 
NaHCO3 (#S6297)  
24 mM 
10.1 g  
 
8.08 g  4.04 g  
 
Add alliquates of stock solutions 
to make up final concentrations: 
 
Stir until all is dissolved then add: 
KCl 4.02 mM 10 ml  8 ml 4 ml  
NaH2PO4 1.16 mM 5 ml  4 ml 2 ml  
Disodium EDTA.2H20 0.5 mM  5 ml  4 ml 2 ml  
MgCl2.6H20 2.5 mM  5 ml  4 ml 2 ml  
CaCl2 3.3 mM 5 ml  4 ml 2 ml  
Final glucose concentration: Stir until all is mixed and check that no CaCl2 precipitates out. 
Then add the glucose and stir. 
Glucose (#G7528) 10 mM 9.0 g 7.2 g  3.6 g  
 Mix well and top up to final volume 





Table A1: Krebs-Henseleit buffer for mouse heart - stabilization phase. 




Palmitic acid stock solution (120 mM) for the CAHF and RAHF phase 
Add 2.99 g sodium carbonate (Na₂CO₃) and 6.15 g palmitic acid, make up to 200 ml final volume with 
38% ethanol. Stir at approximately 60 ˚C. Cover the flask to prevent evaporation. On the day of use, 
heat the stock solution as it solidifies at low temperatures. 
 
Critical -and recovery AHF phase buffer for mouse heart  
Make up buffer standard Krebs-Henseleit buffer as stipulated above except for the glucose and 
addition of the BSA (3%)/1.2 mM palmitate conjugate as follows: 
 
 2 Liter 1 Liter 0.5 Liter 
CAHF phase: (low glucose + BSA/palmitate conjugation) 
Glucose 2.5 mM Add 0.9 g  Add 0.45 g  Add 0.225 g  
RAHF phase: (normal glucose + BSA/palmitate conjugation) 
Glucose 10 mM Add 3.6 g  Add 1.8 g  Add 0.9 g  
Both Phases: 
BSA (3%)/1.2 mM palmitate conjugation according to Lopaschuk and Barr 1997 
BSA 60 g 30 g 15 g 
Palmitic acid  
(from stock solution) 
20 ml 10 ml 5 ml 
 
BSA (Fraction V, Roche Ltd., Basel, Switzerland) 
Palmitic acid (#P0500, Sigma-Aldrich Co. LLC., St. Louis, Missouri, United States) 
Sodium carbonate (#S7795, Sigma-Aldrich Co. LLC., St. Louis, Missouri, United States)  
Ethanol (#E7023, Sigma-Aldrich Co. LLC., St. Louis, Missouri, United States) 
 
  
Table A2: Krebs-Henseleit buffer for mouse heart – CAHF and RAHF phase. 










Figure A2: Constructing mouse ventricular balloons. With the catheter attached to the syringe, 
pull degassed distilled water up into the syringe, making sure there is no air bubbles in the 
catheter. Put the tip of the water-filled catheter into the cone shape. Leave at least a 5 mm 
space between the tips of the cling wrap cone and the catheter. Wind the invisible thread 
neatly around the catheter: leave a tail of thread at the back (syringe side) and start winding 
from the tip of the catheter upward for about 1 cm. The starting point of the “coil” should be 
close to the tip of the catheter – max 1 mm from the tip. Knot off sufficiently to prevent leaks. 
Figure A1: Cling wrap cone for the construction of mouse 
ventricular balloons.  Slowly pull the cling wrap over the 
point of the needle, about 1-2 cm down. Hold the cling 
wrap in close proximity to the needle shaft as this helps to 
not only stretch the cling wrap to its maximum but also to 
“shape” the cling wrap better. 
Figure A3: Mouse ventricular balloon. This balloon shape assures that the whole ventricle is 
filled. Sharp corners will cause damage to the ventricles, causing the heart to fail on the rig.  





A.D.1 Preparation of RIPA buffer (modified Radio Immuno PrecipitAtion buffer) 
and protein extraction  
 
Prepare 100 ml modified RIPA base buffer as follows:  
1. Add 790 mg Tris base (65.21 mM) (#T6791, Sigma-Aldrich Co. LLC., St. Louis, Missouri, United 
States) to 75 ml dH2O. Add 900 mg NaCl (154.00 mM) and stir the solution until all solids are 
dissolved. Adjust the pH to 7.4. 
2. Add 10 ml of 10% Tergitol-type NP-40 (1%) (#74385, Sigma-Aldrich Co. LLC., St. Louis, 
Missouri, United States) to the solution. 
3. Add 2.5 ml of 10% Na-deoxycholate (0.25%) (#D6750, Sigma-Aldrich Co. LLC., St. Louis, 
Missouri, United States) and stir until solution is clear. 
4. Add 1 ml of 100 mM EDTA (1mM) (#D2900000, Sigma-Aldrich Co. LLC., St. Louis, Missouri, 
United States) to the solution. Adjust the volume of the solution to 100 ml using a graduated 
cylinder.  
5. Ideally, the remaining protease and phosphatase inhibitors should be added to the solution 
on the same day you are running the assay. Store at 2-8° C. 
Modified RIPA with inhibitors: Add the appropriate amount of each protease inhibitor to the RIPA 
base so that the final concentrations are: 
Reagents can be purchased from Sigma-Aldrich Co. LLC., St. Louis, Missouri, United States: 
 Phenylmethylsulfonyl fluoride (PMSF) (#7626): 1 mM  
 Leupeptin (#L2884) and benzamidine (#B6505): 1 µg/ml  
 Aprotonin (#A1153): 1 µg/ml  
 Pepstatin (#P5318): 10 µg/ml  
 Activated Sodium orthovanadate (Na3VO4) (#S6508): 1 mM  




 Sodium fluoride (NaF) (#S7920): 1 mM 
 Note: PMSF is extremely unstable in aqueous solutions with a half-life of approximately 30 
minutes and it should be added immediately before use. 
Protein extraction 
Wrap each piece of tissue sample in little squares of aluminium foil (foil folded over 4 x) and place in 
liquid nitrogen. Pour a small amount of liquid nitrogen into mortar and pulverize the frozen sample. 
Carefully unwrap the foil and tip the powdered tissue (keeping it cool) into tubes containing RIPA 
buffer (with inhibitors) – aim to make homogenates that are 1:2 w/v tissue:lysis buffer). Transfer the 
homogenates to fresh pre-chilled microfuge tubes and keep on ice. Once all samples have been 
homogenized, sonicate (Sp-4000 ultrasonic liquid processor, Misonix, New York, United States) for 
15 seconds each and then centrifuge at 12000 rpm (3,312 x g) for 15 minutes at 4°C. Transfer the 
supernatants (protein lysates) to fresh pre-chilled tubes and thereafter perform protein 
determination. Freeze samples at -20°C if not running gels on same day. 
  




A.D.2 Bradford protein determination 
 
Stock solution 5x concentration: 
Dilute 500 mg Coomassie Brilliant blue G250 (#27815, Sigma-Aldrich Co. LLC., St. Louis, Missouri, 
United States) in 250 ml 95% ethanol. Add 500 ml phosphoric acid (W290017, Sigma-Aldrich Co. LLC., 
St. Louis, Missouri, United States) and mix thoroughly. Adjust the volume to 1 L with dH2O. Filter 
(filter paper, 240 mm, Munktell, Bärenstein, Germany) solution and store at 4°C. 
Working solution: 
Dilute the stock solution in a 1:5 ratio (100 ml:500 ml) with dH2O. Filter with 2 filter papers. The 
filtered working solution should be a light brown color and is light sensitive. 
Method: 
Thaw 2 ml of 200 µg/ml BSA stock solution and the protein samples. Work on ice at all times. 
Prepare and mark 2 ml Eppendorf tubes (eppis) for the standard curve. Mark duplicates.  
Prepare standard curve as follows: 
BSA dH2O Concentration 
0 100 µl Blank 
10 µl 90 µl 2 µg 
20 µl 80 µl 4 µg 
40 µl 60 µl 8 µg 
60 µl 40 µl 12 µg 
80 µl 20 µl 16 µg 
100 µl 0 µl 20 µg 
      
                                                                                                          
 For the samples, place 95 µl dH2O into each sample tube and add 5 µl of protein sample to 
appropriate duplicate tubes and vortex (Vortex mixer vm-300, Gemmy Industrial Corp., 
Taipei, Taiwan) briefly. 
 Add 900 µl Bradford working solution to each tube and vortex again. 
Table A3: Standard curve for Bradford protein determination.  




 Incubate tubes at room temp for at least 5 minutes until they equilibrate to room 
temperature.  The reaction is stable for up to 60 minutes. 
 Let the spectrophotometer (Cecil CE 2021, Cecil instruments, Cambridge, England) warm up 
to calibrate, then set wavelength to 595 nm.  
 Read absorbances of standards and samples 
 If absorbance of samples falls outside the range of the highest standard, dilute with RIPA 
buffer and read again – remember to multiply result by dilution.  
 Draw up the standard curve (Microsoft Office 2010, Excel, Redmond, Washington, United 
States) and thereafter determine the unknown protein values (in µg). 
 
  




A.D.3 Sample preparation 
 
Laemmli’s loading buffer 
dH20 3.8 ml 
0.5 M Tris- Hydrogen chloride (HCl), pH 6.8 
(#T6666 Sigma-Aldrich Co. LLC., St. Louis, Missouri, United States) 
1.0 ml 
 Glycerol 
(#818709, Merck Millipore Co., Darmstadt, Germany) 
0.8 ml 
10 % (w/v) sodium dodecyl sulfate (SDS) 
(#L3771, Sigma-Aldrich Co. LLC., St. Louis, Missouri, United States) 
1.6 ml 
0.05 % (w/v) Bromophenol blue 





1. Make a working solution of Laemmli’s sample buffer by adding 850 µl Laemmli’s stock buffer 
solution to 150 µl β-mercaptoethanol  (#1610710, Bio-Rad Laboratories Inc., Hercules, 
California, Unites States) (work in fume hood) and mixing thoroughly on the vortex.  
2. Calculate the appropriate volume of each sample to give equal loading amounts (previously 
calculated on the excel sheet) and calculate the number of sample sets needed. 
3. Add the appropriate volumes of working solution of Laemmli’s, RIPA buffer (as calculated) and 
protein sample to each appropriate tube (work in fume hood). 
4. Close tubes and punch small hole in lid and heat samples on heating block (Incu Block, Labnet 
International, Inc., Edison, New Jersey, United States), at 95˚C for 5 minutes. 
5. Vortex and spin down contents briefly (± 10 sec) and place on ice immediately. 
6. Samples can now either be stored at -20 οC for future use, or be loaded onto the gels. 
 
  
Table A4: Laemmli’s loading buffer.  




A.D.4 Casting and running SDS-PAGE gels 
 
Preparation: 
Collect and clean the clean spacer and short plates (#1653311, Bio-Rad Laboratories Inc., Hercules, 
California, United States) and assemble them in the casting stand with clamps kit (#1658052, Bio-Rad 
Laboratories Inc., Hercules, California, Unites States). Check that the setup is not leaking by pouring 
ethanol between the plates. Remove the ethanol hereafter.  
Make up working solutions of running buffer and TBS-T: 
Reagents can be purchased from Sigma-Aldrich Co. LLC., St. Louis, Missouri, United States: 
10x running buffer (2 liter) 10x TBS (2 liter) 
60.6 g Tris  48.4 g Tris  
288 g Glycine (#50046) 160 g NaCl  
20 g SDS   
Dissolve in 1200 ml, adjust the pH to 7.6 and 
make up to final volume. 
In 1.5 liter d.H2O, first dissolve the Tris and 
glycine and then add the SDS. pH to 8.6. Make 
up to final volume. 
1x working solution (1 liter) 1x working solution TBS-T (1 liter) 
Mix 900 ml d.H2O and 100 ml 10x stock solution. Mix 900 ml d.H2O and 100 ml 10x stock solution, 









Table A5: Working solutions of running buffer and TBS-T.  





Preparing and casting the stain-free gels: 
Make up the desired amount of resolving gel end pour this between the plates up to the top green 
bar on the casting stand, making sure to remove all the bubbles. Leave this to set for 40-60 minutes. 
Gel constituent 6% 8% 10% 12% 15% 
dH20 8.625 ml 7.875 ml 7.125 ml 5.7 ml 5.245 ml 
40% Acrylamide (#A718) solution 2.25 ml 3.0 ml 3.75 ml 4.5 ml 5.625 ml 
1.5 M Tris-HCl, pH 8.8 3.75 ml 3.75 ml 3.75 ml 3.75 ml 3.75 ml 
10% w/v SDS  150 µl 150 µl  150 µl 150 µl 150 µl 
10% w/v APS (#09913) 150 µl 150 µl 150 µl 150 µl 150 µl 
TCE (#T54801) 75 µl 75 µl 75 µl 75 µl 75 µl 
* TEMED (#T702) (add last!) 12 µl 9 µl 6 µl 6 µl 6 µl 
 
When the resolving gel is set, prepare the 4% stacking gel as follows with the same reagents. 
 
 
                G  Gel constituent 4%  
dH20  4.84 ml 
40% Acrylamide solution 1.0 ml 
0.5 M Tris-HCl, pH 6.8 2.0 ml 
20% w/v SDS 40 µl 
10% w/v APS 40 µl 
TEMED (add last) 8 µl 
 
 
Pour between the plates, on top of the set resolving gel and insert the desired comb (#1653359, Bio-
Rad Laboratories Inc., Hercules, California, United States), making sure that it corresponds to the 




Table A6: Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) resolving gel. 
* Tetramethylethylenediamine (TEMED) 
Table A7: Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) stacking gel 




Running the gels: 
Fetch and clean the electrophoresis system (#1658004, Mini-PROTEAN Tetra Vertical Electrophoresis 
Cell, 4-gel, Bio-Rad Laboratories Inc., Hercules, California, United States) 
 Carefully remove the comb then remove the plates from the casting stands and frames and 
place in the U-shaped adaptor with the short plate facing inwards. Insert this assembly into 
the loading system and close the latches to form a buffer dam in the center.  
 Place the assembly in the gel tank and fill with cold 1x running buffer and wash the wells 
with running buffer. 
 Add 7.5 µl of the stained and 5 µl unstained protein marker to each gel. 
 Add the appropriate amount (calculated from Bradford protein quantification) of sample 
slowly into the appropriate lane. 
 Place the green lid with appropriate leads (black to black: red to red) on top of the tank and 
connect to the power pac (#4006038, Power Pac 1000, Bio-Rad Laboratories Inc., Hercules, 
California, Unites States). 
 Run at 110 V (constant), 400 mA for about 2 hours to allow samples to migrate through gel - 
until the sample dye front and smallest standard of the protein marker reaches the bottom 
of the gel. Switch off power and disconnect electrodes. Remove gel plates from the tank. 
 
Activating the stain free whole protein: 
 Gently separate the plates, remove the gel and place it on the tray of the ChemiDoc 
(ChemiDoc MP System, Bio-Rad Laboratories Inc., Hercules, California, United States) and 
close the drawer. 
 Open the accompanying Image Lab program (Image Lab Software, version 5.0, Bio-Rad 
Laboratories Inc., Hercules, California, Unites States), select “new protocol”, under 
“Application” choose “Protein gels” and “Stain free”. Select the 1 minute activation protocol, 
position your gel and run the protocol. Save the image.  




 Immediately proceed to electrotransfer step.  
 
Protein transfer, whole protein imaging and primary anti-body: 
 
 Open the “transfer pack” (#1704157, Trans-Blot Turbo Midi PVDF Transfer Packs,  Bio-Rad 
Laboratories Inc., Hercules, California, Unites States) 
 Following the enclosed instructions, assemble the transfer “sandwich” on the tray of the 
transfer system (# 1704155, Trans-Blot Turbo Transfer Starter System, Bio-Rad Laboratories 
Inc., Hercules, California, Unites States) and roll out the bubbles. Lock the lid in place. 
 Set the system to transfer on the standard “SD 25V 1A” program for 30 minutes.  
 Place the membrane in methanol (#822283, Merck Millipore Co., Darmstadt, Germany) for 
30 seconds and let it air dry completely.  
 Wash the membrane 3 x 5 minutes in TBS-T and place on the tray of the ChemiDoc once 
more. In Image Lab select “new protocol”, under “Application” choose “Blots” and “Stain 
free”. Select the preferred optimization option for your membrane, position your membrane 
and run the protocol. Save the image. This imaging step is to check that the transferring was 
successful but will also be the image that your protein of interest will be normalized to.  
 Block for 2 hours on a shaker (GyroTwister, LabNet, New Jersey, United states) in 5% 
milk or 5% BSA – made up in TBS-T. Wash 3 x 5 minutes in TBS-T.  
 Place membrane in 50 ml falcon tube (50050, Conical tube, SPL life sciences, Gyeonggi-
do, Korea) containing 5 ml of primary antibody diluted in TBS-T (dilution determined by 
product data sheet and optimization) Place on rotator (H5600 Revolver, LabNet, New 
Jersey, United states) in 4°C walk-in fridge overnight. 
Secondary anti-body and protein of interest imaging: 
 Remove the membrane from primary antibody (save antibody – freeze at -20°C) and wash 3 
x 5 minutes in TBS-T. 




 Place membrane in 50 ml falcon tube containing 5 ml of secondary antibody diluted in TBS-T 
(dilution determined by product data sheet and optimization). Place on rotator (SRT9 roller 
mixer, Stuart Bibby scientific Ltd., Staffordshire, United Kingdom) for 1 hour at room 
temperature.  
 Remove the membrane from secondary antibody (save antibody – freeze at -20°C) and wash 
the membrane 3 x 5 minutes in TBS-T. 
 Prepare ECL (Bio-Rad Clarity Western ECL substrate, Bio-Rad Laboratories Inc., Hercules, 
California, Unites States) substrate in a 1:1 ratio of solutions A:B in a foil covered tube. Pour 
off the TBS-T from membrane and add ECL, spreading evenly over surface of membrane.  
 Place the membrane on the tray of the Chemidoc, taking care to remove bubbles and close 
the drawer.  
 In Image Lab select “New protocol”, under “Application” choose “Blot” and “Chemi”. Set the 
imaging area to 12 x 9. Now either choose one of the automatic exposure options (intense 
or faint bands) or manually set the exposure time (optimization) until one of your bands 
(protein of interest) become overexposed (red). Position your membrane and run the 















A.D.5 Densitometry and normalization to whole protein: 
 
In the Image Lab program, open both the whole protein stain free blot image (taken right after 
transferring) and your chemiluminescent protein of interest image.  
 Select “File” and “Create multichannel image”. Drag the stain free blot image to channel 1 
and the chemiluminescent image to channel 2. Click “OK” and the “RGB” button. 
 In the “Analysis tool box”, select “Lane and bands”. Click on the stain free blot to make it the 
active image. In the “Lanes” tab, you can now either automatically detect the lanes or draw 
them manually. Either way you can use the lane adjustment tools to position the lanes. Set 
the “Disc size” to 70 mm. Copy (Ctrl+C) these lanes and paste (Ctrl+V) these lanes onto the 
chemiluminescent image. Select the “Bands” tab and then “Detect bands”, select the 
appropriate sensitivity and click “Detect”. 
 Go back to the “Analysis tool box” and select “Normalization”. Under “Normalization 
channel” select “Stain free blot”.  Select the radio button for “Total lane protein”.  
 Go back to the “Analysis tool box” and select “MW analysis tools”. On the stain free image, 
check the boxes under the lanes where you have loaded your protein standards. Under 
“Standards” select the protein ladders that you have used. 
 On the main toolbar, select “Analysis table” and click the “export analysis table to Excel” 
button. All calculations have been performed by the software.  








Table A8: Representative Western blot images. 3-KAT: 3-keotacyl-CoA thiolase, PDH: Pyruvate 
dehydrogenase 







 Baseline 10-15 min 25-30 min 
RPP 5955.00 ± 291.00 6679.00 ± 321.30 8012.00 ± 477.00 
(dp/dt)max 570.90 ± 38.52 632.10 ± 38.82 710.30 ± 46.73 
Heart rate 394.30 ± 1.62 395.40 ± 2.03 411.30 ± 10.90 
LVDevP 15.10 ± 0.72 16.88 ± 0.76 19.55 ± 1.32 
LVEDP 150.90 ± 27.78 149.20 ± 27.49 144.70 ± 27.24 
LVESP 166.00 ± 28.13 166.10 ± 27.81 164.30 ± 27.12 
Dialysis 
 Baseline 10-15 min 25-30 min 
RPP 4384.00 ± 1198.00 5194.00 ± 1448.00 6110.00 ± 1389.00 
(dp/dt)max 382.60 ±82.55 499.30 ± 123.7 602.60 ± 113.40 
Heart rate 396.40 ± 0.94 369.30 ± 15.07 338.70 ± 25.85 
LVDevP 11.04 ± 3.00 14.56 ± 4.23 17.90 ± 3.59 
LVEDP 175.20 ± 26.60 173.00 ± 26.00 170.50 ± 25.81 










Table A9: Raw perfusion results for filter and dialysis groups.  Units of raw values are as follows: 
LVESP, LVEDP and LVDevP in mmHg, (dp/dt)max in mmHg/s, RPP in mmHg/min and heart rate in 
beats per minute HR: heart rate, RPP: rate pressure product, (dp/dt)max: index of myocardial 
contraction velocity, LVDevP: left ventricular developed pressure, LVEDP: left ventricular end 
diastolic pressure, LVESP: left ventricular end systolic pressure, CAHF: critical acute heart failure, 
TMZ: trimetazidine, SEM: standard error of the mean. 




 Baseline CAHF Phase SAHF Phase 
RPP 16590.00 ± 2213.00 484.60 ± 95.76 2514.00 ± 336.30 
(dp/dt)max 1105.00 ± 133.00 46.16 ± 13.47 193.00 ± 28.03 
Heart rate 395.60 ± 1.11 1088.00 ± 322.20 471.00 ± 51.88 
LVDevP 41.93 ± 5.59 1.68 ± 0.86 5.60 ± 0.91 
LVEDP 92.78 ± 9.45 63.08 ± 10.44 110.30 ± 11.40 





















Table A10: Raw perfusion results for establishing the ex vivo mouse model of acute heart 
failure.  Units of raw values are as follows: LVESP, LVEDP and LVDevP in mmHg, (dp/dt)max in 
mmHg/s, RPP in mmHg/min and heart rate in beats per minute HR: heart rate, RPP: rate pressure 
product, (dp/dt)max: index of myocardial contraction velocity, LVDevP: left ventricular developed 
pressure, LVEDP: left ventricular end diastolic pressure, LVESP: left ventricular end systolic 
pressure, CAHF: critical acute heart failure, TMZ: trimetazidine, SEM: standard error of the mean. 





 Baseline CAHF phase RAHF phase 
RPP 16590.44 ± 2212.90 484.56 ± 95.76 2514.09 ± 336.30 
(dp/dt)max 1105.22 ± 133.05 46.16 ± 13.47 192.98 ± 28.03 
Heart rate 395.58 ± 1.11 1088.27 ± 322.23 470.99 ± 51.88 
LVDevP 41.93 ± 5.59 1.67 ± 0.86 5.60 ± 0.91 
LVEDP 92.78 ± 9.45 63.08 ± 10.44 110.32 ± 11.40 
LVESP 134.71 ± 12.10 64.75 ± 10.50 115.92 ± 10.62 
TMZ at CAHF 
 Baseline CAHF phase RAHF phase 
RPP 18622.26 ± 923.04 656.12 ± 77.05 3723.18 ± 307.75 
(dp/dt)max 1301.16 ± 159.63 28.92 ± 2.84 290.97 ± 30.18 
Heart rate 394.70 ± 2.62 1609.02 ± 64.39 451.87 ± 19.67 
LVDevP 47.20 ± 2.39 0.41 ± 0.06 8.26 ± 0.70 
LVEDP 98.25 ± 8.99 80.85 ± 8.15 125.85 ± 5.83 
LVESP 145.45 ± 7.98 81.26 ± 8.15 134.11 ± 5.55 
TMZ at RAHF 
 Baseline CAHF phase RAHF phase 
RPP 20129.06 ± 766.12 255.50 ± 31.34 4269.98 ± 350.86 
(dp/dt)max 1360.37 ± 62.13 13.80 ± 1.49 322.22 ± 18.38 
Heart rate 388.82 ± 4.58 1426.27 ± 70.26 420.95 ± 30.39 
LVDevP 51.83 ± 2.20 0.18 ± 0.01 10.23 ± 0.75 
LVEDP 137.43 ± 27.59 117.71 ± 27.42 164.83 ± 28.77 







Table A11: Raw perfusion results lean males (n=6).  Units of raw values are as follows: LVESP, 
LVEDP and LVDevP in mmHg, (dp/dt)max in mmHg/s, RPP in mmHg/min and heart rate in beats per 
minute HR: heart rate, RPP: rate pressure product, (dp/dt)max: index of myocardial contraction 
velocity, LVDevP: left ventricular developed pressure, LVEDP: left ventricular end diastolic 
pressure, LVESP: left ventricular end systolic pressure, CAHF: critical acute heart failure, TMZ: 
trimetazidine, SEM: standard error of the mean. 





 Baseline CAHF phase RAHF phase 
RPP 18548.97  ± 1839.97 344.72 ± 61.40 2390.40 ± 429.70 
(dp/dt)max 1202.68 ± 92.22 22.02 ± 3.41 163.84 ± 31.96 
Heart rate 392.13 ± 0.29 1499.71 ± 46.49 477.71 ± 51.20 
LVDevP 47.30 ± 4.68 0.22 ± 0.03 5.20 ± 1.07 
LVEDP 125.95 ± 20.76 111.81 ± 19.02 149.81 ± 16.70 
LVESP 173.25 ± 17.36 112.04 ± 19.01 155.02 ± 16.30 
TMZ at CAHF 
 Baseline CAHF phase RAHF phase 
RPP 16057.13 ± 1850.13 558.33 ± 119.89 2290.67 ± 295.98 
(dp/dt)max 1091.55 ± 135.09 26.52 ± 3.48 154.70 ± 20.30 
Heart rate 394.81 ± 1.62 1585.91 ± 91.25 469.16 ± 26.66 
LVDevP 40.62 ± 4.58 0.35 ± 0.07 4.99 ± 0.70 
LVEDP 118.90 ± 13.61 93.72 ± 15.01 138.07 ± 14.08 
LVESP 159.53 ± 15.40 94.07 ± 15.05 143.06 ± 14.19 
TMZ at RAHF 
 Baseline CAHF phase RAHF phase 
RPP 19034.68 ± 1325.03 221.62 ± 28.10 2977.63 ± 411.68 
(dp/dt)max 1312.90 ± 49.54 11.44 ± 0.51 194.79 ± 23.32 
Heart rate 396.27 ± 3.91 1487.03 ± 126.66 462.03 ± 32.82 
LVDevP 48.00 ± 3.25 0.15 ± 0.01 6.56 ± 0.90 
LVEDP 147.43 ± 21.66 128.37 ± 20.53 171.55 ± 20.72 
LVESP 195.44 ± 20.24 128.52 ± 20.54 178.11 ± 20.67 
  
Table A12: Raw perfusion results obese males (n=6).  Units of raw values are as follows: LVESP, 
LVEDP and LVDevP in mmHg, (dp/dt)max in mmHg/s, RPP in mmHg/min and heart rate in beats per 
minute HR: heart rate, RPP: rate pressure product, (dp/dt)max: index of myocardial contraction 
velocity, LVDevP: left ventricular developed pressure, LVEDP: left ventricular end diastolic 
pressure, LVESP: left ventricular end systolic pressure, CAHF: critical acute heart failure, TMZ: 
trimetazidine, SEM: standard error of the mean. 





 Baseline CAHF phase RAHF phase 
RPP 16289.71 ± 1894.48 873.11 ± 336.58 4269.78 ± 535.97 
(dp/dt)max 1116.99 ± 139.07  25.42 ± 6.51 344.07 ± 43.13 
Heart rate 402.02 ± 5.73 1494.89 ± 183.64 416.93 ± 14.47 
LVDevP 40.37 ± 4.47 0.62 ± 0.28 10.27 ± 1.31 
LVEDP 160.59 ± 22.71 131.62 ± 23.69 175.16 ± 23.37 
LVESP 200.96 ± 24.35 132.24 ± 23.83 185.44 ± 24.01 
TMZ at CAHF 
 Baseline CAHF phase RAHF phase 
RPP 17079.71 ± 2149.35 250.92 ± 20.01 4862.54 ± 697.89 
(dp/dt)max 1237.81 ± 153.30 14.08 ± 1.05 403.26 ± 66.48   
Heart rate 390.32 ± 2.98 1522.87 ± 132.96 403.41 ± 20.07 
LVDevP 43.84 ± 5.63 0.16 ± 0.01 12.27 ± 2.04 
LVEDP 163.06 ± 23.69 150.97 ± 25.29 180.47 ± 22.85 
LVESP 206.91 ± 23.11 151.13 ± 25.28 192.75 ± 22.93 
TMZ at RAHF 
 Baseline CAHF phase RAHF phase 
 RPP 14958.69 ± 1039.71 376.23 ± 54.90 4006.36 ± 439.18 
(dp/dt)max 1140.17 ± 91.60 15.50 ± 2.11 340.82 ± 32.23 
Heart rate 389.18 ± 3.20 1595.62 ± 72.03 377.88 ± 25.19 
LVDevP 38.45 ± 2.74 0.24 ± 0.04 10.52 ± 0.91 
LVEDP 170.02 ± 18.01 137.85 ± 15.55 186.88 ± 16.67 





Table A13: Raw perfusion results lean follicular females (n=6).  Units of raw values are as 
follows: LVESP, LVEDP and LVDevP in mmHg, (dp/dt)max in mmHg/s, RPP in mmHg/min and heart 
rate in beats per minute HR: heart rate, RPP: rate pressure product, (dp/dt)max: index of 
myocardial contraction velocity, LVDevP: left ventricular developed pressure, LVEDP: left 
ventricular end diastolic pressure, LVESP: left ventricular end systolic pressure, CAHF: critical 
acute heart failure, TMZ: trimetazidine, SEM: standard error of the mean. 





 Baseline CAHF phase RAHF phase 
RPP 14579.51 ± 1651.19 464.67 ± 150.92 4846.39 ± 538.99 
(dp/dt)max 1187.81 ± 140.37 24.74 ± 6.58 399.25 ± 53.39 
Heart rate 396.82 ± 5.16 1293.74 ± 136.56 401.48 ± 11.61 
LVDevP 36.94 ± 4.33 0.46 ± 0.22 12.23 ± 1.58 
LVEDP 93.53 ± 13.35 63.19 ± 13.12 106.70 ± 13.30 
LVESP 130.47 ± 14.09 63.66 ± 13.06 118.93 ± 14.00 
TMZ at CAHF 
 Baseline CAHF phase RAHF phase 
RPP 16921.82 ± 1817.65 267.17 ± 42.46 4847.59 ± 510.36  
(dp/dt)max 1203.42 ± 144.97 15.48 ± 2.36 381.00 ± 49.60 
Heart rate 399.93 ± 2.45 1390.17 ± 123.26 442.67 ± 23.43 
LVDevP 42.20 ± 4.30 0.18 ± 0.01 11.10 ± 1.21 
LVEDP 132.32 ± 25.15 109.52 ± 24.56 149.73 ± 23.76 
LVESP 174.53 ± 23.56 109.71 ± 24.55 160.83 ± 23.35 
TMZ at RAHF 
 Baseline CAHF phase RAHF phase 
 RPP 20754.22 ± 1354.62 323.84 ± 65.10 6695.62 ± 817.95 
(dp/dt)max 1483.47 ± 115.19 14.17 ± 1.50 540.25 ± 70.12 
Heart rate 394.65 ± 2.84 1529.01 ± 56.64 414.26 ± 12.71 
LVDevP 52.61 ± 3.48 0.21 ± 0.04 16.41 ± 2.20 
LVEDP 166.19 ± 22.14 144.39 ± 22.56 188.83 ± 23.36 





Table A14: Raw perfusion results lean luteal females (n=6).  Units of raw values are as follows: 
LVESP, LVEDP and LVDevP in mmHg, (dp/dt)max in mmHg/s, RPP in mmHg/min and heart rate in 
beats per minute HR: heart rate, RPP: rate pressure product, (dp/dt)max: index of myocardial 
contraction velocity, LVDevP: left ventricular developed pressure, LVEDP: left ventricular end 
diastolic pressure, LVESP: left ventricular end systolic pressure, CAHF: critical acute heart failure, 
TMZ: trimetazidine, SEM: standard error of the mean. 





 Baseline CAHF phase RAHF phase 
RPP 13983.18 ± 2410.90 444.18 ± 70.35 2112.03 ± 326.94 
(dp/dt)max 965.00 ± 167.91 20.68 ± 3.96 163.30 ± 23.56 
Heart rate 384.16 ± 11.08 1307.46 ± 195.11 407.14 ± 16.44 
LVDevP 36.34 ± 5.87 0.39 ± 0.09 5.13 ± 0.68 
LVEDP 59.83 ± 6.86 29.40 ± 7.94 77.71 ± 6.30 
LVESP 96.18 ± 6.52 29.79 ± 7.87 82.84 ± 6.71 
TMZ at CAHF 
 Baseline CAHF phase RAHF phase 
RPP 19291.76 ± 1953.15 190.55 ± 27.56 1937.27 ± 274.60 
(dp/dt)max 1375.89 ± 122.23 11.96 ± 1.76 140.43 ± 14.91 
Heart rate 396.26 ± 2.20 1327.96 ± 136.30 466.16 ± 24.94 
LVDevP 48.64 ± 4.86 0.14 ± 0.01   4.09 ± 0.48 
LVEDP 127.47 ± 16.21 113.69 ± 17.15 152.03 ± 17.19 
LVESP 176.12 ± 16.83 113.84 ± 17.16 156.12 ± 17.01 
TMZ at RAHF 
 Baseline CAHF phase RAHF phase 
 RPP 17091.87 ± 1871.77 189.09 ± 24.45 3341.99 ± 684.70 
(dp/dt)max 1171.45 ± 125.58 10.93 ± 0.66 228.29 ± 54.29 
Heart rate 391.76 ± 3.73 1569.94 ± 85.98 503.02 ± 26.42 
LVDevP 43.49 ± 4.56 0.12 ± 0.02 6.95 ± 1.62 
LVEDP 167.01 ± 24.39 151.84 ± 27.39 185.39 ± 25.35 





Table A15: Raw perfusion results obese females (n=6).  Units of raw values are as follows: LVESP, 
LVEDP and LVDevP in mmHg, (dp/dt)max in mmHg/s, RPP in mmHg/min and heart rate in beats per 
minute HR: heart rate, RPP: rate pressure product, (dp/dt)max: index of myocardial contraction 
velocity, LVDevP: left ventricular developed pressure, LVEDP: left ventricular end diastolic 
pressure, LVESP: left ventricular end systolic pressure, CAHF: critical acute heart failure, TMZ: 
trimetazidine, SEM: standard error of the mean. 





Baseline raw values  
 N1 N2 N3 N4 N5 N6 Average SEM 
RPP 14893.15 15381.79 7705.60 23327.67 20770.48 17463.97 16590.44 2212.90 
(dp/dt)max 1229.52 1105.66 561.73 1490.52 1310.62 933.25 1105.217 133.05 
HR 393.20 395.25 394.84 395.69128 393.71 400.80 395.58 1.11 
LVDevP 37.88 38.92 19.52 58.95 52.75 43.57 41.93 5.59 
LVEDP 107.96 49.63 92.55 112.99 88.26 105.30 92.78 9.45 
LVESP 145.84 88.55 112.07 171.94 141.02 148.87 134.71 12.10 
LVEDP 107.96 49.63 92.55 112.99 88.26 105.30 92.78 9.45 
CAHF phase raw values  
RPP 428.10 876.43 257.07 443.21 274.27 628.28 484.56 87.41 
(dp/dt)max 67.96 51.20 98.58 27.45 18.34 13.42 46.16 12.30 
HR 117.95 1760.14 51.25 1690.17 1542.58 1367.54 1088.27 294.16 
LVDevP 3.63 0.50 5.02 0.26 0.18 0.46 1.67 0.78 
LVEDP 69.53 17.39 62.44 96.55 66.06 66.49 63.08 9.53 
LVESP 73.16 17.89 67.45 96.81 66.24 66.95 64.75 9.59 
RAHF phase raw values  
RPP 2299.72 3830.25 1981.00 1625.15 2179.72 3168.71 2514.09 307.00 
(dp/dt)max 195.82 322.35 160.09 119.48 178.02 182.11 192.98 25.59 
HR 394.71 398.83 407.72 553.60 376.55 694.53 470.99 47.36 
LVDevP 5.83 9.60 4.86 2.94 5.79 4.56 5.60 0.83 
LVEDP 114.09 66.63 94.50 150.08 121.35 115.31 110.32 10.41 
LVESP 119.92 76.23 99.36 153.01 127.14 119.87 115.92 9.69 
Raw RAHF/Raw CAHF (as a percentage)  














































































Table A16: Calculating raw perfusion results into a percentage ratio. Data represents the last 
ten minutes of each phase. Units of raw values are as follows: LVESP, LVEDP and LVDevP in 
mmHg, (dp/dt)max in mmHg/s, RPP in mmHg/min and heart rate in beats per minute.  RPP: rate 
pressure product, (dp/dt)max: index of myocardial contraction velocity, LVDevP: left ventricular 
developed pressure, LVEDP: left ventricular end diastolic pressure, LVESP: left ventricular end 
systolic pressure, CAHF: critical acute heart failure, RAHF: recovery acute heart failure, SEM: 
standard error of the mean. 




 Control animals CAHF treated animals RAHF treated animals 
 CAHF  
(% of Baseline) 
RAHF 






(% of Baseline) 
RAHF 



























Lean males 3.1 3 17.4 19.2 5.6 6.4 3.5 2.3 21.6 24.8 6.2 10.8 56.0 73.1 18.1 24.4 
Obese 
males 








3.2 2.1 54.1 47.5 16.9 22.6 1.6 1.4 32.4 37.6 20.2 26.9 80.6 85.3 25.2 40.6 
Obese 
females 
3.6 2.5 18.7 22.0 5.2 8.8 1.1 1.0 12.0 12.8 10.9 12.8 62.0 49.6 17.2 19.8 
 
 
Table A17: Comparing the effects of the ex vivo acute heart failure (AHF) model and trimetazidine (TMZ) treatment on all groups (n=6). The first RAHF 
column estimates the improvement as a percentage of the initial baseline (CAHF percentage x fold improvement in RAHF). Data represents the last ten 
minutes of each phase. RPP: rate pressure product, (dp/dt)max: index of myocardial contraction velocity, CAHF: critical acute heart failure, RAHF: recovery 
acute heart failure. 
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